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B220

220 Kd isoform of CD45; Pan B cell marker

BSA

Bovine serum albumin

CD3e

T cell receptor-associated complex; pan T cell marker

CD4

Cell surface marker present on helper T cells

CD8

Cell surface marker present on cytotoxic T cells

CD llb

Cell surface marker present on granulocytes and macrophages

ELISA

Enzyme-linked immunosorbent assay

FACS

Fluorescent activated cell sorter

FCS
FE
FSC
FITC

Foetal calf serum
Faecal pellet extract
Forward light scatter
Fluorescein isothiocyanate

FL1

FITC fluorescence emission detector

FL2

PE fluorescence emission detector

FL3

Cychrome fluorescence emission detector

Gr-1
IL
LPS
MHC

Cell surface marker present on granulocytes
Interleukin (eg. IL-1, IL-2, etc)
Lipopolysaccharide
Major histocompatibility complex

NBS

Newborn calf serum

OMP

Outer membrane proteins

OVA

Ovalbumin

PBL

Peripheral blood leukocytes

PBS

Phosphate-buffered saline

PE

Phycoerythrin

PMN

Polymorphonuclear leukocytes

RPMI

Rosewell Park Memorial Institute (culture medium)

R TW

Respiratory tract washing

SAMA4
SDS

Skin And Mucosal Adjuvant Version 4
Sodium dodecyl sulfate

Abbreviations

Vll

ssc
Thy 1.2

Side (light) scatter
Cell surface marker present on thymus-derived cells; Pan T cell
marker

Tris

Tris-hydroxymethylaminomethane

VW

Vaginal washing

YAC-1

NK cell-sensitive cell line

Superscripts used to indicate levels of expression of cell surface molecules
detected by FACS analysis:

~

undetectable

+

detectable (low to high expression)

Cell phenotypes as determined by more than one cell surface marker are
indicated consecutively with the level of expression of each marker as
indicated in the following example:

CD3B220+ is equivalent to:

Abbreviations

CD3 Undetectable, B220 detectable
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SUMMARY
There is a need to produce safe, highly immunogenic vaccines that can elicit
both systemic and mucosal immune responses. Control over the type of
immune responses elicited following immunization has traditionally been
confined to manipulating the immunogenicity of vaccines with adjuvants
and altering the immunization route. In doing so, most studies focus
predominantly on the ability of vaccines to elicit humoral

im m une

responses. As result, the modulatory effect of immunization

route or

adjuvant on the immune response, in particular, the nature and extent of
changes

to leukocyte

populations

following

immunization,

and

the

importance of these changes for eliciting the final immunological outcomes
remain poorly characterized. Knowledge of these changes may contribute to
the development of safe and effective vaccines.

Immunization by the intradermal route elicits strong immune responses in
different animal species. Therefore, one aim of this project was to quantify
the changes in leukocyte populations in different murine
intradermally immunized

tissues of

mice that may contribute to the adaptive

immune responses ultimately elicited. Mice were immunized with either
SAMA4, a generic liposome-iscom hybrid skin and mucosal adjuvant
(Adjuvant

group),

A ctinobacillus

outer

membrane

p leu ro p n eu m o n ia e

proteins

(OMP

(OMP)

Antigen

purified

group),

from

SAMA4-

adjuvanted OMP (OMP Vaccine group), or PBS (Control group).

Sum m ary

IX

Intradermal administration

of OMP vaccine

greatly altered

leukocyte

homeostasis and haematopoiesis in the tissues examined. A significant
component of the strong innate cellular responses elicited by SAMA4antigen complexes was recruitment

of polymorphonuclear

leukocytes

(PMN) and monocytes to the blood, spleen and lungs. Significant thymus
and bone marrow depletion were also rapidly induced by the SAMA4-OMP
vaccine. The absence of similar responses in mice given OMP or SAMA4
alone suggested that antigen and adjuvant interacted synergistically to
produce the effects observed. Identical changes to leukocyte populations
were elicited when the innocuous antigen, ovalbumin, replaced OMP in the
SAMA4 complexes, therefore excluding the possibility of any effects from
toxic bacterial or adjuvant components on the results obtained.

Intradermal immunization with OMP stimulated strong systemic IgG and
IgA and mucosal IgG responses. However, complexing of OMP with SAM A4
significantly prolonged the duration

of the

responses

and increased

reactivity against T dependent antigens in OMP. Cytotoxic responses against
OVA-expressing cell lines also occurred only in the OVA Vaccine group.
These results suggested that enhanced antigen processing by PMN was a
beneficial product of the strong innate immune responses elicited in these
mice. Mucosal antibody responses against OMP were demonstrated in both
the OMP Vaccine and OMP Antigen groups by increases in OMP-specific IgG
and IgA antibodies in respiratory tract washings and increases in the number
of IgG and IgA antibody secreting cells in lung digests of immunized mice

Summary

x

following intranasal re-exposure to a sub-immunogenic dose of OMP. Both
groups also cleared live A. p leu ro p n eu m o n ia e from the lungs more rapidly
than Control mice, and had significantly lower morbidity. Therefore, this
route

was efficacious

for eliciting

protective

systemic

and

mucosal

immunity against the respiratory pathogen, A. pleuropneumoniae.

Sum m ary
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CHAPTER 1
General Introduction

1.1

INTRODUCTION

Many attenuated live or inactivated organisms have been successfully used
as vaccines to prevent disease (Table 1.1) [1]. For safety and economic
reasons, subunit vaccines that contain only a restricted number of putative
protective antigens are also being developed [1-3]. One prominent example
of this is acellular pertussis vaccines that are being evaluated to replace
current cellular vaccines [4-7]. Irrespective of whether whole cell or subunit
vaccines are used, generation of immunity depends on the qualitative and
quantitative characteristics of the immune responses induced by vaccination
[8]. Therefore, there is a requirement to produce vaccines that are safe and
strongly immunogenic in order to activate innate and adaptive im m une
mechanisms.

Because the majority

of human

and animal

pathogens

colonize and invade via the mucosal surfaces of the lung, gut or urogenital
tracts [9], there is an additional requirement for vaccines to elicit both
mucosal and systemic immune

responses. In practice, adjuvants

and

different vaccination routes are used to achieve these attributes.

1.2

1.2.1

ADJUVANTS AND THE IMMUNE RESPONSE

Adjuvants increase the immunogenicity of vaccines

Adjuvants

are

widely

used

in

vaccines

to

increase

the

im m une

responsiveness against co-administered antigens [3]. According to Byars et al

Chapter 1
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TABLE 1.1
Disease

Vaccines containing attenuated or live organisms [1]
Vaccination route

Agent used

Cholera

killed Vibrio cholerae

SC, IM, ID

Influenza

killed Influenza virus

IM

Measles

live Measles virus

SC

Mumps

live Mumps virus

SC

Pertussis

killed Bordetella pertussis

IM

Plague

killed Yersinia pestis

IM

Polio

live or killed Polio virus

Oral, IM

Rabies

killed Rabies virus

IM, ID

Rubella

live Rubella virus

SC

Small pox

live Vaccinia virus

ID

Tuberculosis

live attenuated M ycobacterium bovis

ID, SC

Typhoid

killed Salmonella typhi

SC, Oral

Yellow fever

killed virus

SC

SC: subcutaneous; ID: intradermal; IM: intramuscular

[10], adjuvant action encapsulates a range of desirable activities that results
in increased immune responsiveness against administered antigens, and
that ultimately confers protection against disease. The requirement for safe,
highly immunogenic vaccines that elicit strong mucosal immune responses
has increased the prominence

of adjuvant

in vaccine design [8, 11].

However, because of the heterogeneity in the chemical composition of
adjuvants, and differences in the recommended delivery routes of vaccines,
unravelling the precise mechanisms

of adjuvant

action and defining

favourable attributes of adjuvants has proven difficult [3, 11]. Consequently,
despite the use and research into adjuvants over at least 80 years by many

Chapter 1
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different groups [12-17], the choice of adjuvants

for incorporation

in

commercial vaccines is currently still limited. Alum is used in hum an
vaccines [1, 8, 11], while the situation for veterinary vaccines is only slightly
better, with DEAE-Dextran and saponin-based adjuvants also available for
use [18,19].

The concern for safety is one factor resulting in the paucity of suitable
adjuvants. Adjuvants, including those commonly used in commercial
vaccines (eg. alum) and experimental immunology (eg. Freund's complete
and

incomplete

adjuvants,

Muramyl

Dipeptide,

Quil

A

and

im m unostim ulating complexes or iscoms), can elicit local and systemic
adverse post-vaccination reactions [1, 20, 21]. Although the reactions are
usually mild and self limiting, documented reactions to vaccines include:
local tissue damage at the site of injection [22], fever [23] or systemic effects
[20, 24]. Apprehension over such adverse reactions has, in cases like the
pertussis vaccine, deterred widespread acceptance of vaccination [25]. In
agriculture, local reactions to vaccination reduce carcass quality and decrease
economic returns [22, 24].

Humoral or cell-mediated immune responses are effectively used to assess
vaccine efficacy, and allow comparisons to be made between different
formulations of the same vaccine [20, 26-32], By contrast, the absence of wellaccepted parameters that define adjuvant action has resulted in an ad h o c
approach to

investigating

adjuvant

action

and

comparing

different

adjuvants [15, 26, 28, 33-40]. Consequently, adjuvant selection is often
Chapter 1
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confined to pragmatic considerations, such as shelf-life and com m ercial
availability, with less consideration devoted to determining which vaccine
formulations most efficiently elicit the immune response desired [39].

1.2.2

Established adjuvant action

Adjuvants can greatly influence the way antigens are detected and processed
by the immune system. Macrophage activation is one well established action
by which adjuvants stimulate responses against antigens [14, 15, 41, 42].
However, one common, yet incorrect, perception is that adjuvants activate
macrophages by similar mechanisms. Recent comprehensive reviews of
adjuvant action [8, 11], demonstrate that the mechanisms of adjuvant action
are poorly understood. The examples below illustrate the wide variation in
mechanisms used by adjuvants to improve antigen presentation and initiate
immune responses.

1.2.1.1 R ep ository (zvater-in-oil em u lsion ) adju van ts. Repository adjuvants,
such as alum and Freund's complete adjuvant, were initially believed to
form an 'antigen depot' at the injection site, allowing the slow release of
antigen and prolonging the time for antigen uptake by antigen presenting
cells (APC) [12]. Prolonged antigenic stimulation by slow antigen release
from the depot was also thought to account for the persistence of high
serum antibody levels over long periods [43]. The evidence now indicates
that the presence of small amounts of antigen on the surface of follicular
dendritic cells located within the lymphoid follicles of draining lymph
nodes sustains the long-term antibody response [44].
Chapter 1
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Aluminium phosphate or aluminium hydroxide-precipitated antigens have
been widely used in human and animal vaccines [10, 45]. Aluminium salts
can increase antibody synthesis, particularly the IgG l subclass in mice [10]. By
contrast, Freund's adjuvant is limited to use in experimental im m unology
because of the painful granulomas that form at the injection site, and the
carcinogenicity
emulsification

of

the

mineral

oil

and

emulsifier.

Additionally,

of protein antigens also results in the denaturation of

unstable antigens and can result in loss of protective epitopes, rendering the
vaccine unsuitable for use [10].

1.2.1.2 O il-in-w ater em u lsio n s. Oil-in-water emulsions are generated when
adjuvants such as N-acetylmuramyl-L-analyl-D-iso-glutamine or muramyl
dipeptide (MDP) are combined with antigen. MDP is a component of the
mycobacterial cell wall and is responsible for the adjuvant activity of
Freund's adjuvants. Oil-in-water emulsions do not form a depot following
injection

[46]. Also, because antigen is added to preformed emulsions,

antigens are not subjected to the mixing or shearing forces encountered
during the emulsification process used to prepare Freund's adjuvant.
Antigens in MDP vaccines can, therefore, be expected to retain their original
structure. It is believed that multimeric antigen presentation on the surface
of adjuvant

oil microdroplets facilitates antigen uptake by APC [46].

Activated C3b bound to the surfaces of antigen-coated MDP particles is also
believed to be targeted by follicular dendritic cells, facilitating endocytosis
and antigen processing [24].

Chapter 1
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MDP and its analogues, including a-aminobutyryl

derivatives,

Syntex

Adjuvant Formulation (SAF; N-acetyl muramyl-L-threonyl-D-isoglutamine
MDP analogue) and lipophilic derivatives (such as N-acetyl muramyl-Lalanyl-D-isoglutaminyl-L-alanine-phosphatidylethanolamine)

have

been

used experimentally to stimulate both cell-mediated and humoral im m une
responses [10, 46, 47]. Like Freund's adjuvant, the adverse side-effects render
MDP and many of its derivatives unsuitable for routine human or anim al
vaccination [10].

1.2.1.3 L ip id A. Lipid A, a component of the lipopolysaccharides of Gram
negative bacteria has significant ability to activate macrophages [10]. The
mechanism of action is also believed to involve the regular arrangement of
antigen on the surface of the oil microdroplets, enhancing uptake by APC
[46]. Synthetic lipid A and Lipid A analogues, such as monophosphoryl lipid
(MPL), have been produced in an attempt to minimize the toxicity of this
adjuvant. The efficacy of MPL has also been enhanced by the addition of
bacterial cell wall derivatives and trehalose dymycolate, which is responsible
for the toxicity attributed to the mycobacteria in Freund's complete adjuvant
[46].

1.2.1.4 B acterial toxins. Binding of cholera toxin (CT) or cholera holotoxin
subunit B (CTB) to the GMl ganglioside receptors in the gut-associated
lymphoid tissue is thought to facilitate its uptake [9]. Genetic fusion of CTB
or Escherichia

Chapter 1
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poorly
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immunogenic

heterologous proteins and administration

as a purified

fusion protein or as a heterologous fusion protein expressed in live bacterial
vectors may serve as potent mucosal antigens for inducing specific antibody
production [48].

1.2.1.5 H ydrocarbon adju van ts. Hydrocarbons, especially those with chain
lengths around C16 are potent adjuvants and lead to strong induction of
cellular immune responses [46]. The mechanism of action is unclear but
modification of antigens by conjugation with fatty acids is known to favour
the development

of a strong delayed type hypersensitivity

response.

Electrostatic association of aliphatic amines, such as dimethyl dioctadecyl
ammonium bromide (DDA Bromide) and avridine b^N-dioctadecyl-N^N'bis(2-hydroxyethyl)propanediamine, with antigen introduces lipid groups
that may generate organized particulate structures of high molecular weight
and improve antigen uptake by APC [46, 49].

1.2.1.6 C ytokines. Stimulation of cytokine synthesis has been identified as an
important part of adjuvant action. Cytokines such as interferon-gamma
(IFN-y), IL (interleukin)-l and IL-2 [50], and colony stimulating factors (CSF)
such as Macrophage-CSF and Granulocyte/Macrophage-CSF [51], mediate
macrophage activation and the induction of adaptive immune responses.
DDA bromide and avridine, for example, strongly induce IL-1 production in
stimulated macrophages [46]. As a result, a number of cytokines, such as IL-1
[34], IL-2 [52], IL-12 [53] and IFN-y [50] have been evaluated for use as
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adjuvants [51]. However, despite the success of several trials, a range of
concerns regarding the toxic effects of multiple cytokine doses, the timing of
doses during the maturation

of immune

responses, the targeting of

cytokines to the appropriate cells, the pleiotropic effects of cytokines,
including

the

induction

immunogenicity

and

of acute

inflammatory

responses,

species-specificity of cytokines,

and

currently

the

render

cytokines impractical as adjuvants [54].

12.1.7 Im m u n o-stim u latin g com p lex es.

Immuno-stimulating complexes

(iscoms) comprise one of the most exhaustively investigated adjuvants [17,
37, 39, 55-89]. Iscoms are synthetic, cage-like structures formed from the
binding of Quil A and cholesterol [46, 66, 69, 70, 73, 74, 90]. Quil A is a
saponin with well established strong adjuvant activity even at low doses [10,
70]. Once formed, iscoms have exposed regions capable of hydrophobic
interaction

with

amphipathic

protein

antigens.

It is

believed

that

multimeric presentation of antigens increases uptake by APC [69]. A wide
range of protein antigens

(predominantly

viral

proteins)

have

been

incorporated into iscom-based vaccines (Table 1.2). The use of preformed
iscoms has also been investigated to improve the immunogenicity of small
peptides, namely Luteinizing hormone releasing hormone, and peptide
fragments of the b-chain of human chorionic gonadotrophin and a malaria
circumsporozoite epitope

Chapter 1
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TABLE 1.2

Examples of vaccines using iscom technology

Organism

Reference

Influenza A virus

[62,91]

Herpes simplex virus type 1

[57]

Parainfluenza virus

[92]

Coxsackie B3 virus

[93]

Pseudorabies virus

[84]

Human immunodeficiency virus-1

[61]

Hepatitis B virus

[75,94]

Measles virus

[56,95]

Bovine herpes virus 1

[83]

Salm onella

Heidelberg

[96,97]

Salmonella

enteritidis

[96,97]

N eisseria gonorrhoeae

[63]

In contrast to the good incorporation of hydrophobic proteins, iscoms
incorporate hydrophilic proteins poorly [39, 72, 76]. Partial dénaturation with
acid to expose hydrophobic residues [72, 75, 98], covalent attachment of fatty
acids such as palmitic acid [76, 99], and addition of phosphatidyl choline [66],
have been used to overcome this limitation. Using a novel liposome-iscom
hybrid

formulation

version

4,

of iscoms, SAMA4 (Skin and Mucosal A djuvant

Patent No. PCT/AU95/00206), Chin et al [100-102] have

demonstrated that antigen

uptake into

iscoms

is facilitated by first

entrapping antigens within unilamellar liposomes. This approach retains
the biological properties of iscoms and improves incorporation of both
hydrophobic and hydrophilic protein antigens into the iscom vehicle [100
103].
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Iscom-based vaccines can elicit very high serum antibody, delayed-type
hypersensitivity (DTH), and class 1 MHC-restricted cytotoxic T cell responses
when administered by peripheral and mucosal routes [73, 102]. Several
factors are believed to contribute to the potent immunostimulating effect of
iscoms. First, the hydrophobic nature of iscoms is thought to enable efficient
and rapid uptake of iscom-associated antigens by APC, thereby m inim izing
the loss of antigen [17, 87]. W atson et al (1989) [37] demonstrated that
antigens incorporated into iscoms are more rapidly taken up by peritoneal
macrophages than antigen emulsified with incomplete Freund's adjuvant.
A prominent neutrophil response was obtained following im m unization
with iscoms in this study but the importance of such a response was not
investigated. Previous work by Beh et al (1985) [35] also demonstrated that
injected antigen associates with neutrophils during its clearance from the
injection

site into draining lymph nodes and spleen, indicating that

neutrophil involvement is important in the immune response following
vaccination.

Second, multimeric antigen presentation to APC is believed to enhance the
immunogenicity of antigens and facilitate activation of APC [59, 86, 87, 90,
92] while the in-built presence of an adjuvant (Quil A) exerts a significant
immunostimulatory effect [46]. The amount of Quil A required to exert an
adjuvant effect in iscoms is several-fold lower than is required when Quil A
is used alone as a conventional adjuvant [69, 71]. Because of this it has been
shown to be safe when administered by intramuscular, subcutaneous and
intranasal routes [67, 78, 99].
Chapter 1

page 11

Interaction between Innate and Adaptive Immune Systems
Activation of macrophages, such as by vaccination, results in the release of
cytokines, complement proteins, coagulation factors and other factors, that
can cause marked and prolonged effects on the recirculation pattern of
lymphocytes,

granulocytes

and

other

macrophages.

Increasing

the

localization of immune effector cells to draining lymph nodes increases
their exposure to antigen and can ultimately lead to induction of adaptive
immune responses [104-106]. Recent studies [107-117] showing how the
innate and adaptive arms of the immune systems interact may help explain
the precise mechanisms by which specific adjuvants enhance induction of
immune responses.

Increased interaction between the innate and adaptive immune

systems

occurs as a result of enhanced phagocytosis, processing and presentation of
antigen by different types of APC, and the release of soluble mediators, such
as IL-1, IL-2 and IFN-y, by activated APC and T cells. The cytokines released
stimulate the growth, proliferation and differentiation of effector cells
involved in the immune response. Primary induction of naive T helper
cells is predominantly effected by one type of APC, called the dendritic cell
[111]. Once activated, T cells can then respond to a broader range of APC,
including macrophages, granulocytes and lymphocytes [108, 112, 113, 118].
The antigenic epitopes presented to T cells by APC determine the antigenic
specificity and the character of the adaptive immune response by directing
the differentiation of T helper cells into Thl and/or Th2 clones [116].
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Protein antigens taken up by phagocytic cells are processed into oligopeptide
fragments

through

two

distinct

pathways.

Exogenously

encountered

antigens, for example, antigens administered by vaccination,

or those

produced extracellularly during bacterial infections, are endocytosed and
proteolytically cleaved into peptide fragments in acidic endosomes in the
cytosol

of

APC

[119].

Peptide

fragments

bind

to

class

II

m ajor

histcompatibility complex (MHC) molecules and are displayed on the surface
of APC for specific recognition by T cell receptors (TCR) on CD4+ T helper
cells. Expression of class II MHC glycoproteins on APC is increased during
phagocytic activity and following stimulation by cytokines, such as IFN-y,
released by activated T helper cells [120, 121]. There is some evidence that
steroid hormones may also affect expression of class II MHC molecules [122].
Class II MHC-antigenic peptide complexes predominantly induce an increase
in antigen-specific antibody production by B cells.

Endogenous antigens, generated within the cytoplasm of cells infected by
intracellular pathogens, are proteolytically cleaved into peptide fragments in
proteasomes in the cytosol. Antigenic peptide fragments associate with class
I MHC molecules and |3-2-microglobulin and are expressed on the cell
surface of affected cells [119, 123]. Engagement of MHC class I-antigenic
peptide complexes with CD8+ T cells increases the level of MHC-restricted
cytotoxicity against affected cells.
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The level of expression of class I or II MHC glycoproteins is an im portant
determinant of the antigen presenting ability of the APC encountering
antigen, and indirectly of the immunogenicity of administered antigens.
George et al (1989) [107] demonstrated that peritoneal macrophages, w hich
have low expression of class II MHC molecules, presented antigen poorly to
co-cultured T cells in vitro. By comparison, skin-derived Langerhans cells,
with higher expression of class II MHC molecules, presented antigen with
greater efficiency, and had a concomitantly greater increase in the number of
proliferating T cells in vitro [107]. DeKruyff et al (1992) [110] and Gajewski et
al (1991) [109] further noted that the type of APC that initially encountered
the antigen plays an important role in determining the character of the
immune response that predominates in different lymphoid tissues. For
example,

activated B cells were

able

to

more

efficiently

stimulate

proliferation of Th2 clones than macrophages [109]. Macrophages, on the
other hand, preferentially stimulated proliferation of Thl cells.

Mikszta et al (1996) [117] demonstrated

that differences in the MHC

haplotype can influence T cell responsiveness to antigenic epitopes, and
affect the immunogenicity of different antigens. MHC haplotype differences
are manifested as variations in antigenic peptide binding affinity to class II
MHC molecules, or differences in the ligand density at the cell surface, both
of which affect antigen processing and presentation by APC [114]. Peptides
with high binding affinity to class II MHC molecules, or peptides that are
presented at high ligand density preferentially induce Thl

responses,

whereas peptides with lower binding affinities to class II MHC molecules or
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with lower ligand densities at the cell surface prime for Th2 responses [114,
116,117].

The complement
immune

protein system is another component of the innate

system that affects induction of adaptive immune

responses.

Binding of C3 fragments to antigen facilitates the uptake and clearance of
antigen by APC in the lymph nodes and spleen [124]. Dempsey et al (1996)
[115] demonstrated that complement activation by antigen reduces the
threshold concentration of antigen required for immunogenicity. Binding of
the C3d fragment of C3 to its receptor (CD21) on the surface of B cells acts as a
bridge that crosslinks

B

cell

CD19 and

CD21, effecting

the

signal

amplification required for normal T-dependent B cell activation [115]. In one
study in which C3d proteins were coupled to the antigen hen-egg lysozyme
(HEL), each additional C3d molecule attached to the HEL molecule enhanced
the immunogenicity of HEL ten-fold [115].

Further advances in the understanding of the interactions between the
innate and adaptive immune systems, such as those described above, may
provide explanations for the different aspects of adjuvant action, and a
means of more effectively manipulating the immune response. Despite the
contributions of previous studies [13, 14, 17, 34, 35, 44, 125, 126], the in v i v o
effects of adjuvant on the different leukocyte populations, in particular, the
nature and extent of changes to leukocyte populations, or the importance of
these changes for eliciting the final immunological

outcomes remains

poorly characterized.
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1.2

1.2.1

MUCOSAL IMMUNITY AND VACCINATION ROUTE

Is mucosal IgA important?

The mucosal

surfaces of the lung gut and urogenital tracts contain

specialized mucosa-associated lymphoid tissues that act as inductive sites for
eliciting immune responses against mucosal pathogens [127, 128]. With the
exception of the female genital tract [129], mucosa-associated lymphoid
tissues contain

predominantly

IgA-committed

B cell precursors with

relatively fewer IgG and IgM-secreting cells [128]. Systemic lymphoid tissues,
by comparison, contain predominantly IgG and IgM-committed precursors,
with only a small proportion of IgA-committed precursors. McDermott and
Bienenstock (1979) [130], Weisz-Carrington et al (1979) [131], Mirski et al
(1981) [132] and others [133, 134] also demonstrated that lymphoblasts from
mucosa-associated lymphoid tissues migrate almost exclusively to other
mucosal sites, while lymphoblasts from peripheral lymph nodes migrate
preferentially to other peripheral sites. This preferential migration may, in
part, be due to expression of organ-specific recognition mechanisms on
migrating lymphoblasts, such as the cell surface markers L-selectin, CD44
and CD71 [135]. Such differences in the anatomical distribution, organization
and antibody isotype responses of different lymphoid tissues have given rise
to the now well established notion of a network of mucosal lymphoid
tissues, or common mucosal immune system, that is functionally separate
to the systemic immune system [136].
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The discovery by Mossman et al [137, 138] and others [109, 139-143] of distinct
T helper cell clones (Thl and Th2 cells) provided further support for a
common mucosal immune

system. The temporal sequence of cytokine

production by T helper cells, as well as the profile of cytokines released by T
helper cells in response to activation, dictate the type of adaptive im m une
response that is elicited [141, 144]. T cells residing in mucosa-associated
lymphoid tissues predominantly secrete Th2 cytokines, IL-4, IL-5, IL-6, IL-10
and Transforming growth factor (TGF)-(3, which promote IgA production
and secretory immune responses [145]. By comparison, T cells residing in
peripheral lymphoid tissues, such as skin-draining lymph nodes and spleen
secrete predominantly T h l cytokines, IL-2 and interferon-gamma, which
generate systemic immune responses [145].

Different studies have demonstrated that declines in the numbers of CD4+ T
cells, or production of TGF-P by these cells, results in low serum and
mucosal IgA levels [146-148]. Thymectomized or athymic mice, for example,
which have low or absent CD4+ T cells, have diminished serum and gut IgA
responses following systemic immunization, although levels of IgM or IgG
are not substantially diminished [149, 150]. Furthermore, reconstitution of
depleted animals with thymus, or intraperitoneal injection of thymus cells,
results in the reappearance of near normal levels of serum IgA and a
considerable increase in intestinal IgA plasma cells [150]. IgA deficiency,
concomitant with low TGF-p levels [151] and low CD4+ cell numbers [152],
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also causes a combined immunodeficiency syndrome that is associated with
increased susceptibility to infections [153].

IgA is the predominant immunoglobulin present in mucosal secretions, and
constitutes greater than 80% of all antibodies isotypes produced in mucosaassociated tissues

[127, 148]. Secretory IgA present in mucosal secretions

possesses two additional components not found on other secreted or
circulating

immunoglobulins.

These

components

are

the

secretory

component (SC) and the J chain [154], The J chain is synthesized by IgAsecreting plasma cells and joins two IgA molecules together. The SC is
synthesized by epithelial cells and is essential for the transport of IgA from
the blood to the mucosa by epithelial cells which line the exocrine glands
[119]. Secretory IgA is selectively transported into the external secretions,
with only a small amount entering the systemic circulation [155]. The
smaller quantities of predominantly monomeric IgA found in serum are
produced primarily by the bone marrow. Serum IgA contributes little to
external secretions, although export occurs via a hepatobiliary route in
species such as sheep and man [128, 155].

Early studies demonstrated the importance of locally secreted antibodies in
protecting against mucosal pathogens of the respiratory tract, such as
parainfluenza

virus

[156] and respiratory syncytial virus

[157]. Many

subsequent studies [91, 158-165] have reinforced the notion that secreted
antibodies, primarily IgA, can protect against mucosal pathogens. Secreted
IgA is believed to inhibit microbial adherence and neutralize toxins more
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efficiently than other immunoglobulin isotypes [148]. IgA also mediates
antibody-dependent cellular cytotoxicity and interferes with the utilization
of growth factors such as iron by bacteria [166]. By preventing absorption of
antigenic material, IgA prevents local inflammation that would otherwise
damage the integrity of the mucosal surfaces [148].

Mucosal IgA is involved in the immune response to infections in the
urinary tract [167], gut [168], respiratory tract [169] and skin [170] in different
species. The correlation between locally secreted IgA and mucosal protection
is also

strengthened

individuals,

by other

with otherwise

data demonstrating

normal

cellular

that IgA-deficient

immune

responses

(for

example, transient deficiency in early childhood), are more likely to suffer
from recurrent infections than individuals with normal IgA levels [171-173].
Schmitt et al (1994) [170] also reported that IgA deficiency in dogs was
associated with a significant

decrease in

capacities by polymorphonuclear

chemotactic

granulocytes, reflecting

and phagocytic
a decline

in

opsonophagocytosis.

1.2.2

Mucosal immunity and immunoglobulin isotypes other than IgA

According to Beard and Ferrante (1989) [174] the contribution of non-IgA
isotypes may be an important undervalued factor in mucosal immunity. As
well as containing IgA-committed plasma cell precursors, the mucosaassociated lymphoid tissues contain IgG and IgM plasma cell precursors [128].
The early lymphoblast transfer studies of McDermott et al (1979) [130]
demonstrated that, like IgA lymphoblasts, relatively large numbers of the
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available IgG lymphoblasts preferentially migrate between different mucosaassociated lymphoid tissues. McDermott and Bienenstock (1979) [130], WeiszCarrington et al (1979) [131], Mirski et al (1981) [132] and others also
demonstrated that smaller,

but detectable numbers

of IgG and IgA

lymphoblasts from peripheral lymph nodes localize in the lung and small
intestine and differentiate into immunoglobulin-secreting
Additionally,

transudation

of serum

antibodies

plasma cells.

to mucosal

surfaces,

particularly IgG, also occurs in a range of animal species [175-178]. IgG is
therefore a major component of mucosal secretions from the gut, lung and
reproductive tracts because of local production and/or transudation from
the serum [129, 179].

Elevations in mucosal IgG are usually present concurrently with elevations
in mucosal IgA in respiratory tract washings [6, 156, 180], intestinal washings
[175], milk, bile [181] and genital secretions [129] in response to infection or
vaccination. These findings suggest that serum antibodies, and locally
produced immunoglobulin

isotypes other than IgA, may be im portant

contributors to the protection of mucosal surfaces. However, the finding of
several immunoglobulin

isotypes in mucosal secretions also makes it

difficult to assess the individual contributions to protection of each. Separate
studies demonstrated that serum antibodies were associated with reduced
viral titres [158, 159], reduced morbidity [156], or complete protection [182]
following viral infection. Similarly, increases in serum antibodies following
vaccination against Vibrio ch olerae [183], A ctinobacillus p le u r o p n e u m o n ia e
[184] and rotavirus [185] were also correlated with protection. In another
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study, mice vaccinated against Sendai virus, produced IgG and IgA in the
lung mucosa, and serum IgA [160]. Significantly, passive immunization of
mice with either IgA or IgG also elicited equivalent levels of protection
against Sendai virus [186].

Marx et al (1989) [167] found that the level of mucosal IgA in the urinary
tract of patients with bladder catheters, cystotomies, urinary tract infections,
urosepsis, chronic

glomerulonephritis

and renal transplants, was not

correlated with susceptibility to urinary tract infections. Even a complete
lack of mucosal IgA in the urinary tract of patients was not necessarily
associated with

increased

incidence

in

urinary

tract infections

[187].

Significantly however, IgG subclass deficiencies are associated with increased
incidence of upper and lower respiratory tract infections [172, 174, 188, 189],
bacterial meningitis [190, 191] and clostridial diarrhoea in children [192]
suggesting that IgG is important for protection. Kzuizenga et al (1990) also
found that IgA deficient individuals secreted larger quantities of IgM into
lacrimal fluid [193]. Together, the data suggests at least a complementary
protective role for IgG or IgM in mucosal secretions with IgA, and a
compensatory role for these immunoglobulin

isotypes in cases of IgA

deficiency.

1.2.3

Mucosal immunity and the vaccination route

With few exceptions, notably polio and typhoid vaccines which can be
administered orally, the vast majority of vaccines are given by peripheral
routes, either intramuscularly, subcutaneously or intradermally (Table 1.1)
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[1,194]. This is as much because of the practicability of the peripheral routes
[3, 6] as the success of the vaccines given by these routes against systemic
diseases, such as Hepatitis B [11]. However, most human

and anim al

pathogens colonize and invade via the mucosal surfaces [195]. Consequently,
the widely held view is that vaccines delivered by peripheral routes are poor
inducers of mucosal IgA, and primarily result in increased production of
serum antibodies which provide only incomplete or no protection against
mucosal pathogens [6, 136, 148, 196]. Incomplete protection may actually
contribute to the development of asymptomatic carriers and the persistence
of the disease in the community [197]. A number of studies [198-200] have
also indicated that systemic lymphoid tissues, which
peripheral vaccination, may suffer age, nutrition

are targeted by

and disease-associated

declines in immune function. If so, the protective efficacy of peripheral
vaccination in these affected groups may be compromised [9].

Mucosal vaccination strategies are of special interest because of the potential
benefits achieved from targeting the common mucosal immune system [9,
136]. Proponents of mucosal vaccination strategies envisage that any of the
mucosal routes, which include oral, nasal, rectal and urogenital routes, may
be useful for generating protective immune responses against im portant
mucosal pathogens [6, 9, 129, 166, 201]. Significantly, combinations

of

different mucosal routes, or mucosal and peripheral routes, may even be
more effective than immunization

by strictly mucosal routes [6]. The

combination of subcutaneous and oral doses, for example, elicited higher
intestinal IgA responses in women than was possible when either route was
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used individually [202]. Nedrud et al (1987) [160] reported that combined
oral/intranasal immunization improved protection against Sendai virus.
Reuman et al (1990) [203] also demonstrated improved recovery of mice after
combined nasal/oral immunization with killed respiratory syncytial virus.

It is anticipated

that mucosal

vaccination

strategies will

avoid

the

limitations of peripheral vaccination by inducing both mucosal and systemic
responses, and have greater community acceptance than injected vaccines
[9]. However, despite the intensive efforts devoted to developing mucosal
vaccination strategies, only few, for example a vaginal vaccine against
recurrent urinary tract infection [204] or oral vaccination against cholera [9]
have reached the level of clinical evaluation. Some of the reasons for the
poor progression

of

mucosal

vaccination

strategies

from

laboratory

evaluations to commercialization are discussed below.

1.2.3.1 Im m u n o to léra n ce.

Oral administration of high doses of soluble

antigen induces antigen-specific tolerance [205]. Such immunotolérance is
the result of anergy [205] and prevents inappropriate immune responses
being mounted against innocuous antigens. At low doses, tolerance is the
result of active cytokine-mediated (TGF-p and IL-4) suppression of the
immune response by T cells induced by vaccination

[205]. Low antigen

doses, such as those in mucosal vaccines, can induce antigen-specific
tolerance at the mucosal surface, rendering the vaccine ineffective [206,
207].
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1.2.3.2 In n ate m echanism s. Orally or intranasally administered antigens are
cleared rapidly by the action of innate physical and chemical protective
mechanisms (for example bronchociliary clearance in the respiratory tract,
and gastric acids and proteolytic enzymes in the gastro-intestinal tract) [119],
possibly contributing to the lack of responses to some mucosal vaccines.
The relatively small surface area of the mucosa-associated lymphoid tissues
compared to the large surface area of the mucosal epithelium also makes
targeting of mucosal

vaccines

more

difficult than

for peripherally

administered vaccines [82,129, 208, 209].

A recent study by Wira et al [122] suggested that antigen presentation, and
therefore the response to mucosal vaccination, in the female reproductive
tract may be enhanced or suppressed at different stages of the reproductive
cycle by changes in the levels of hormones

such as oestradiol and

progesterone. If so, then the stage of the reproductive cycle at the time of
vaccination may be another important consideration for a successful
outcome following vaccination. Thapar et al [82] for example, housed
female mice adjacent to male mice in order to induce oestrus concurrently
with daily vaginal application of vaccine-laden tampons. Even so, no
antibody production occurred locally.

1.2.3.3 A n ato m ical su bcom p artm en talization o f the com m on
im m u n e system .
mucosal
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One of the major attractions for the development of

immunization

originating

from

m u c o sa l

strategies

mucosa-associated

is

the

capacity

lymphoid

of

tissues

lymphoblasts
to

specifically
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migrate to other mucosal sites [127, 130-132, 136, 148]. This m igration
pattern has the potential to generate protective immune
distant mucosal

sites

[136]. Ruedl

et

al

(1993)

responses at

[133] for

example,

demonstrated that oral immunization enhanced the host response in the
respiratory tract against a number of respiratory pathogens. In another
study by Yoshimura et al (1991) [210], intraduodenal and intragastric
immunization decreased the morbidity in guinea pigs from otitis media.
Vancott et al (1994) [211] also demonstrated that the antigen-specific
antibody secreting cells generated by oral immunization migrated to the
bronchus-associated lymphoid tissues and were associated with complete
protection against porcine respiratory corona virus.

However, despite such optimistic results, subcompartmentalization

of

mucosal lymphoid tissues into different anatomical regions actually results
in restricted migration patterns of immune lymphocytes [136]. Holmgren et
al (1996) [212], for example, found that intranasal immunization stimulated
strong IgA responses in the upper respiratory tract and vagina, but not the
gut. Vancott et al (1994) [211] found that intranasal immunization against
transmissible gastroenteritis virus only partially protected mice against
enteric viral infection, whereas oral immunization

provided complete

protection. In studies by Haneberg et al (1994) [213], Holmgren (1996) [212]
and McDermott et al (1996) [214] oral im m unization elicited good im m un e
responses in saliva, upper gut and duodenum, but not the lower gut,
rectum, or upper respiratory tract. Conversely, an intrarectal route was the
best means for eliciting lower gut and rectal responses, but did not elicit
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responses in the upper gut or at more distant sites [212, 213]. Similarly, oral
im m unization with an oral cholera vaccine induced only weak antibody
responses in the female genital tract compared to direct local intravaginal
im m unization

[129]. Kozlowski et al (1997) [208] found that significant

rectal, vaginal or oral antibody responses were only obtained by local
im m unization at the respective sites. These observations currently place
strong limitations

on

the

practical

usefulness

of

certain

mucosal

vaccination routes for eliciting protective immunity at distant mucosal
sites.

Different approaches have been used to improve the responsiveness to
mucosal vaccines. The quantity of antigen administered and the number or
frequency of vaccine doses is often much greater for mucosal vaccines than
is necessary using peripheral vaccination strategies [89, 148, 215]. Because of
this, practical and economic considerations are an important factor.

Alternatively, the suitability of a number

of mucosal

adjuvants

that

overcome mucosal tolerance and increase the immunogenicity of antigens
is current under evaluation [21, 215, 216]. Cholera toxin [217], the cholera
toxin B subunit [148, 195], Escherichia coli heat labile toxin [218], muram yl
dipeptide [136] and iscoms [73] are all effective at overcoming mucosal
tolerance to orally administered vaccines. However, because of the potential
for adverse side-effects, such as bystander responses against normal flora,
adjuvant toxicity, or local inflammation,

the safety of some of these

form ulations is still being evaluated [3, 9, 136]. A number of alternative
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vaccine delivery systems, including live attenuated recombinant bacterial
and viral vaccines [6,194, 218-220] or liposome-entrapped vaccines [221], that
may overcome tolerance and bypass the problems of toxicity, are also being
investigated.

1.2.4

Mucosal immunity and peripheral vaccination

Central to the tenet that peripheral immunization routes are unable to elicit
protective levels of mucosal immunity is the finding that T cells in mucosaassociated lymphoid tissues predominantly secrete Th2 cytokines (IL-4, IL-5,
TGF-P), which promote IgA production and secretory immune responses
[145], whereas T cells in systemic lymphoid tissues predominantly secrete
Thl cytokines (IL-2, IFN-y), which promote serum antibody responses.
Flowever, Daynes and Araneo [145, 222] have demonstrated that T cells
within a particular lymphoid compartment are not irreversibly committed
in a functional sense to effect either Th l or Th2 responses, but may be re
programmed in v iv o by the use of immunomodulators. They found that
mice immunized subcutaneously, concurrently with topical applications of
1,25-dihydroxy vitamin D, a natural immunosuppresant
from

Thl

to Th2

cytokine

production,

causing

[223], switched

antigen-specific

IgA

production [145].

In fact, there are many examples in the literature where mucosal im m une
responses are elicited alongside systemic responses following peripheral
immunization
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subcutaneous

[202], and

intradermal

immunizations

explanation for the ability of peripheral immunization

[102,

161].

One

routes to elicit

significant mucosal immune responses may be the im m unom odulatory
properties of adjuvants used in the vaccination regimes, such as iscoms [82],
Freund's

adjuvant

im m unization

[225] and SAMA4

[102].

Alternatively,

peripheral

routes may be inherently capable of mucosal im m une

responses. W hether immunization without the use of adjuvant elicits the
same response has not been tested in these cases.

The intradermal route is not as frequently used for vaccination as the
intramuscular and subcutaneous routes [1]. However, previous studies have
shown that intradermal vaccination can elicit greater and more rapid
immune responses [1, 226], and with much smaller antigen doses [227] than
the other routes. Recently, the intradermal route has also been shown to be
more effective for eliciting antigen-specific responses to DNA vaccines than
either intrasplenic or intranasal immunizations [228]. Chin et al [100, 103]
demonstrated that bacterial antigens complexed with the adjuvant, SAMA4,
stimulated strong antigen-specific IgG and IgA antibodies in the respiratory
tract washings of intradermally immunized sheep and pigs. When other
adjuvants were used intradermally instead of SAM A4 (incomplete Freund's
adjuvant, aluminium hydroxide, or algammulin, cholera toxin B or antigen
entrapped in microspheres) mucosal immune responses were not elicited
[102].
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One reason for the ability of the intradermal route to effectively stimulate
both mucosal and systemic antibody responses may be that the skin, like the
mucosal surfaces of the gut, lung and reproductive tract, is a natural site
where exogenous antigens are encountered. As a result the dermis of the
skin

is

well

endowed

with

specialized

lymphoid

tissues

and

a

comprehensive range of immune effector cells capable of rapidly initiating
immune responses [228]. Damaged kératinocytes produce IL-1, IL-6, TN F-a
and heat shock proteins that rapidly activate

and recruit

APC and

lymphocytes to the site of injury [229]. Langerhans cells, a dendritic cell that
resides in the skin, macrophages and polymorphs located in the skin can
phagocytose antigen, rapidly migrate to skin-draining lymph nodes and
initiate immune responses [35, 230].

1.3

PROJECT AIMS

The demonstration by Chin et al [100-103] that intradermal im m unization
with SAMA4-containing vaccines induces antigen-specific systemic and
mucosal immunity is significant given that such responses are major public
health and veterinary objectives for disease prevention.

The effect of

immunizing via the intradermal route and the effect of SAMA4 on the
immune response remain poorly characterized, in particular, the nature and
extent of changes to leukocyte populations following immunization, and
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the importance of these changes for eliciting the final im m unological
outcomes. In this context, the objectives of this project were:

• To examine by flow cytometry the effects of intradermal im m unization
on the distribution of leukocyte populations in lymphoid and n o n 
lymphoid compartments of the mouse (Chapters 2, 3 and 4).

• To assess the hum oral

and cellular immune

response in mice to

intradermal immunization (Chapters 5 and 6).

• To examine in mice the protective efficacy of an intradermal vaccine
against the mucosal pathogen A. pleuropneumoniae
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CHAPTER 2
Flow Cytometric Analysis of
Leukocyte
Populations
in
Intradermally Immunized Mice

2.1

INTRODUCTION

Most studies of adjuvant action focus on the ability of adjuvants to enhance
humoral immune responses against co-administered antigens [11, 26, 28, 31,
34, 35, 44, 82, 126, 231]. Consequently there has been little advance in
understanding the mechanisms of adjuvant action. Earlier studies [13, 14, 34,
126] provided useful insights into adjuvants, such as identifying substances
with adjuvant properties, describing differences in the rate of antigen
clearance from the injection site [35] or mode of antigen presentation by
different adjuvants [17, 44, 125], and identifying macrophage activation and
alteration of lymphocyte recirculation patterns as a fundamental action of
many adjuvants [14-16, 41]. However, as documented by Nervig et al

[11]

and Powell et al [8], the development of a wide range of adjuvants that differ
in formulation and delivery routes has made it difficult to study or compare
the mechanisms

of adjuvant action. It is also significant that despite

intensive research efforts, and the development of a plethora of adjuvants,
very few adjuvants are registered for use in commercial vaccines [39].

Previous studies have demonstrated that antigens complexed with the
liposome-iscom

hybrid adjuvant,

SAMA4, can stimulate IgG and IgA

responses in the respiratory, reproductive and gastrointestinal tracts, and
serum

antibodies when

Intradermal injection

given intranasally or intradermally

of SAMA4-adjuvanted

ovalbumin

[100-102].

also generates

strong antigen-specific T cell cytotoxicity (described in Chapter 6 and
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published elsewhere [102]). Therefore, this adjuvant was used as a model to
investigate the effect on leukocyte populations in mice.

To examine the adjuvant effect of SAM A4, outer membrane proteins (OMP)
from the Gram-negative

bacterium, Actinobacillus

p leu ro p n eu m o n ia e,

were complexed with SAMA4. Antibodies specific against OMP are present
in convalescent sera of infected swine and are important for protection
against disease [232-236]. Additionally, OMP are extensively shared between
the different A. p leu ro p n eu m o n ia e serovars [237] and may provide cross
protection against different serovars. To attribute cellular changes to the
individual effects of antigen, adjuvant or adjuvanted antigen, mice were
also immunized intradermally with adjuvant (SAMA4) or antigen (OMP)
alone. Flow cytometry provided a simple technique for quantifying the
effects of immunization with the different components.

2.2.

2.2.1

MATERIALS AND METHODS

Mice

Female BALB/c mice aged 8 to 12 weeks were purchased from a commercial
supplier (CSIRO Animal Production and Processing Facility, North Ryde,
Australia) and maintained at 23±1 °C under a 12 h diurnal cycle. Antibiotic
free commercial mouse pellets and water were supplied ad libitum.
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2.2.2

Preparation of outer membrane proteins

Outer membrane

proteins

(OMP) were purified from

A ctinobacillu s

pleur opneumoniae, serovar 1, strain HS54 [238] as described previously [239,
240]. Briefly, bacteria were centrifuged (10,000 g for 20 min at 4
washed three
resuspended

times
in

10%

with

sterile

(w/v)

saline

sucrose

(0.85%
dissolved

NaCl)
in

°C) and

before
10

mM

being
N2-

hydroethypiperazine N'-2-ethane sulfonic acid (HEPES) buffer, pH 7.2,
containing 5 mM phenylmethylsulfonylfluoride (PMSF; Sigma, St. Louis,
MO, USA). Total bacterial cell homogenates were prepared with 3 cycles in a
20 K French pressure cell at 845 kg cm2. Cellular debris and particulate
matter were removed by centrifugation (10,000 g for 30 min at 4 °C). Total
membrane vesicles in the supernatant were pelleted by ultracentrifugation
(150,000 g for 90 min at 4 °C) through 20% sucrose in 10 mM HEPES, pH 7.2.
Inner membrane protein vesicles were extracted with sodium laurel
sarcosinate (SLS) at a final concentration of 2% w/v (in 10 mM HEPES, pH
7.2). The suspension was rotated overnight at 4 °C and then layered onto a
discontinuous sucrose gradient composed of successive layers of 20, 40 and
60% (w/v) sucrose (in 10 mM HEPES, pH 7.2) and centrifuged at 150,000 g for
90 min at 4 °C. The band at the 40%/60% interface was aspirated and diluted
with 10 mM HEPES, pH 7.2 before centrifugation at 150,000 g for 90 min. The
resulting pellet of outer membrane proteins was resuspended in 10 mM
HEPES, pH 7.2.
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2.2.3

Vaccine preparation and im m unization schedule

An adjuvanted vaccine was prepared by com plexing OMP with SAMA4, a
skin and mucosal adjuvant, as described previously [102]. Briefly, OMP (1
mg/ml) was solubilized in 0.1% MEGA-10 (decanoyl-N-m ethylglucam ide;
Sigma) prepared in 4.5 ml of a 25 mM HEPES, 0.15 M NaCl, pH 7.4 buffer.
OMP-containing liposomes were formed by sonicating

OMP (Branson

Sonifier Cell Disruptor B15 with microtip attachm ent; 70% full power, 3 x 1
min

cycles)

in

the

trim ethyl-am m onium

presence

of

N -(l-(2,3-dioleoyloxy)propal)-N ,N ,N -

methyl sulphate (DOTAP; Boehringer M annheim ,

Castle Hill, NSW, Australia). Im m unostim ulating complexes (iscoms)
were prepared by mixing

the liposomes

with

0.2%

MEGA-10

[69]
(final

concentration), 0.75 mg phosphatidyl choline, 0.75 mg cholesterol and 0.06%
Quil A (Superfos Biosector a/s, Frydenlundsvej 30, DK-Vedbaek, Denmark).
The mixture was rotated slowly overnight at room temperature. SAM A4
was prepared in an identical manner, except that OMP was excluded from
the formulation.

Each dose of OMP in the vaccine or as antigen given alone, delivered a
maximum of 30 pg protein, determined by a commercial bicinchoninic acidbased protein estimation kit (Pierce Chemical Co., Illinois, USA) and 0.6 ng
Quil A. Mice (65 per group) were vaccinated intraderm ally with 100 ¡ti of
either PBS, pH 7.2 (Control group), SAMA4 (Adjuvant group), OMP (OMP
Antigen group) or SAMA4-OMP (OMP Vaccine group) on Days 0 and 7.
Before injection, an area on the middle to upper back of the mouse was
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shaved using hair clippers. A fold of skin was held between the index finger
and thumb and the preparation injected at one site. A vesicle or blister
formed at the injection site and disappeared over several hours. On Days 0,
1, 3, 6, 8, 11, 14, 21 and 28, four mice from each group were euthanased by
intraperitoneal injection with 50 ^il of 300 mg/ml sodium pentobarbitone
(Jurox, Silverwater, NSW, Australia). Mice were exsanguinated and the
spleen, lung and thymus were removed.

2.2.4

Tissue processing and recovery of cells for flow cytometry

Spleens were teased in ice-cold FACS buffer (PBS containing 1% {v/v} foetal
calf serum {FCS} and 0.1% {w/v} NaN3, pH 7.2) and released cells were
pelleted by centrifugation (200g for 10 min at 4 °C). Erythrocytes were
removed by hypotonic lysis in 4.5 ml of distilled water. Isotonicity was
restored immediately by the addition of 0.5 ml of Hanks Balanced Salt
Solution (10 times normal concentration; Trace Scientific, Clayton Vic,
Australia) and 5 ml of ice-cold FACS buffer. The cells were centrifuged and
resuspended in ice-cold FACS buffer. Thymocytes were obtained by gently
forcing the thymus through a stainless steel sieve. The cells were pelleted by
centrifugation (200g for 10 min at 4 °C) and resuspended in ice-cold FACS
buffer.

Peripheral blood leukocytes (PBL) were prepared from blood samples pooled
from pairs of mice in each group. Erythrocytes were lysed with 0.83%
ammonium chloride lysing buffer (0.83% { w / v}N H 4C1, 0.1% {w /v}K H C 03,
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and 0.004% {w/v} Na4EDTA) [241]. PBL were washed three times in ice-cold
FACS buffer.

Lung cell suspensions were prepared by collagenase-digestion of lung tissue
[242, 243]. Briefly, the pulmonary vasculature in euthanased mice was
perfused through the pulmonary artery with PBS, pH 7.2. Lungs were then
removed, finely minced with a scalpel blade and suspended in 10 ml of
RPMI-1640 (Life Technologies, Mulgrave, Vic, Australia) supplemented with
10% (v/v) newborn calf serum

(NBS; Life Technologies),

150 U/ml

collagenase type VIII, EC 3.4.24.3 (Sigma) and 50 U/ml deoxyribonuclease I,
EC 3.1.21.1 (Sigma). The tissue pieces were shaken at 250 rpm for 90 min at 37
°C on a benchtop flask shaker (Adolf Kuhner AG Basel CH Minishaker) and
then passed through a stainless steel sieve to remove undigested debris.
Filtered cells were washed twice with ice-cold FACS buffer.

Each batch of collagenase was tested before routine use to determine to
optimum concentration for release of cells from lung tissue. Lungs were
removed from mice (n = 5) and divided into equal portions by weight. Lung
pieces were minced and digested with different amounts of collagenase and
the numbers of viable cells recovered enumerated with a haemocytometer
(Reichert Scientific Instruments, Buffalo, NY, USA). Fig. 2.1 shows the cell
recovery for one batch of collagenase.
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2.2.5

Histology

Spleens were removed from freshly killed mice belonging to the Control
and OMP Vaccine groups and fixed in 10% (v/v) phosphate-buffered
formalin. The spleens were embedded in paraffin using standard techniques.
Sections of 1 ¡im thickness were prepared and stained with haematoxylin
and eosin (H&E) for microscopic examination.
15-1

75 U /m l
90 min

150 U /m l
45 min

150 U /m l
300 U / ml
530U/ml
I----------------------|----------------- *
90 min

Digestion Conditions
FIGURE 2.1. Optimization of collagenase activity for digestion of lung tissue
for lot 83H6846.

2.2.6

Phenotypic staining of cells

Routinely, cell numbers were quantified using a haemocytometer

and cell

suspensions adjusted to 2 x 107 cells/ml with ice-cold FACS buffer. 1 x 10
cells (in 50 \d of ice-cold FACS buffer) were added to each well of a 96-well
round-bottom plate and incubated for 5 min at room temperature with 0.02

Chapter 2

page 38

M-8

anti-Fcy

n/IH

monoclonal antibody, clone 2.4G2 (Pharmingen, San

Diego, CA, USA) to decrease non-specific Fey II/Ill-mediated antibody
binding to different cell types. Cells were then incubated with anti-m urine
monoclonal antibodies obtained from Pharmingen (Table 2.1).

TABLE 2.1. List of antibodies used for flow cytometry
Specificity

Label

C D 3 -e

F IT C

H a m s t e r Ig G

1 4 5 -2 C 1 1

[24 4 ]

T h y 1 .2

F IT C

R a t Ig G 2 b

3 0 -H 1 2

[244]

a ß T cell r e c e p t o r

F IT C

H a m s t e r Ig G

H 5 7 -5 9 7

[24 5 ]

yô T ce ll r e c e p t o r

PE

H a m s t e r Ig G

GL3

[244]

CD4

F IT C o r P E

R a t Ig G 2a

R M 4 -5

[244]

C D 8a

P E o r B io tin

R a t Ig G 2 a

5 3 - 6 .7

[244]

C D llb (M a c -la M )

B io tin

R a t Ig G 2 b

M l / 70

[246]

G r-1

PE

R a t Ig G 2 b

R B 6 -8 C 5

[247]

C D 4 5 R /B 2 2 0

PE

R a t Ig G 2 a

R A 3 -6 B 2

[248]

Class

Clone

Reference

The different antibody cocktails contained combinations of 0.04 pg of FITCconjugated anti-CD3 (clone 1 4 5 -2 0 1 ), 0.04 pg of PE-conjugated anti-CD4
(clone RM4-5), 0.04 pg of PE-conjugated anti-CD45R/B220 (clone RA3-6B2),
0.05 pg PE-conjugated anti-Gr-1 (clone RB6-8C5), 0.2 pg of biotin-conjugated
anti-Mac-1 (clone M l/ 70) or 0.1 fig of biotin-conjugated anti-CD 8a (clone 53
6.7) in a total volume of 50 pi. Cells were incubated in the dark at 4 °C for 40
min and then washed three times by repeated centrifugation (300g for 5 m in
at 4 °C) and resuspension in ice-cold FACS buffer. Cells stained w ith
biotinylated conjugates were incubated with 0.1 pg streptavidin-Cy-chrom e

Chapter 2

page 39

(Pharmingen) dissolved in 100 ¡al FACS buffer at 4 °C for another 40 min and
washed as previously described. Cells were fixed in 200 ^1 of FACS Lysing
Solution (Becton-Dickinson, Mountainview, CA, USA) for flow cytometry.

2.2.7

Flow cytometry

Flow cytometry of cells was performed

using

a FACSORT

(Becton-

Dickinson) equipped with a 15 mW air cooled argon-ion laser operating at a
fixed wavelength of 498 nm. The fluorescent signals were collected through
a 530 nm filter for FITC (FL1), a 585 nm filter for PE (FL2) and a 630 nm filter
for Cy-chrome (FL3). Optimal instrument settings were established before
each run according to the manufacturer's instructions (Table 2.2). Identical
preparations of cells were stained with species-matched immunoglobulin
isotype controls (purchased from Pharmingen) to determine positive and
negative cut-offs. FSC (forward light scatter) and SSC (side light scatter)
parameters were recorded linearly and fluorescence intensity recorded
logarithmically. A minimum of 10,000 events were acquired and data were
stored in list mode for each sample.

Acquired data was analysed with CellQuest research software (BectonDickinson). Fig 2.2a depicts leukocyte populations separated on the basis of
their FSC and SSC properties. Fig. 2.2b and Fig. 2.2C, respectively, depicts the
same cells separated on the basis of the fluorescent intensity of specific
fluorescent cell surface markers. Cells located in the lower left quadrant were
considered negative for both cell surface markers, while cells located in the
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upper right quadrant were positive for both cell surface markers. Cells
located in the upper left or lower right were positive for the corresponding
cell surface marker. The identity of different leukocyte populations was,
therefore, deduced from the level of expression of fluorescent cell surface
markers (Table 2.3).

TABLE 2.2. Typical FACSort instrument settings for detection of threecolour fluorescence

Voltage

Amp Gain

Mode

FSC

EOO

1.65

Linear

SSC

372

1.00

Linear

FL1

653

1.00

Log

FL2

554

1.00

Log

FL3

641

1.00

Log

Parameter

Detectors

Com pensation
FL1 - %FL2

0.4

FL2 - %FL1

36.5

FL2 - %FL3

2.6

FL3 - %FL2

17.8
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FIGURE 2.2. (a) Two-dimensional FSC/SSC dot plot of a splénocyte
suspension. Region RI corresponds to acquired events having light scatter
attributes of lymphocytes and monocytes. Region R2 corresponds to acquired
events with light scatter attributes of granulocytes, (b) Two-dimensional dot
plot of the same splenocyte suspension stained with FITC-anti-CD4 and
Biotin-anti-CD8 cell surface markers (c) Two-dimensional dot plot of the
same splenocyte suspension stained with PE-anti-Gr-1 and Biotin-anti-Mac-1
cell surface markers.
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Absolute cell numbers for the different phenotypes were obtained by
m ultiplying the total cell counts for each cell suspension obtained using a
haemocytometer [249] by the percentage value obtained by flow cytometry.

TABLE 2.3.

Cell surface expression
leukocyte populations

Leukocyte Population

of leukocyte

by different

markers

CD3

CD4

CD8

T helper cells

+

+

-

-

-

-

T cytotoxic cells

+

-

+

-

-

-

B cells

-

-

-

+

-

-

Monocyte /macrophage

-

-

-

-

-

+

Granulocytes

-

-

-

-

+

+

B220

Gr-1

Mac-1

+ : Denotes positive for cell surface expression;
Denotes negative for cell surface expression

2.2.8

Assessment of thymocyte viability by flow cytometry

In a separate experiment, in v iv o cell necrosis and apoptosis in the thymus
from the different groups (3 mice per group) were determined, at 12 h
intervals over a 60 h period, following intradermal immunization. To assess
cell necrosis, thymocytes were stained with 0.1% trypan blue (Sigma) for 2
min and enumerated with a haem ocytom eter. A large number of m ethods
are available for detecting apoptosis in cells [250-265]. Staining cells with
either

a hypotonic

solution

of propidium

iodide

[252]

or

7-am ino

actinomycin D [253] are two such methods routinely employed for the
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detection of apoptosis in vitro. Therefore, a preliminary experiment was
conducted to establish instrument parameters for detection of apoptosis by
flow cytometry using these methods.

A stock solution of dexamethasone (10'3 M) was prepared by dissolving
0.0043 g of dexamethasone Acetate (Sigma) in 10 ml AR ethanol. The stock
solution was diluted 100-fold with RPMI-1640 supplemented with 54 mg/ml
sodium benzyl penicillin (Commonwealth Serum Laboratories, Parkville,
Australia),

90 mg/ml

(Cytosystems,

streptomycin

Castlehill,

(Cytosystems) 58 mM

NSW,

sulfate

Australia),

(3-mercaptoethanol

(CSL), 2mM
2 mM

L-glutamine

sodium

(Biorad, North

pyruvate

Ryde, NSW,

Australia) and 10% (v/v) FCS (Life Technologies).

Pooled thymocytes from 2 female BALB/c mice aged 8 to 12 weeks were
obtained as described above. Dexamethasone was used to induce apoptosis in
murine thymocytes [264]. Aliquots of 2 x 106 cells were resuspended to a final
volume

of 2 ml

in

dexamethasone

to

give

final

dexamethasone

concentrations ranging from 10'5 to KT8 M. Cells were incubated in 24 well
tissue culture plates for 21 h in a humidified 5% C 0 2 incubator at 37 °C.

22.8.1 Hypotonic

Propidium

Iodide

M ethod. 1 ml of each thymocyte

suspension was centrifuged (200 g for 10 min at 4 °C) and gently resuspended
with 1 ml hypotonic propidium iodide (PI) solution (50 fxg/ml propidium
iodide {Pharmingen} in 0.1% {w/v} tri-sodium citrate {BDH, Poole, England}

Chapter 2

page 44

plus 0.1% {v/v} Triton X-100 {Sigma}) in 12 x 75 ml polypropylene tubes
(Technoplas, St.Mary's, Australia). The tubes were stored overnight at 4 °C in
the dark before flow cytometry [252]. The propidium iodide fluorescent
signals of individual nuclei were acquired at a low flow rate on the flow
cytometer through the 585 nm filter (FL2) and the data recorded on a linear
scale. FSC and SSC were simultaneously measured on a logarithmic scale.
FL2-area and FL2-width were measured on a linear scale and used to exclude
cell debris and dead cells as previously described [266]. A minimum of 10,000
events were collected per sample.

Apoptotic and live

cells displayed

measurable area versus width parameters, whereas debris demonstrated
negligible width or area and low FSC and SSC parameters. Data was stored in
list mode

and

analysed using

CellQuest

research

software

(Becton-

Dickinson). Logarithmic scale histograms for cells in cell cycle were obtained
[266]. Using this technique, apoptotic nuclei were distinguished by their
hypodiploid DNA content from the diploid DNA content of normal nuclei.

22.8.2 7-am ino-actinom ycin-D

m eth o d .

Thymocytes were initially stained

with FITC anti-CD4 and PE anti-CD8 antibodies, as described in above. For
detection of apoptosis cells were washed twice in PBS, pH 7.2, resuspended
in 200 pi of 20 pg/ml 7-amino actinomycin D (7-A AD; (Calbiochem, La Jolla,
CA, USA) in ice-cold FACS buffer and incubated at 4 °C in the dark for at
least 20 min before flow cytometry [253]. At least 10,000 events were collected
using a FACSORT through the 530 nm filter for FITC (FL1) and the 585 n m
filter for PE (FL2). The red fluorescence from 7-AAD was collected through
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the 630 nm filter (FL3). Data was recorded on a logarithmic scale. FSC and
SSC were simultaneously measured on a logarithmic scale. Cell debris was
excluded by raising the FSC threshold. The correct threshold value was
selected experimentally. Dead, apoptotic and live cells were distinguished by
logarithmic scale dot plots of phenotypically gated subpopulations [266].

2.2.9

Assessment of natural killer (NK) cell cytotoxicity in intradermally
immunized mice

22.9.1

Im m unization

of

m ice.

BALB/c

mice

(2

per

group)

were

intradermally immunized with 100 \d of either PBS, pH 7.2 (Control group),
SAMA4 (Adjuvant group), OMP (OMP Antigen group) or SAMA4-OMP
(OMP vaccine group) on Days 0 and 7. Mice were kept at 23 ± 1 °C under a 12
h day/night cycle. Antibiotic-free commercial mouse pellets and water were
supplied ad libitum.

2.2.92 Positive control fo r assessm ent of NK cell activity. Splenic NK cells
were generated by subcutaneously immunizing one mouse with 5 x 106
plaque-forming units (pfu) of Semliki Forest Virus (SFV) on one occasion
[267]. These cells were used as a positive control.

2.2.9.3Target cell lines used and 51 C hrom ium -labelling

o f target cells. N K-

susceptible YAC-1 thymoma

P815 mastocytoma

tumour

cells

were

provided

cells and NK-resistant
by Dr Arno

Mullbacher

(Division

of

Immunology and Cell Biology, John Curtin School for Medical Research).
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YAC-1 and P815 target cells were suspended at a concentration of 6 x 106
cells/ml in 500 pi of F15 medium (Gibco-BRL, Life Technologies, Mulgrave,
Vic, Australia) supplemented with 5% (v/v) FCS and incubated with 100 pi
of 6 mCu/ml 51Cr (Amersham, Arlington Heights, IL, USA) for 1 h at 37 °C.
Cells were washed twice and resuspended in F15 medium to give a final cell
concentration of 2 x 105 cells/ml.

22.9.4 Phenotyping of effector cells. Splenocyte suspensions (107 cells/ml)
were prepared in F15 medium as described in Chapter 6, Section 6.2.4.
Splenocytes were obtained from the SFV-immunized mouse on Day 2 post
infection and from intradermally immunized mice on Day 9 (Day 2 post
immunization).
populations,

To

determine

the

phenotype

splenocytes were selectively

of

the

effector

depleted by treatment

cell
with

antibodies and complement. Cells (107) were incubated for 30 to 40 min at 4
°C with either 50 pi of anti-Thy 1.2 (Serotec, Australian Laboratory Services,
Rockdale, Australia; clone F7D5; 1/400 dilution), 250 pi of anti-CD8 (Olac,
Bicester, Oxon, UK; clone 31M; 1/30 dilution) or 100 pi of anti-asialo GM:
(Wako Chemicals, US; 1/100 dilution). Cells were incubated for a further 45
min at 37 °C after adding 100 pi of rabbit complement (Low Tox M; Cedar
Lane Laboratories, Hornby, Ontario, Canada). Following incubation, cells
were washed twice in F15 medium and resuspended in 1 ml of the same
medium for use in NK cell assays.
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2.2.9.5Measurement of NK cell activity. NK cell activity was assayed by a 6 h
51Cr-release assay as described elsewhere [267]. Splenocytes (effector cells)
were assayed in triplicate for cytotoxicity against 2 x 104 51Cr-labelled YAC-1
target cells by incubating cells at effector-to-target ratios ranging from 30:1 to
1:1. After incubating cells at 37 °C for 6 h in a humidified C 0 2 incubator, 100
pi of cell-free supernatants were removed and the radioactivity measured in
a gamma-counter. To measure non-specific cytotoxicity, splenocytes were
incubated with 51Cr-labelled P815 mastocytoma tumour cells in a similar
fashion. Spontaneous 51Cr release was determined by incubating 51Crlabelled target cells in

culture

medium.

Maximal

51Cr release

was

determined by incubating 51Cr-labelled target cells in 2% Triton X-100.
Percentage cytotoxicity was calculated as follows:

% cytotoxicity =

Experimental release - spontaneous release

x

100%

Total release - spontaneous release

2.2.10

Statistical analyses

Except for the assessment of thymocyte viability, the experiments described
were repeated on three separate occasions. The results reported here
represent the combined mean (± standard error of the mean, or sem). The
means of different groups at individual time points were compared by two
tailed Students f-test. Changes were considered significant at P < 0.05.
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2.3

2.3.1

RESULTS

Cellular changes in the spleen following intradermal immunization

No significant differences were detected in the body weights of mice in the
different groups following immunization (Fig. 2.3a). Over the same period,
the spleens of mice in the OMP Vaccine group increased in weight and were
significantly heavier than the spleens in all other groups between Day 3 (P <
0.05) and Day 21 (P < 0.0005) (Fig. 2.3b). The spleens of mice in the Adjuvant
group also increased in weight by 2-fold on Day 3 (P < 0.008) before declining
by Day 8. In response to the booster injection with adjuvant, spleen weight
increased again (2-fold) at Day 11 (P

< 0.01) in the Adjuvant group.

Thereafter spleen weight returned to normal by Day 21. Smaller increases in
spleen weight of about 1.4-fold were observed between Days 11 and 14 in
mice belonging to the OMP Antigen group (P < 0.0005).

Splenocyte numbers in the different treatment groups remained unchanged
following primary immunization (Fig. 2.4) but rose significantly (2- to 3-fold)
in all groups (except controls) in response to booster im m unization,
reaching a peak at Day 8 (P < 0.02). Splenocyte numbers in mice belonging to
the OMP Antigen

group returned to normal

levels rapidly whereas

splenocyte elevations in mice from the Adjuvant group were sustained for a
slightly longer period. The greatest and most sustained elevations

in

splenocyte numbers were elicited following booster immunization of mice
in the OMP Vaccine group. Splenocyte numbers in this group did not return
to normal until Day 21.
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Day
FIG URE 2.3. Temporal change in (a) total body weight and (b) spleen weight
of mice from Control (unfilled squares), OMP Antigen (unfilled diamonds),
Adjuvant (filled circles) and OMP Vaccine (filled diamonds) groups
following intraderm al im m unization. Each data point represents the m ean
(± sem) of at least 4 mice per group. Arrows designate the time of
vaccination.

FIGURE 2.4. Temporal change in total splenocyte numbers in mice from
Control (unfilled squares), OMP Antigen (unfilled diamonds), A djuvant
(filled circles) and OMP Vaccine (filled diamonds) groups following
intradermal immunization. Each data point represents the mean (± sem) of
at least 4 mice per group. Arrows designate the time of vaccination.
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The proportion of granulocytes (Mac-1+Gr-1+) increased significantly (3-fold)
by Day 3 after primary immunization in mice from the OMP Vaccine group
(P < 0.001) (Fig. 2.5). This rise was enhanced by a further 4.6-fold follow ing
the second injection, peaking between Days 8 to 11 (P

< 0.005). The

proportion of granulocytes declined thereafter but remained significantly
elevated for greater than 28 days (P < 0.0005). Injection of either antigen or
adjuvant elicited much smaller increases in granulocyte numbers over the
same period, with the second injection having no booster effect. By contrast,
splenic

macrophages

(Mac-1+Gr-T) rose much

more

slowly

follow ing

vaccination, and then only less than 2-fold in mice from the OMP Vaccine
group (Fig. 2.6).

Significant changes in splenic T cells (CD3+CD4+ and CD3+CD8+) or B cells
(CD3'B220+), as a proportion of total lymphocyte numbers, were not detected
by flow cytometry over 28 days in all groups (Fig. 2.7a to c). This was m ost
likely because only relatively few T or B cell clones had specificity toward the
administered antigen. Small discrepancies in total percentages of phenotypes
reflected the sum of errors generated from a) variations between different
experiments; b) lack of absolute cut-off points for positivity of staining; and
c) the sum of percentages from different stains. This result demonstrated
that, although immunization did not significantly alter the total lymphocyte
population,

antigen-specific T and B cell clones

were

stimulated

by

im m u n ization .
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60

% Granulocytes

FIGURE 2.5. Temporal change in the percentage of Gr-1+Mac-1+ cells
(granulocytes) in the spleens of mice from Control (unfilled squares), OMP
Antigen (unfilled diamonds), Adjuvant (filled circles) and OMP Vaccine
(filled diamonds) groups following intradermal immunization. Each data
point represents the mean (± sem) of at least 4 mice per group. Arrows
designate the time of vaccination.

Day
FIGURE 2.6. Temporal change in the percentage of Gr-TMac-l+ cells
(macrophages) in the spleens of mice from Control (unfilled columns), OMP
Antigen (hatched columns), Adjuvant (stippled columns) and OMP Vaccine
(filled columns) groups following intradermal immunization. Each data
point represents the mean (± sem) of at least 4 mice per group.
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Histological analysis of spleen sections was conducted to examine changes
elicited by intradermal immunization. At Day 11, H&E sections showed that
splenic lymphoid nodules were comparable in size and number in both
Control and OMP Vaccine groups. However, compared to Controls (Fig.
2.8a), the red pulp in mice from the OMP Vaccine group was greatly
expanded, due to congestion with blood, with an increased frequency of
megakaryocytes (Fig. 2.8b). Oedema was also indicated by the separation of
red pulp from the subcapsular region and an increase in interstitial space.
Compared to mice from the Control group, the prominent myeloblasts and
metamyelocytes in the red pulp adjacent to trabeculae indicated an increase
in splenic haematopoiesis in mice in the OMP Vaccine group, (Fig. 2.8c and
d). The peri-arteriolar sheaths were more prominent in mice from the OMP
Vaccine group than in the Control group, with many of the macrophages
surrounding the arterioles also having fine cytoplasmic vacuolations.
Together, these observations suggested increased phagocytic activity, arising
from immunization [16]. Pyknotic debris and mitotic figures were more
noticeable in mice from the OMP Vaccine group than in mice from the
Control group (Fig. 2.8c and d).

2.3.2

Cellular changes in the lung following intradermal immunization

Prior to their removal, the vasculature of individual lungs was perfused
extensively with PBS to minimize contamination of lung cell preparations
with leukocytes from the peripheral circulation. Total recoverable cell
numbers in collagenase-digested lung tissue from the four treatment groups
did not change significantly over the 28-day period (2.9a). However,
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Day

Day

Day

FIGURE 2.7. Temporal change in the percentage of (a) CD3+CD4+ cells (T helper cells), (b) CD3+CD8+ (cytotoxic T cells)
and (c) CD3'B220+ cells (B cells) in the spleens of mice from Control (unfilled squares), OMP Antigen (unfilled
diamonds), Adjuvant (filled circles) and OMP Vaccine (filled diamonds) groups following intradermal immunization.
Each data point represents the mean (± sem) of at least 4 mice per group.

FIGURE 2.8. Spleens taken on Day 11 following primary im m unization
from mice belonging to the Control (a and c) and OMP Vaccine groups (b
and d) showing cellular changes following immunization. Note increase in
megakaryocytes (1) and polymorphs (2) in mice from the OMP Vaccine
group compared to mice from the Control group. Note also increased
haematopoiesis along trabeculae (3) with myeloblasts (4), metamyelocytes (5)
and mitotic figures (6) being more prominent in the OMP Vaccine group
compared to Controls, (a and b) x 100 magnification, (c and d) x 400
magnification.
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granulocyte numbers increased significantly as a proportion of total cell
numbers in the lungs of mice from the OMP Vaccine group at Day 3 (P <
0.005) (Fig. 2.9b). This increase was attributed to extravasation of granulocytes
(predominantly polymorphonuclear leukocytes, or PMN) into the lung
interstitium . The increase in interstitial granulocytes in the lungs was
significantly enhanced (10-fold) by the second vaccine injection, peaking at
Day 11 (P < 0.00001). Granulocyte numbers then returned to normal by Day
28. In mice from the OMP Vaccine group the temporal changes in lung
granulocytes coincided with the changes detected for splenic granulocytes.
An increase in cells with monocyte/macrophage morphology was also
observed in the interstitium of H&E-stained sections of lung tissues. The
increase in this cell type in the lungs was not quantified, however. Injection
of either adjuvant or antigen alone elicited relatively minor increases (2 to
2.5-fold) in the proportion of lung granulocytes (P < 0.05). The proportion of
CD3+CD4+, CD3+CD8+and CD3'B220+ populations remained unchanged in all
groups over this period (Fig. 2.10).

2.3.3

Cellular

changes

in

peripheral

blood

following

intradermal

im m unization
The leukocyte distribution in peripheral blood can provide a measure of
leukocyte homeostasis throughout the body [268-270]. Therefore, peripheral
blood leukocytes (PBL) populations were quantified on Days 3, 14 and 21
following im m unization

(Table 2.4). Compared to all other groups, PBL

numbers in mice belonging to the OMP Vaccine group rose significantly (2.3fold) by Day 3 (P < 0.05) and continued to be significantly elevated (3-fold) at
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Day
FIGURE 2.9. Temporal change in (a) total cell numbers and (b) the
percentage of Gr-1+Mac-1+ cells (granulocytes) in the lungs of mice from
Control (unfilled squares), OMP Antigen (unfilled diamonds), Adjuvant
(filled circles) and OMP Vaccine (filled diamonds) groups following
intradermal immunization. Each data point represents the mean (± sem) of
at least 4 mice per group. Arrows designate the time of vaccination.

Day 14 (P < 0.05), before returning to normal by Day 21. Increases at Day 3 in
these mice were due to elevations in both granulocytes and monocytes.
Blood granulocyte numbers rose significantly (5-fold) by Day 3 and remained
elevated at Day 14 (P < 0.02) before returning to normal by Day 21. Blood
monocyte numbers also rose significantly (3-fold) by Day 3 (P < 0.05) and
remained elevated (4-fold) at Day 14 (P < 0.05) before returning to normal by
Day 21. Blood granulocyte, but not monocyte, numbers rose significantly (2
fold) at Day 14 in mice from the OMP Antigen group (P

< 0.01). Blood

granulocyte or monocyte numbers did not change significantly in mice from
the Adjuvant group over this period.
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FIGURE 2.10. Temporal change in the percentage of (a) CD3+CD4+ cells (T helper cells), (b) CD3+CD8+ (cytotoxic T
cells) and (c) CD3'B220+ cells (B cells) in the lungs of mice from Control (unfilled squares), OMP Antigen (unfilled
diamonds), Adjuvant (filled circles) and OMP Vaccine (filled diamonds) groups following intradermal
immunization. Each data point represents the mean (± sem) of at least 4 mice per group. Arrows designate the time
of vaccination.

TABLE 2.4. Changes in total leukocyte, granulocyte and monocyte numbers
in the peripheral blood of mice belonging to Control, OMP Antigen,
Adjuvant and OMP Vaccine groups at Days 3, 14 and 21 following
intradermal immunization. Results show the mean (± sem) of 4 mice in
each treatment group.

Post-immunisation Day:
Group

3

14

21

Total

Control

3.1 ± 0.6

1.7 ±0.6

4.2 ± 0.8

Cell No.

Adjuvant

2.7 ± 0.3

2.2 ± 0.9

3.6 ± 0.1

(x 106 /ml)

Antigen

1.6 ± 0.8

3.3 ± 0.2

4.4 ± 0.9

Vaccine

7.0 ± 0.5

5.2 ± 0.1

3.6 ± 0.6

Total

Control

6.9 ±1.9

3.9 ±0.1

11.7 ± 3.2

Granulocytes

Adjuvant

6.5 ± 1.4

3.1 ± 1.0

00
o
+1
rH
OO

(x 10^/ml)

Antigen

4.8 ± 1.7

9.1 ± 0.4

10.5 ± 2.3

Vaccine

36.0 ± 3.6

13.1 ± 2.7

13.4 ± 0.4

Total

Control

4.4 ± 1.1

3.3 ± 1.9

8.5 ± 1.6

Monocytes

Adjuvant

4.6 ± 1.6

4.9 ± 2.2

7.1 ± 0.8

(x lO^/ml)

Antigen

3.1 ± 1.6

5.7 ± 0.2

9.4 ± 2.1

Vaccine

13.1 ± 1.7

13.1 ± 0.4

6.3 ± 1.5
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2.3.4

Cellular

changes

in

the

thymus

following

intradermal

im m unization
Total thymocyte numbers decreased in all groups following im m unization
(Fig. 2.11). In mice belonging to the OMP Vaccine group, cell numbers
declined by 95% within 3 days after primary immunization (P

< 0.002).

Thymocyte numbers in this group remained low until Day 11 (P < 0.0005)
before spontaneously climbing to be significantly greater (by 50%) than all
other groups at Day 28 (P < 0.005). The supranormal thymocyte numbers in
the Vaccine group at Day 28 probably reflected a period during which
baseline

thymocyte

levels

were

being re-established.

Much

smaller

thymocyte losses occurred in Control (25%), Adjuvant (65%) and OMP
Antigen groups (57%) within 6 days after primary immunization. These
losses were not statistically significant. Thymocyte numbers in these groups
spontaneously returned to normal by Day 8 and did not elicit further
declines as a result of booster immunization.

The decline in thymocyte numbers in mice from the OMP Vaccine group
was predominantly due to loss of CD3'CD4+CD8+ double positive (DP) cells
(Fig. 2.12). DP cells in these mice declined by 88% within 3 days after primary
immunization (P < 0.02). Cell numbers returned to about 50% of norm al
levels by Day 8 but booster immunization caused another drop in DP cells to
about 25% of pre-immunization levels by Day 11 (P < 0.004). Thereafter, DP
cells returned to normal by Day 21. DP cell numbers also fell by 50% within 3
days after the first adjuvant injection in the Adjuvant group, but this fall
was not significant due to the variability of responses between individual
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FIGURE 2.11. Temporal change in total thymocyte numbers in mice from
Control (unfilled squares), OMP Antigen (unfilled diamonds), Adjuvant
(filled circles) and OMP Vaccine (filled diamonds) groups following
intradermal immunization. Each data point represents the mean (± sem) of
at least 4 mice per group. Arrows designate the time of vaccination.

FIGURE 2.12. Temporal change in DP cell numbers in mice from Control
(unfilled squares), OMP Antigen (unfilled diamonds), Adjuvant (filled
circles) and OMP Vaccine (filled diamonds) groups following intradermal
immunization. Each data point represents the mean (± sem) of at least 4
mice per group. Arrows designate the time of vaccination.
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mice. Absolute declines in CD3CD4CD8*, CD3+CD4+CD8‘ and CD3+CD4CD8+
cells following immunization were also elicited in mice belonging to the
OMP Vaccine group (Fig. 2.13a to d). Similar losses were not evident in mice
belonging to the Control, Adjuvant or OMP Antigen groups.

2.3.5

Assessment of thymocyte viability by flow cytometry following

intradermal immunization
In a preliminary experiment, cells stained with a hypotonic solution of
propidium iodide displayed a diploid DNA peak (M2) which constituted
about 83% of total DNA, a minor broad peak (M l) in the hypodiploid range
(6% of total DNA) to the left of the diploid DNA, and a small peak (M3)
corresponding to supradiploid DNA (2% of total DNA) to the right of the
diploid DNA region Fig. 2.14a. All concentrations

of dexamethasone

induced apoptosis in treated cells. Fig. 2.14b shows a histogram of cells
treated overnight with 10'5 M dexamethasone and stained with hypotonic
propidium iodide. Treated cells displayed a greatly increased hypodiploid
peak (M l: 72 to 77% of total DNA) relative to the size of the diploid peak
(M2: 10 to 17% of total DNA), and little supra diploid DNA (M3).
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FIGURE 2.13. Temporal change in the numbers of (a) CD3 CD4 CD8' cells, (b) CD3+CD4+CD8' cells and (c) CD3+CD4 CD8
cells in the thymus of mice from Control (unfilled squares), OMP Antigen (unfilled diamonds), Adjuvant (filled
circles) and OMP Vaccine (filled diamonds) groups following intradermal immunization. Each data point represents
the mean (± sem) of 3 mice per group.
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FIGURE 2.14. Histogram plots of thymocytes that were incubated overnight
in (a) culture medium or (b) culture medium supplemented with 10'5 M
dexamethasone. Regions M l, M2 and M3 represent the hypodiploid, diploid
and supradiploid DNA regions, respectively.

Cells stained with 7-A AD divided into 3 groups as described elsewhere [241].
Non-apoptotic cells were 7-AAD', early apoptotic were 7-AADdim, and late
apoptotic or dead cells were 7-AAD+. On this basis the majority of untreated
cells (84%) were non-apoptotic, with a smaller percentage being apoptotic
(8%) or dead (8%) after overnight incubation in culture medium (Fig. 2.15a).

All dexamethasone-treated cells showed a decline in the percentage of live
cells (7-AAD*), and an increase in early apoptotic cells (7-AADdim) and late
apoptotic and dead cells (7-AAD+). Fig. 2.15b is depicts cells treated overnight
with 10'5M dexamethasone and stained with 7-AAD. The percentages of 7AAD', 7-AADdimand 7-AAD+after dexamethasone treatment were 62%, 25%
and 12%, respectively.
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FIGURE 2.15. Contour plots of thymocytes that were incubated overnight in
(a) culture medium or (b) culture medium supplemented with 10'5 M
dexamethasone. Regions R l, R2 and R3 represent the live, early apoptotic
and late apoptotic or dead cells, respectively.

Both methods allowed discrimination between live, apoptotic and dead cells
following treatment with dexamethasone. In addition, the 7-AAD staining
method allowed simultaneous

discrimination

of cells on the basis of

phenotype.

Assessment of thymocyte loss over the first 60 h period following primary
vaccination demonstrated that total viable thymocyte numbers in the OMP
Vaccine group fell to plateau within the first 36 h (Fig, 2.16a). Viable cell
numbers in the Adjuvant group declined more slowly over the same
period, while no significant changes were observed in the Control and OMP
Antigen groups. Surprisingly, dead (trypan-blue positive) cell numbers did
not increase above the background level in any group (Fig. 2.16b) even
though viable cell numbers fell, and a significant increase (6-fold) in the
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FIGURE 2.16. Temporal change in the numbers of (a) total viable thymocytes, (b) total dead thymocytes and (c) the
percentage of apoptotic DP cells in the thymus of mice from Control (unfilled squares), OMP Antigen (unfilled
diamonds), Adjuvant (filled circles) and OMP Vaccine (filled diamonds) groups following intradermal im m unization.
Each data point represents the mean (± sem) of 3 mice per group.

level of thymocyte apoptosis (measured using 7-AAD) was detected within
24 h in the OMP Vaccine group (P < 0.05) (Fig. 2.16c).

2.3.6

NK cell cytotoxicity in intradermally immunized mice

Splenocytes from SFV-immunized mice were used as a positive control for
NK cytotoxicity because these cells are strongly cytotoxic against NKsensitive YAC-1 target cells (Fig. 2.17a) [267]. The cytotoxicity of SFV
splenocytes was almost completely abrogated (84% decline) by depletion of
effector splenocytes with anti-asialo-GM! antibody plus complement (Fig.
2.17b). The NK cytotoxic activity of splenocytes from SFV-immunized mice
was partially abolished (33% decline) following treatment with anti-Thy 1.2
plus complement (Fig. 2.17c), but was unaffected by treatment with anti-CD8
plus complement

(Fig. 2.17d). By comparison,

Control mice had low

background NK activity. These results were consistent with previous
findings by Mullbacher and King (1989) indicating that NK cells had a Thy
1.2"CD8’asialo-GM1+ phenotype [267].
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FIGURE 2.17. Percentage residual splenic cytotoxic activity in mice from
Control (unfilled columns), Adjuvant (hatched columns), OMP Antigen
(stippled columns), OMP vaccine (filled columns) and SFV infection groups
(wavy). Figures show residual activity following treatment with either (a)
complement only (b) anti-asialo-GM! plus complement, (c) anti-Thy 1.2 plus
complement or (d) anti-CD8 plus complement. Values represent the mean
of triplicate cultures.

Splenocytes from the Adjuvant, OMP Antigen and OMP Vaccine groups had
low NK activity, ranging from 1 to 17%. The level of NK activity was
unaffected by selective depletion of splenocytes with anti-Thy 1.2, anti-CD8
or anti-GMr
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2.4

DISCUSSION

Flow cytometry was used to compare changes in leukocyte populations
following intradermal immunization. The simultaneous multiparameter
measurements possible with flow cytometry allowed differentiation of cell
populations in heterogeneous cell suspensions prepared from different
tissues with minimal number of purification steps, such as gradient density
centrifugation, which have the potential to cause artefactual losses of total
cell numbers and specific cell groups [271]. Flow cytometric detection of light
scattering through selected angular ranges by cells provides inform ation
about relative cell size (forward light scatter, or FSC) and surface complexity
(side light scatter, or SSC), allows discrimination of cell debris and dead cells
from live cells, and can be used to distinguish between different cell
populations,

for example,

erythrocytes,

lymphocytes,

monocytes

and

granulocytes [271]. Additionally, fluorescent light emissions at different
wavelengths by fluorophores like fluorescein isothiocyanate, phycoeurythin
and cy-chrome bound to antibodies against specific cell markers provide
information on the relative proportions of different cell populations in the
sample [271].

The effect on leukocyte populations was assessed in mice following
intradermal immunization with either SAMA4-OMP (OMP Vaccine group),
SAMA4 alone (Adjuvant group), OMP antigen alone (OMP Antigen group)
or PBS (Control group). The significant change in cell numbers in the OMP
Vaccine group may have resulted from systemic toxic effects of Quii A, as
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reported by others [37, 59, 69, 79]. However, while some contribution of
adjuvant toxicity to changes in cell numbers cannot be excluded, the
amount of Quil A administered in each SAMA4 dose was only 0.6 \xg. This
value is 20-fold lower than that used by other groups for the formulation of
systemic adjuvants [69, 78]. Certainly, the much less dramatic changes in cell
numbers seen when SAMA4 was administered on its own argued against
Quil A toxicity as a major cause of changes in leukocyte populations.

From previous work done by others [272-275] demonstrating the necrotic
effects of bacterial toxins or LPS, it was also possible that the presence of one
or more toxic bacterial components in the purified OMP preparations may
contribute to the observed cellular changes. If so, then one would expect that
intradermal immunization with OMP alone would elicit similar cellular
changes to those seen in the OMP Vaccine group. The strain of A.
p leu r o p n e u m o n ia e used to purify OMP produces at least one strongly
haemolytic and cytotoxic RTX toxin, APX1 [276-278]. However, this toxin was
not detected in OMP preparations, either by SDS-PAGE or immunoblotting
with anti-haemolysin antibodies (Chapter 7). OMP preparations alone were
also unable to induce necrotic cell death in in vitro analyses (J. Chin,
personal communication). Another inducer of inflammation produced by
Gram-negative bacteria is lipopolysaccharide (LPS). Capsular polysaccharides
and LPS were detected in OMP preparations (Chapter 6). However, because
identical amounts of the same OMP batch were used to immunize mice in
the OMP Antigen and OMP Vaccine groups, one would expect almost
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identical responses in both groups if LPS mediated the cellular changes
detected. The absence of a strong cellular response in all other groups clearly
indicated that the cellular responses elicited by the OMP Vaccine group were
due to a synergistic interaction

between the

antigen

and adjuvant

components.

An increase in the numbers of myeloblasts, macrophages, granulocytes
(predominantly

immature

polymorphonuclear

leukocytes)

and

megakaryocytes in the splenic red pulp of mice in the OMP Vaccine group
contributed

to

immunization.

the

increases

in

spleen

size

following

the

second

Granulocytes and macrophages are recognized as m ajor

components of inflammatory and immunological reactions in the body
[279]. During the period of heightened cellular activity these cell types
emigrate in a non-random fashion to the site of inflammation where they
are involved in host defense, and to the draining lymph nodes and spleen
where they participate in generation of adaptive immune responses [35, 104,
106]. In mice, activation of innate immune responses during periods of
heightened demand for phagocytic cells, for example, during infection or
stress, results in upregulation of splenic haematopoiesis [280, 281]. It was
possible, based on the flow cytometric and histological data, that the cellular
changes following immunization
haematopoiesis.

The

rapid

were also due to upregulated splenic

increases

in

circulating

Gr-l'M ac-l+ cells

(macrophage/monocytes) in the OMP Vaccine group may also have been
complemented by the recruitment of tissue macrophages and the release of
monocytes from the bone marrow [106].
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The

increased

numbers

of

granulocytes

and

monocyte/macrophage

numbers in the lung tissue of the OMP Vaccine group were consistent with
an increase in the numbers of cells that had undergone margination and
extravasation into the lung intersitium [282]. The increased numbers of
granulocyte and macrophage trafficking through lymphoid
lymphoid

tissues

thus

reflected the

systemic

effects

and non

of intradermal

immunization. Unlike the small cellular changes seen in the blood, spleens
and lungs of mice in the Adjuvant or OMP Antigen groups, intradermal
immunization with SAMA4-OMP complexes was effective in evoking a
strong innate cellular response.

NK cells are also an important component of the innate immune response.
Chronic NK cell deficiency, for example, is often associated with an
increased susceptibility to infection [283] and enhanced tumour susceptibility
[284]. NK cells also modulate differentiation of haematopoietic progenitor
cells during myelopoiesis in vitro [285] and B cell genesis in the bone
marrow in vivo [286]. Increased NK cytotoxic activity may therefore, have
been an important additional component of the overall response, especially
in the OMP Vaccine group.

Like human NK cells, murine NK cells express cell surface markers that
allow them to be phenotypically quantified by flow cytometry [287-291]. In
mice, these markers include NK1.1, Thy 1, Mac-1 and asialo-GMj [287, 288,
292, 293]. Unfortunately, these markers are also expressed by other m urine
cell types, such as monocytes, granulocytes and thymocytes [119, 294]. The
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monoclonal antibody, PK136, used to detect expression of NK1.1, is the most
specific for identifying NK cells [295], but does not react with NK cells in
BALB/c mice. The lack of suitable NK-specific markers in BALB/c mice
precluded the use of flow cytometry in this study. Instead, splenic NK cell
activity was assessed by an in vitro cytotoxicity assay as previously described
[267]. Increases in NK cytotoxic activity were not detected following
immunization in any group, suggesting little involvement by this cell type.
However, at least one other study [296] has also reported the lack of
detectable NK cell cytotoxicity following immunization. It was possible that
omission of steps to specifically enrich for NK cells may have compromised
the sensitivity of the assay performed in these studies.

In the thymus, the rapid depletion of thymocytes following primary and
secondary immunization with OMP vaccine was predominantly due to loss
of DP cells, although all other thymocyte phenotypes were also affected. DP
cells are highly susceptible to changes in the thymic micro-environment,
and an array of conditions, such as, viral infection [297], y-irradiation [298],
chemical toxicity [299, 300], withdrawal of growth factors and increased
glucocorticoid levels
Surprisingly,

[301] can

significant

thymic

increase
depletion

cell

necrosis

and

apoptosis.

induced by vaccination

is

unreported, but was seen in the current study to be an important event.
Enumeration of dead and apoptotic cells also demonstrated that most of
these cells did not accumulate intrathymically. These results are consistent
with other studies [259, 302, 303] suggesting that dead or dying cells are very
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rapidly phagocytosed by resident macrophages. Alternatively, it has also
been suggested that apoptotic cells die extrathymically [304, 305].

The inability of adjuvant or OMP alone to induce such strong thymic
depletion was consistent with the weaker inflammatory responses observed
in these mice. The rapidity and magnitude of thymocyte loss in the OMP
Vaccine group together with the small (6-fold) but significant increase in
apoptosis

occurring

within

24

h

post-immunization,

suggested

hormonally induced rather than activation-induced mechanism

a

of cell

death [301, 306]. If such prominent thymocyte loss has any physiological
significance and is not simply an irrelevant "bystander" response, then one
possibility may be that rapid loss of immature

thymocytes prevents

tolerance being inappropriately induced against a strong immunogen
(SAMA4-adjuvanted OMP). The supranormal thymocyte levels later in the
post-immunization

period reflected an interval

of increased

T cell

production, potentially shifting the antigenic repertoire of developing cells
toward those
Intrathymic

with

greater

circulation

specificity for

the

immunizing

of activated leukocytes or antigen

antigen.
from

the

periphery increases during an immune response [307-309] and may also
have provided an antigen-driven stimulus for increased turnover of T cells.

A strong innate immune

response is necessary for induction of strong

adaptive immune response [116]. The strong adjuvant activity of SAMA4 is
reflected in

its ability

to

evoke

strong

innate

immune

responses,

particularly, the recruitment of PMN. The finding of qualitatively similar
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cellular changes following immunization with SAMA4-ovalbumin (OVA)
complexes (Chapter 3) also indicates that the adjuvant effect is probably
independent of antigen-type. Since intradermal immunization with OVA
alone (OVA Antigen group) did not elicit antigen-specific antibody (Chapter
5) or cytotoxic responses (Chapter 6), these data suggest that complexing of
antigen with SAMA4 enhances

the immunogenicity

of antigens and

promotes their efficient uptake and processing by phagocytic cells.

The changes elicited when SAMA4 is complexed with different antigens
may be similar to the effects elicited by other adjuvants. Although such
effects have

not

been

specifically investigated

for

most

adjuvants,

knowledge of the presence and extent of changes to the immune system may
be helpful for developing vaccines whose components are efficacious and
safe. As demonstrated

here,

flow cytometric measurement

of post

immunization changes in the cell populations that are targeted by vaccines
can provide a precise measure of the effects of vaccination.
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CHAPTER 3
Effect of Antigen-type
on
Cellular
Changes
in
Intradermally Immunized Mice

3.1

INTRODUCTION

Complexing bacterial OMP with SAMA4 elicited a rapid cellular im m une
response in intradermally
responses

elicited were

immunized

due

to

toxic

mice. The possibility that the
components

present

in

OMP

preparations or the adjuvant was small since mice given only OMP or
SAMA4 alone elicited much weaker cellular responses. The significantly
greater response obtained when

OMP and SAMA4

were complexed

suggested that antigen and adjuvant acted synergistically. Nevertheless, it
was not known

whether

the

changes

described in

Chapter 2 were

representative of the type of biological responses that would be elicited when
other antigens were similarly complexed with the adjuvant. To determine
this, groups of mice were intradermally immunized mice with ovalbumin
(OVA), a simple, well-characterized [35, 98, 99, 310, 311] and innocuous
protein antigen [312], either alone or complexed with SAMA4.

It is noteworthy that OVA is also a hydrophilic protein. Hydrophilic proteins
are incorporated poorly into iscoms, resulting in low immunogenicity [39].
A number

of

different

methods

have

been

used

to

increase

the

hydrophobicity of hydrophilic proteins and enhance their uptake by iscoms.
These methods include covalent attachment of palmitic acid [76, 99],
chemical denaturation to expose hydrophobic residues [55, 98], or chemical
coupling to hydrophobic carrier proteins [64, 65, 88]. Chin et al [100-102]
demonstrated that antigen uptake into iscoms can be facilitated by first
entrapping antigens within liposomes. This approach retains the biological
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properties of iscoms, but with superior rates of incorporation of hydrophobic
or hydrophilic proteins [102]. As part of this current study, the magnitude of
the cellular changes elicited following intradermal immunization

with

SAMA4 complexes containing unmodified OVA or palmitoylated OVA was
also compared.

3.2

3.2.1

MATERIALS AND METHODS

Preparation of palmitoylated ovalbumin

Ovalbumin, (Grade III; Sigma) was chemically modified by palmitoylation (J.
Chin, personal communication). Briefly, OVA (50 mg dissolved in 50 ml
borate buffer/saline, pH 8.8) was combined with 300 pi palmitoyl chloride
(Sigma) suspended in 20 ml anhydrous ether. The mixture was slowly
rotated for 3 days at 25 °C and then dialysed extensively against PBS, pH 7.2
for 48 h at 25 °C.

3.2.2

Immunization of Mice and Sampling Schedule

OVA vaccine, palmitoylated OVA (POVA) vaccine or OMP vaccine were
prepared by complexing OVA, POVA or OMP with SAMA4, respectively, as
described in Chapter 2. Female BALB/c mice aged 8 to 12 weeks (52 per
group) were immunized intradermally with 100 pi of either PBS, pH 7.2
(Control group), OVA

(OVA Antigen group) or SAMA4-OVA

(OVA

Vaccine group) on Days 0 and 7. Mice received 30 pg protein, as determined
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by a commercial bicinchoninic add-based protein estimation kit (Pierce), in
each dose of OVA antigen or OVA vaccine. Because the cellular responses in
the previous study with the OMP vaccine returned to normal by Day 28
following vaccination (Chapter 2), in this study, the cellular changes in the
spleen, lung and thymus were assessed on Days 0, 1, 3, 6, 8, 11, 14 and 21.
Single-cell suspensions were prepared, enumerated using a haemocytometer
and stained for flow cytometry as described in Chapter 2.

The responses to OVA and POVA were compared in a separate experiment.
Mice (8 per group) were intradermally immunized with 100 ¡^1 of either PBS,
pH 7.2 (Control group), SAMA4-OVA (OVA Vaccine group) SAMA4-POVA
(POVA Vaccine group) or SAMA4-OMP (OMP Vaccine group). Mice were
euthanased as described above on Days 11 and 14. Single-cell suspensions
were prepared from pooled spleens, thymi or lungs were stained for flow
cytometric analysis as described in Chapter 2.

3.2.4

Statistical analyses

The mean values in the different groups at individual time points were
compared by two-tailed t-test. Changes were considered significant at P <
0.05.
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3.3

3.3.1

RESULTS

Cellular changes in the spleen following intradermal immunization
with OVA

Total body weights of mice in the different treatment groups did not change
significantly during the 21-day period following immunization (Fig. 3.1a).
Neither did spleen weights of mice from the Control or OVA Antigen
groups change significantly over this period (Fig 3.1b). By comparison the
spleens of mice in the OVA Vaccine group increased in weight (almost 2.5fold) and were significantly heavier than spleens in either Control or OVA
Antigen groups between Days 3 (P < 0.005) and 14 (P < 0.0001). Spleen
weights in the OVA Vaccine group returned to normal by Day 21.

Splenocyte

numbers

did not

change

significantly

following

primary

immunization in the different groups (Fig. 3.2a). Following the second
injection, however, cell numbers rose (2-fold) in the OVA Vaccine group,
reaching a peak at Day 11 (P < 0.02). Thereafter, cell numbers returned to pre
immunization levels between Days 14 to 21. The increase in total splenocyte
numbers was predominantly due to an increase in Gr-1+Mac-1+ cells, or
granulocytes. The proportion of granulocytes in mice from the OVA Vaccine
group increased significantly (2-fold) to a peak at Day 1 (P < 0.05) before
dropping again by Day 3 (Fig. 3.2b). The second injection elicited a greater
increase (5-fold), peaking at Day 8 (P < 0.05) before also returning to norm al
levels by Day 14. Splenic granulocyte numbers in mice from the OVA
Antigen group changed only slightly over the same period.
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FIGURE 3.1. Temporal changes in (a) total body weight and (b) spleen weight
of mice from Control (unfilled squares), OVA Antigen (unfilled diamonds)
and OVA Vaccine (filled diamonds) groups following intradermal
immunization. Each data point represents the mean (± sem) of 4 mice per
group. Arrows designate the time of vaccination.

FIGURE 3.2. Temporal changes in (a) total splenocyte numbers and (b) Gr1+Mac-1+ cells (granulocytes) in mice from Control (unfilled squares), OVA
Antigen (unfilled diamonds) and OVA Vaccine (filled diamonds) groups
following intradermal immunization. Each data point represents the m ean
(± sem) of 4 mice per group. Arrows designate the time of vaccination.
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CD3+CD4+, CD3+CD8+ and CD3'B220+ cells, which represent helper T cell,
cytotoxic T cell and B cell phenotypes, respectively, did not change
significantly as a proportion of the total lymphocyte numbers in the spleens
of Controls, OVA Antigen or OVA Vaccine groups over the first 21 days
after immunization (Fig. 3.3a-c). However, in parallel studies, significant
increases in serum OVA-specific antibody levels (Chapter 5) and strong
cytotoxic T cell activity (Chapter 6 and [102]) demonstrated that antigenspecific T and B cell clones were stimulated by immunization.

3.3.2

Cellular changes in the lung following intradermal immunization

Total cell numbers in collagenase-digested lung tissue from mice belonging
to the OVA Vaccine group increased after the second immunization (Fig.
3.4a). By comparison, cell numbers in the other groups did not change
significantly over the 21-day period. Flow cytometry demonstrated

a

significant (6-fold) increase in the granulocyte population, peaking 1 day
after the first OVA vaccine dose (P < 0.005) before returning to normal by
Day 6 (Fig. 3.4b). Granulocyte numbers rose again, by almost 10-fold, one day
after the second OVA Vaccine dose (P < 0.02) and rapidly returned to norm al
by Day 14. In the OVA Antigen group, granulocyte numbers rose briefly (4
fold) between Days 1 and 3 (P < 0.02) but were unaffected by the second
antigen injection. CD3+CD4+, CD3+CD8+ and CD3'B220+ cell populations did
not change significantly in the lungs of mice from the OVA Antigen and
OVA

Vaccine

Chapter 3

groups

over

the
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period

(Fig.

3.5a-c).
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Day

Day

Day

FIGURE 3.3. Temporal change in the percentage of (a) CD3+CD4+ cells (T helper cells), (b) CD3+CD8+ (cytotoxic T cells) and (c)
CD3'B220+ cells (B cells) in the spleens of mice from Control (unfilled squares), OVA Antigen (unfilled diamonds) and OVA
Vaccine (filled diamonds) groups following intradermal immunization. Each data point represents the mean (± sem) of at
least 4 mice per group.
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FIGURE 3.4. Temporal changes in (a) total cell numbers and (b) Gr-1+Mac-1+
cells (granulocytes) from the lungs of mice from Control (unfilled squares),
OVA Antigen (unfilled diamonds) and OVA Vaccine (filled diamonds)
groups following intradermal immunization. Each data point represents the
mean (± sem) of 4 mice per group. Arrows designate the time of vaccination.

3.3.3

Cellular

changes

in

the

thymus

following

intradermal

im m unization
Thymocyte numbers were unaffected by either one or two injections of OVA
antigen (Fig. 3.6a). However, intradermal injection of OVA vaccine triggered
a significant decline in thymocyte numbers, which fell by greater than 90%
by Day 6 after the first injection (P < 0.02). Thymocyte numbers in this group
remained low until Day 8 before spontaneously returning to normal levels
by Day 21 (P < 0.002). The period of thymocyte depletion in the OVA Vaccine
group was not as prolonged as previously observed in the OMP Vaccine
group

C h a p te r 3

following

the

second

vaccine

dose

(Chapter

2).

p a g e 84

Chapter 3
FIGURE 3.5. Temporal change in the percentage of (a) CD3+CD4+ cells (T helper cells), (b) CD3+CD8+ (cytotoxic T cells) and (c)
CD3"B220+ cells (B cells) recovered from the lungs of mice from Control (unfilled squares), OVA Antigen (unfilled diamonds)
and OVA Vaccine (filled diamonds) groups following intradermal immunization. Each data point represents the mean (±
sem) of at least 4 mice per group.
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The decline in thymocyte numbers in the OVA Vaccine group was due
predominantly to the loss of DP cells (Fig. 3.6b). DP cell numbers in this
group fell by greater than 90% in the first 6 days (P < 0.02) before
spontaneously returning to normal levels. The rate of recovery of DP cell
was unaffected by the second OVA vaccine injection. By comparison,
CD4+CD8', CD4"CD8+ and CD4CD8' subpopulations were unaffected by
intradermal immunization with OVA antigen or OVA vaccine (Data not
shown).

FIGURE 3.6. Temporal changes in (a) total thymocyte numbers and (b)
CD4+CD8+ cells (DP cells) in mice from Control (unfilled squares), OVA
Antigen (unfilled diamonds) and OVA Vaccine (filled diamonds) groups
following intradermal immunization. Each data point represents the mean
(± sem) of 4 mice per group. Arrows designate the time of vaccination.
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3.3.1

Comparison

of

cellular

changes

following

intradermal

immunization with OVA, POVA and OMP vaccines
The OVA Vaccine and POVA Vaccine groups elicited almost identical
increases in spleen weight (Fig. 3.7a), splenocyte (Fig. 3.7b) and granulocyte
numbers (Fig. 3.7c) on Days 11 and 14. However, these increases were less
prominent than the changes detected in the OMP vaccine group over the
same period (Chapter 2). The percentage of T or B cells in the different
Vaccine groups remained unchanged at Days 11 and 14 (data not shown).

In the lungs, total cell numbers changed only slightly in the different
Vaccine groups at Days 11 and 14 (Fig, 3.8a). The proportion of granulocytes
in the lungs of the OVA Vaccine and POVA Vaccine groups rose by
equivalent amounts at Day 11 before returning to normal by Day 14 (Fig.
3.8b). However, these increases were much less than that present in the OMP
Vaccine group. The percentage of T or B cells in the different Vaccine groups
did not increase at Days 11 and 14 (data not shown).

Almost identical declines in thymocyte numbers were detected in the OVA
Vaccine and POVA Vaccine groups at Days 11 and 14 (Fig. 3.9a). The smaller
declines in thymocyte numbers in these groups, compared to the OMP
Vaccine group, possibly reflected the timing of the measurement as well as
the longer period of thymocyte depletion detected in the latter group.
Although it was likely that a decline in DP cells accounted for the drop in
total thymocyte numbers, measurements at Days 11 and 14 detected only
minor declines in DP cells for both groups (Fig. 3.9b). By comparison, m uch
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FIGURE 3.8. Change in (a) total cell numbers and (b) the percentage of Gr1+Mac-1+ cells (granulocytes) recovered from the lungs of mice from Control
(unfilled columns), OVA Vaccine (hatched columns), POVA Vaccine
(stippled columns) and OMP Vaccine (filled columns) groups following
intradermal immunization. Each column represents the mean of 4 mice per
group.
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FIGURE 3.9. Change in (a) total thymocyte numbers and (b) the percentage
of CD4+CD8+ cells (DP cells) from the thymus of mice from Control (unfilled
columns), OVA Vaccine (hatched columns), POVA Vaccine (stippled
columns) and OMP Vaccine (filled columns) groups following intradermal
immunization. Each column represents the mean of 4 mice per group.
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greater declines in total thymocyte and DP cell numbers were present at this
time in the OMP Vaccine group.

3.4

In

terms

of the

different

DISCUSSION

biological

responses,

the

findings

clearly

demonstrated that synergism between adjuvant and antigen com ponents
was not dependent on the antigen-type. Injecting mice with SA M A 4-O V A
complexes also confirmed that the type of cellular response elicited was not a
specific attribute of the antigen used, but most probably reflected SA M A 4
action generally. In fact, the types of cellular changes elicited in the different
tissues following intraderm al im m unization with OVA vaccine or OMP
vaccine were, temporally and phenotypically, almost identical. As predicted
from the results in Chapter 2, the most significant cellular changes were
triggered in the OVA Vaccine group, with few changes in the OVA A ntigen
group.

The results demonstrated clear similarities in the cellular responses to
different antigens complexed with SAMA4. The increases in granulocytes in
the spleen and lungs suggested that, as for the OMP Vaccine

group,

im m unization significantly increased the recruitm ent of phagocytic cells.
Although not specifically investigated, it was also possible that enhanced
splenic haematopoiesis and recruitment of cells from different tissue sources
played a significant role in cellular mobilization in the OVA Vaccine group,
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as in the OMP Vaccine group. The loss of DP cells in the thymus of the OVA
Vaccine group also suggested strongly that increased apoptosis and necrosis
was associated with intradermal immunization in this case.

In quantitative terms the duration and magnitude of the cellular changes in
the OVA Vaccine group were less remarkable than those elicited by the OMP
Vaccine group in Chapter 2. This is despite the fact that both OVA and OMP
vaccines contained equivalent

amounts

of protein or adjuvant.

One

explanation for the weaker cellular responses was the lower incorporation of
OVA into SAMA4. It is well established that hydrophilic proteins, such as
OVA, are poorly incorporated into iscoms compared with amphipathic or
hydrophobic proteins, such as membrane proteins [39, 57, 58, 60, 63, 70, 97].
The expectation, therefore, was that a hydrophobically modified form of
OVA, such as palmitoylated OVA, which readily incorporates into iscoms
[99], would elicit quantitatively greater cellular responses. Contrary to this
expectation,

the

similar

biological

responses

to immunization

with

hydrophilic (native) or hydrophobic (palmitoylated) forms of OVA indicated
that incorporation of proteins into SAMA4 was probably similar for both
OVA and palmitoylated
innocuous

protein

OVA.

antigen

OVA is a single homogeneous

[312]. Therefore,

it was likely

that

and
the

quantitative differences in responses between the OVA and OMP Vaccine
groups were due to the greater heterogeneity and molecular and antigenic
complexity, and hence immunogenicity, of bacterial OMP.
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In summary, two dissimilar antigens gave essentially identical cellular
responses. A mechanistic explanation for the synergism detected between
antigen and SAMA4 requires further investigation. However, Morein et al
[69, 92] and others [37, 59, 87] have suggested that complexing of antigen with
iscoms slows the rate of clearance, reducing antigen loss. Induction of an
inflammatory response and release of inflammatory

cytokines by the

accumulation of antigen-iscom complexes in skin-draining lymph nodes
and spleen may enhance uptake and processing of antigens [39]. Binding of
iscoms to DEC 205, a recently identified carbohydrate binding protein present
on the surface of phagocytic cells [313] has been suggested as a mechanism for
the

greater uptake of iscoms

by APC [39]. Finally,

presentation of antigen on the surfaces of the

the

m ultim eric

cage-like, pentagonal

dodecahedral iscoms [74] is also believed to promote

more

efficient

attachment and uptake of antigen and activation of phagocytic cells than
occurs in the absence of adjuvant,

or with

conventional

repository

adjuvants, such as Freund's adjuvant or aluminium hydroxide [69-71].
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CHAPTER 4
Flow Cytometric Analysis of Cell
Population Changes in the Bone
Marrow
of
Intradermally
Immunized Mice

4.1

INTRODUCTION

The bone marrow is the primary source of erythroid (erythrocytes), myeloid
(monocytes/macrophages, granulocytes and megakaryocytes) and lymphoid
(B lymphocytes, Natural Killer cells and thymus seeding progenitors) cell
lineages which ultimately populate peripheral lymphoid and non-lymphoid
tissues [119, 281, 314-317]. These different lineages arise from bone marrowderived self-renewing multipotential cells, called haematopoietic stem cells
[318, 319]. Lineage-committed lymphoid and myeloid cells also undergo
further

maturation

and

differentiation

in

the

peripheral

organ

compartments.

Myeloid and lymphoid cell homeostasis in the peripheral tissues is
maintained

by hormonal

and cytokine modulation

of bone marrow

haematopoiesis [320] and removal of activated or self-reactive cells by
apoptosis

[268,

321].

To

meet

the

normal

cellular

demands

for

haematopoietic cells in the adult mouse, nearly all the bony cavities are
filled with red marrow [280]. During periods of increased demand, such as
infection or stress, haematopoiesis in the spleen, which is retained as a
haematopoietic organ in the adult mouse, compensates for the lack of
marrow reserve haematopoietic capacity [280, 322].

As the main site of synthesis for haematopoietic cell lineages, the bone
marrow is directly affected by any provocation of the immune system, such
as in disease [323-327]. The morphological and cellular changes detected in
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the spleen following intradermal immunization with the OMP vaccine or
OVA vaccine described in Chapters 2 and 3, respectively, provided evidence
of an immunization-induced increase in demand for haematopoietic cells
and upregulation of splenic haematopoiesis.

The magnitude

of these

changes also suggested that bone marrow haematopoietic activity must also
be affected by intradermal immunization. This study examined the effects of
intradermal immunization

on the bone marrow concurrent with the

changes observed in the other organs.

4.2

4.2.1

MATERIALS AND METHODS

Immunization of Mice and Sampling Schedule

Female BALB/c mice aged 8 to 12 weeks (15 per group) were im m unized
intradermally with 100 fxl of either PBS, pH 7.2 (Control group), SAMA4
(Adjuvant Group), OMP (OMP Antigen group) or SAMA4-OMP (OMP
Vaccine group) on Days 0 and 7.

The investigations described in Chapters 2 and 3 demonstrated that cellular
changes in the blood, spleen or lungs were maximal (or near maximal) at
Days 3 and 14. By Day 21 the different cell populations were returning
toward pre-immunization levels. Based on these findings, assessment of
changes in the different leukocyte populations in the bone marrow was
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focused at three time points, Days 3, 14 and 21 following intradermal
im m unization.

4.2.2 Tissue processing and recovery of bone marrow cells for flow cytometry
To obtain femoral bone marrow cells, both hind femurs were removed from
each mouse. The surrounding muscle was stripped from the bone with
forceps and the bone marrow cells were flushed from the marrow cavity of
each femur with 1 ml ice-cold FACS buffer. Bone marrow cells from each
pair of femurs were combined and pelleted by centrifugation at 200 g for 10
min at 4 °C before being resuspended in 1 ml ice-cold FACS buffer. Cells in
each pool

of paired femurs

per mouse

were enumerated

using

a

haemocytometer and stained for flow cytometry as described in Chapter 2.

4.2.3

Enumeration of haematopoietic progenitor cells

Haematopoietic stems cells (HSC) can be identified in bone marrow
preparations on the basis of their undifferentiated phenotype. It is now
generally accepted that HSC express the leukocyte differentiation antigen,
Thy 1.2, but lack expression of the lineage markers: B220 (B cell lineage), CD4
and

CD8

(T

cell

lineage),

Gr-1

(granulocyte

lineage)

and

Mac-1

(myelomonocytic cell lineage) [318-320, 328]. Consequently HSC have a Thy
1.2+CD4'CD8'B220'Gr-l'Mac-l' phenotype (abbreviated to Thy 1.2Tineage‘).
HSC also have the capacity for spontaneous self-renewal [329], and are able to
preferentially seed and repopulate lymphoid organs depleted by irradiation
[318, 320,328, 330].
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Recovery and accurate enumeration of HSC is difficult, however [318-320].
To obtain an indication of the effects of immunization on HSC in this study,
BM cells were initially identified on the basis of their forward light scatter
properties (FSC) and surface expression of Thy 1.2 (Fig. 4.1a) [320, 328]. Thy
1.2+ cells were then subdivided on the basis of their expression of defined
leukocyte lineage markers (Fig. 4.1b) [320, 328]. Because of the recognized
limitations of the method for accurately quantifying numbers of HSC
numbers in unenriched cell preparations, cells identified by flow cytometry
as having the phenotype, Thy 1.2+lineage", were collectively referred to as
putative haematopoietic progenitor cells, a grouping of bone marrow cells
that included

both

HSC

and

the

immediate

multilineage

ancestor

populations of lymphoid and myeloerythroid cells.

4.2.4

Assessment of Cell Viability by Flow Cytometry

Increases in apoptosis and necrosis were detected in the thymus shortly after
intradermal immunization (Chapter 2). Because immature B-lineage cells
undergo apoptosis during normal development in a manner analogous to
CD4+CD8+ cells in the thymus [331], a separate in vivo experiment was also
conducted to determine if cell necrosis and apoptosis were increased in the
bone marrow following immunization. The levels of apoptosis and necrosis
were determined in groups of 3 mice at 12 h intervals over a 60 h period
following intradermal immunization. For detection of apoptosis, BM cells
were initially stained with PE anti-CD45R/B220 as described in Chapter 2,
washed twice in PBS, pH 7.2 and then resuspended in 200 pi of 20 pg/ml 7-
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A AD. Cells were incubated at 4 °C in the dark for at least 20 min before FACS
analysis. The proportion of dead, apoptotic and live B220+ cells were
distinguished by logarithmic scale histograms [266]. To assess cell necrosis,
bone marrow cells were stained with 0.1% trypan blue for 2 min, before
being enumerated using a haemocytometer.

(a)

(b)

Forward Scatter

CD4/CD8/B220/Gr-1

FIGURE 4.1. Identification of haematopoietic progenitor cells, (a) Cells
recovered from the femoral bone marrow were identified on the basis of
FSC and expression of Thy 1.2. (b) Thy-1.2+ cells were further subdivided on
the basis of their expression of the lineage markers: CD4 and CD8 (T cells),
B220
(B
cell lineage),
Gr-1
(granulocyte lineage)
and
Mac-1
(monocyte/macrophage lineage). Cells located in the upper left, upper right
and lower right quadrants expressed lineage differentiation markers. Cells
located in the lower left quadrant were phenotypically Thy 1.2+CD4'CD8’
B220‘G r-l‘M ac-l' and were, therefore, regarded as lineage-undifferentiated
haematopoietic progenitor cells.
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4.2.5

Statistical analyses

The means of different groups at individual time points were compared by
two-tailed t-test. Changes were considered significant at P < 0.05.

4.3

4.3.1

RESULTS

Changes in total bone m arrow cell num bers follow ing intraderm al
vaccination

Compared to mice in the Control group, total bone marrow (BM) cell
numbers in each femur pair in the OMP Vaccine and Adjuvant groups
decreased significantly (40%) by Day 3 (P < 0.05) (Fig 4.2). A smaller decline
(25%) in BM cell numbers in mice from the OMP Antigen group at Day 3
was not significant. Cell num bers were normal by Day 14 in all groups. At
Day 21, however, BM cell num bers in the OMP Vaccine group were
significantly higher (1.5-fold) than in all other groups (P < 0.01).

4.3.2

Changes in B-lineage cells follow in g intraderm al vaccination

The decline in BM cell numbers at Day 3 in the OMP Vaccine or A djuvant
groups was predominantly due to a drop in Thy'B220+ cells, which includes
pro- and pre-B cell precursors and mature B cells [119] (Fig 4.3). In the OMP
Vaccine group, Thy'B220+ cells, fell to 14% of pre-im m unization levels by
Day 3 (P < 0.01). Cells num bers in this group were also low (30% of pre
im m unization levels) at Day 14 (P < 0.001) but then rose to be significantly
higher (2.3-fold) than in controls by Day 21 (P < 0.001). At Day 21, Thy‘B220+
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FIGURE 4.2. Temporal changes in total BM cell numbers in mice following
intradermal immunization with either PBS (unfilled columns), adjuvantonly (hatched columns), OMP antigen (stippled columns) or OMP vaccine
(filled columns). Each data point represents the mean (± sem) of 4 mice per
group.

FIGURE 4.3. Temporal changes in Thy'B220+ cells (immature and mature B
cells) in mice following intradermal immunization with either PBS
(unfilled columns), adjuvant-only (hatched columns), OMP antigen
(stippled columns) or OMP vaccine (filled columns). Each data point
represents the mean (± sem) of 4 mice per group.
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cells numbers in the OMP Vaccine group were also 20% higher than in the
Adjuvant group (not significant at P < 0.05), and 71% higher than in the
OMP Antigen group (P < 0.05) at Day 21. This increase in Thy'B220+ cell
numbers

to supranormal levels

possibly reflected a short

period

of

overcompensation before re-establishment of baseline levels.

Thy'B220+ cell numbers in the Adjuvant group fell by 76% by Day 3 (P < 0.05)
but returned to normal by Day 14. At Day 21, Thy*B220+ cell numbers were
significantly greater (2-fold) than in Controls (P < 0.05). Thy‘B220+ cells in the
OMP Antigen group fell by 30% by Days 3 and remained at this level on 14.
At Day 21 Thy*B220+cells numbers in this group increased 1.5-fold above the
level in the Control group.

4.3.3

Changes in granulocytic and myelomonocytic lineage cells following
intradermal vaccination

The numbers of Mac-1+Gr-1+ cells (which includes immature and mature
granulocyte lineage cells) did not change significantly after intradermal
vaccination, except in the OMP Vaccine group (Fig 4.4a). In this group, Mac1+Gr-1+ cell numbers rose significantly (1.6-fold) at Day 21 (P < 0.05). By
contrast, Mac-1+Gr-T cell numbers

(which includes promonocytes and

monocytes) increased 1.7-fold in the Adjuvant (P < 0.05) and OMP Antigen
groups (P < 0.05) and 4-fold in the OMP Vaccine group (P < 0.0002) at Day 14
(Fig. 4.4b). Mac-1+Gr-1' cell numbers were normal in all groups at Day 21.
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4.3.4

Changes in haematopoietic progenitor cells following intradermal
vaccination

Thy 1.2+ lineage' (CD4‘ CD8' B220" Gr-T Mac-T) haematopoietic progenitor
cells (which includes both the primitive haematopoietic stem cells and the
immediate multilineage ancestors of lymphoid, and myeloerythroid cell
populations) typically accounted for less than 0.5% of total bone marrow
cells in the femur pairs over the 21-day period. Compared to controls,
femoral haematopoietic progenitor cell numbers dropped (60%) in both the
OMP Vaccine and Adjuvant groups by Day 3 (P < 0.05), before returning to
normal at Day 14 (Fig. 4.5). Haematopoietic progenitor cell numbers in the
OMP Vaccine group were then significantly higher (1.3-fold) than in all
other groups at Day 21 (P < 0.05). Haematopoietic progenitor cell numbers in
the OMP Antigen group were also slightly lower than in the Control group
on Days 3 (not significant at P < 0.05), 14 (P < 0.05) and 21 (not significant at P
< 0.05).

4.3.5

Cell viability following intradermal immunization

Viable BM cell numbers in the Control and OMP Antigen groups did not
decline significantly following intradermal injection (Fig. 4.6a). However,
significant losses in viable BM cell numbers were detected in the Adjuvant
and OMP Vaccine groups within the first 24 h post-immunization. The
rapid decline in viable cell numbers was not associated with an increase in
the number of dead (Fig. 4.6b) or apoptotic cells (Fig. 4.6c) in the bone
marrow

above

the

background

level

during

the

first

60 h

post

immunization. The decline in BM cell numbers in the first 60 h postChapter 4
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FIGURE 4.4. Temporal changes in (a) Mac-1+Gr-1 + cells (granulocyte lineage
cells) and (b) Mac-1+Gr-1" cells (monocyte lineage cells) in mice following
intradermal immunization with either PBS (unfilled columns), adjuvantonly (hatched columns), OMP antigen (stippled columns) or OMP vaccine
(filled columns). Each data point represents the mean (± sem) of 4 mice per
group.
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FIGURE 4.5. Temporal changes in haemopoietic progenitor cell numbers in
mice following intradermal immunization with either PBS (unfilled
columns), adjuvant-only (hatched columns), OMP antigen (stippled
columns) or OMP vaccine (filled columns). Each data point represents the
mean (± sem) of 4 mice per group.
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FIGURE 4.6. Temporal changes in (a) viable bone marrow cell numbers (b) dead cells and (c) percentage apoptotic B220+ cells
over a 60 h period following intradermal immunization in Control (unfilled squares) Adjuvant (filled circles) OMP antigen
(unfilled diamonds) and OMP Vaccine groups (filled diamonds). Data represents the mean (± sem) of 3 mice per group.
Arrows designate time of intradermal vaccination.

immunization was predominantly due to a drop in both B220+ cells (Fig.
4.7a) and granulocyte-lineage cells (Fig. 4.7b), but also included other cell
types that were not identified phenotypically in this study (Fig. 4.7c).

4.4

DISCUSSION

This study was undertaken to determine what changes occurred in the bone
marrow

following

intradermal

immunization

with

different vaccine

formulations. Upregulation of splenic haematopoiesis is the principal
mechanism in mice for responding to the acute increase in demand for
phagocytic cells [280]. Splenic haematopoiesis

and splenic hyperplasia

following administration of 89Sr [332, 333], infection with Moloney m urine
leukaemia

virus

[334], malaria

[325] and

other

diseases

occurs

as

compensation for the BM depletion present in these circumstances. It was
likely that this was also true for the OMP Vaccine or OVA Vaccine groups
following immunization.

The

most prominent

effect of intradermal

immunization on the bone marrow was a rapid decline in haematopoietic
progenitor and lineage-committed cell populations, beginning within 12 to
24 h post-immunization. The decline occurred in all the im m unization
groups, but was most striking in the Adjuvant and the OMP Vaccine groups,
confirming an important role for the adjuvant in stimulating these events.
This finding of significant bone marrow depletion induced by vaccination,
like the dramatic depletion of the thymus, has not been previously reported.
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FIGURE 4.7. Temporal changes following intradermal immunization in the numbers of (a) 13220+ lineage cells, (b)
granulocyte lineage cells and (c) all other cells in bone marrow from Control (unfilled squares), OMP antigen (unfilled
diamonds), Adjuvant (filled circles) and OMP vaccine (filled diamonds) groups. Each data point represents the mean (± sem)
of 3 mice per group. Arrows designate time of intradermal vaccination.

It is important to note that although the decline in cell numbers occurred in
all the cell lineages identified, the B cell lineage suffered the greatest losses.
Previous studies [331, 333] have estimated that at least 60 to 70% of pre-B cells
undergo apoptosis during normal B cell, so this may account for B220+ cell
losses. The magnitude of B220+ cell losses in the bone marrow following
intradermal immunization was also reminiscent of the dramatic DP cell loss
occurring simultaneously in the thymus (Chapter 2). Although newly
formed B cells are continuously exported from the bone marrow to the
spleen, the absence of a parallel decline in peripheral B cell numbers, or
histological evidence of an increase in splenic lymphopoiesis suggested that
splenic B cell numbers were not sensitive to short term changes in bone
marrow lymphopoiesis. The suggestion by Xenocostas et al (1991) [324], that
long-lived recirculating B cells in the spleen maintain splenic B cell levels,
may account for these findings.

The rapidity and magnitude of BM cell depletion suggested that an increase
in apoptosis was the most likely mechanism. Colony stimulating factors
(CSF) and cytokines secreted by bone marrow stromal and haematopoietic
cells control the survival, proliferation and development of BM cells [335
337]. CSF (IL-3, Granulocyte Macrophage (GM)-CSF, Granulocyte (G)-CSF,
Macrophage (M)-CSF, stem cell factor, IL-6) and chemokines, IL-7 and Pre-Bcell growth stimulating factor/stromal cell-derived factor-1 (PBSF/SDF-1),
are essential for growth and differentiation of haematopoietic stem cells and
lineage-committed cells [338, 339]. Modulation of serum and bone marrow
CSF levels by cytokines (such as IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-11, IL-12, ILChapter 4
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13, IFN-y,

TN F-a

and

M IP-la)

released

by

activated

granulocytes,

macrophages, T lymphocytes, and bone marrow cells during infection,
inflammation or stress, can affect haematopoiesis [327, 330, 340-352]. Other
immunomodulators,

including heat shock proteins, steroid hormones,

prostaglandins, kinins and complement proteins, that may be released into
the chemical milieu during stress or inflammatory responses can also
inhibit bone marrow haematopoiesis [353-357]. A decline in the level of any
essential

factors,

in

response

to

administration

of

SAMA4-antigen

complexes, may have resulted in increased BM cell apoptosis and necrosis
[338, 355, 358, 359].

Surprisingly, the rapid decline in BM cell numbers in the OMP Vaccine
group was not associated with detectable increase in dead and apoptotic cells.
It was likely that rapid removal

of early apoptotic cells by resident

macrophages [303, 360, 361] resulted in the low level of apoptotic and dead
cells in vivo. Nevertheless, from this result it was apparent that although
flow cytometry with DNA intercalatants (7-AAD and PI) could detect
apoptosis in vitro (as shown in Chapter 2), where phagocytic removal of cells
is minimized [252, 266, 362-364], it had limited usefulness for detecting
apoptosis in vivo in my hands. Alternative techniques, such as in situ
terminal deoxynucleotide transferase-mediated dUTP nick end-labelling
(TUNEL), detection of apoptosis-related markers (such as CD69 and CD25)
[263] or measurement of mitochondrial transmembrane potential [261], to
name just three, may more readily detect early increases in apoptosis and
necrosis in vivo [259],
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Compared to the large decline in B lineage cells, granulocyte and monocyte
losses were only short-lived. Granulocytes could be readily distinguished
from the monocytic lineage by the expression of the Gr-1 surface antigen
[247, 365], but the monoclonal antibody, M l/70, used in this study to detect
Mac-1+Gr-T cells [246, 366], could not distinguish between monocytes,
macrophages and dendritic cells (DC). This antibody reacts with CDllb, a
component of the surface adhesion molecule, CDllb/CD18, expressed on
granulocytes, monocytes, macrophages and DC [246, 366]. Although DC are
the most potent inducers of activation of naive T cells, they only represent a
minor population compared to monocytes and macrophages [111, 367, 368].
Therefore, the rapid rise detected in the circulating numbers of Mac-1+Gr-T
cells in the OMP Vaccine group following intradermal im m unization
(Chapter 2) was consistent with increases predominantly in monocytes and
macrophages. Activation of Mac-1+Gr-T cells is a potent stimulator of bone
marrow cell proliferation [323, 326, 327]. Cycling of activated Mac-1+Gr-1'cells
into the bone marrow may have been one stimulus for increases in the d e
novo synthesis of haematopoietic cells of all lineages.

Exposure to antigen in the form of SAMA4-OMP complexes, was a potent
stimulus for bone marrow depletion. However, this study did not address all
the questions regarding the effect of immunization on the bone marrow.
Future studies may need to investigate the impact of immunization on the
rate of migration of granulocyte and macrophage colony-forming units to
the spleen, and thymus-seeding progenitors to the thymus, as a direct
measure of BM performance following immunization. The skin possesses a
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comprehensive range of immune effector cells, such as Langerhans cells, a
type of DC that resides in the skin, and macrophages and polymorphs that
can phagocytose antigen and initiate immune

responses [35, 230]. The

question of whether or not the skin route uniquely provokes the BM
responses

detected can be addressed by assessing

immunization

routes.

Preliminary

data

indicate

changes
that

by other

intramuscular

immunization also provokes a greater declines in BM (and thymus) cell
numbers than by intradermal immunization, whereas the subcutaneous
route provokes only a minimal response (data not shown). Splenic NK cell
activity on Day 9 following intradermal immunization was not increased
(Chapter 2). However, the apparent link between NK-like cell activity and
BM depletion [286] needs to be further examined. Additional studies,
including in situ staining of bone marrow may also indicate the impact of
immunization on bone marrow stromal cells, which nurse the developing
cell lineages. Finally, it remains to be determined whether or not other host
species are similarly affected by immunization.
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CHAPTER 5
Generating
Mucosal
Systemic
Immunity
Intradermal Vaccination

and
By

5.1

Actinobacillus

INTRODUCTION

p l e u r o p n e u m o n i a e , a Gram-negative

etiological agent responsible for pleuropneumonia
commercially

available

bacterins

reduce

the

coccobacillus, is the
in pigs [369]. Current

morbidity

and

mortality

associated with acute infections but do not prevent animals from becoming
chronically infected or asymptomatic carriers of the disease [370]. One m ajor
deficiency of commercial vaccines is that bacterins primarily provide serovarspecific protection, whereas immunity from natural infection is believed to be
cross-protective against all serovars

[371-373]. To further

improve

the

protective efficacy of vaccines, virulence factors of A. p l e u r o p n e u m o n i a e ,
such as capsular polysaccharide [235], haemolysin [278], lipopolysaccharide
(LPS) [374], IgA proteases [375], permeability factor or outer membrane proteins
(OMPs) [376] have also been evaluated, but with varying degrees of success.

While considerable effort has been directed towards an assessment of the
protective capacity of different antigen preparations of A. p l e u r o p n e u m o n ia e ,
little attention has been given to the immunization route. It is surprising that
pleuropneumonia vaccines are primarily administered intramuscularly or
subcutaneously [370, 377] even though these delivery routes are not renown
for promoting mucosal immunity.

The ability to elicit mucosal IgA is

considered to be an important requirement in the development of protective
immunity against a range of respiratory pathogens like A. p l e u r o p n e u m o n i a e
[196, 378]. However, currently numerous factors, such as inefficient antigen
delivery, mucosal tolerance and the lack of suitable mucosal adjuvants, make
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most mucosal vaccination strategies impracticable [9].

Intradermal immunization

with

SAMA4

promotes

both mucosal

and

systemic antibody responses in different livestock species without any adverse
immunological or physiological side-effects [100, 102]. Intranasal re-exposure
to the immunizing antigen also elicits strong IgG and IgA responses in both
serum

and

respiratory

tract

washings,

indicating

that

intradermally

immunized animals developed local and systemic immunological memory
[102]. Therefore, this study was undertaken to determine whether intradermal
immunization with SAMA4-OMP complexes promoted systemic and mucosal
immunity in mice. Since capsular polysaccharides and lipopolysaccharides are
co-purified with proteins during OMP extraction [237, 240], the antibody
specificity of the immune response toward the polysaccharide components of
OMP was also examined.

5.2

5.2.1

MATERIALS AND METHODS

Immunization of Mice and Sampling Schedule

Female BALB/c mice aged 8 to 12 weeks were immunized intradermally
(78/group) with 100 [d of either PBS, pH 7.2 (Control group), SAMA4
(Adjuvant Group), OMP (OMP Antigen group) or SAMA4-OMP (OMP
Vaccine group) on Days 0 and 7, as described in Chapter 2.
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On weeks 0, 1, 2, 3, 4, 6, 13 and 21, mice from each treatment group were
euthanased by intraperitoneal injection with 50 pi of 300 mg/ml sodium
pentobarbitone (Jurox). Blood was collected after euthanasia and allowed to
clot at room temperature for 1 h before being centrifuged at 1500 g for 10
min. Respiratory tract washings (RTW) were obtained by inflating and
deflating the lungs 5 times with 1 ml PBS. Vaginal washings (VW) were
obtained by repeatedly flushing the vagina 20 times with 200 pi PBS. Faecal
extracts (FE) were prepared by homogenizing faecal pellets in PBS (200 pi per
pellet) containing 0.05% (w/v) Thiomersal (BDF1) and 1 mM PMSF (Sigma).
Cells and other debris were removed

from

RTW,

VW

and FE by

centrifugation (1500 g for 10 min). Serum, RTW, VW and FE were stored at 20 °C.

5.2.2

Preparation of deproteinised polysaccharide-rich samples from OMP

OMP purified from A. p leu r o p n e u m o n i a e contained both protein and
polysaccharide components. Polysaccharides were purified by proteinase K
digestion of OMP proteins [379]. Briefly, a stock OMP solution (900 pg OMP
suspended in 180 pi PBS) was diluted with 60 pi of 4x non-reducing Laemmli
buffer [380] and 50 pi of 600 pg/ml proteinase K solution (Boehringer
Mannheim), and incubated at 37 °C for 2 h. The sample was heated at 95 °C
for 10 min, and allowed to cool. A second proteinase K digestion step was
done for 1 h at 37 °C to ensure complete digestion of OMP proteins. OMPderived polysaccharide preparations contained no protein detectable by
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silver-staining of polyacrylamide gels, and were stored at -20 °C until use.

5.2.3

Determination of anti-OMP and anti-polysaccharide responses by
enzyme-linked immunosorbent assay (ELISA)

OMP- or polysaccharide-specific immunoglobulins in serum, RTW, V W
and FE were detected by ELISA. A 25 ^ig/ml OMP solution was prepared by
diluting stock OMP (5 mg OMP/ml PBS) with coating buffer (50 m M
bicarbonate buffer, pH 9.6, 0.15% {w/v} Na2C 03, 0.29% {w/v} NaH C03). The
stock deproteinised polysaccharide-rich fraction was diluted in coating buffer
by an equivalent amount. In separate assays, 50 ^il of the OMP or OMPderived polysaccharide preparations were dispensed into each well of 96well plates (Immulon, Dynatech Labs, USA) and incubated overnight at 4 °C.
Unbound antigen was removed with 2 washes of distilled water, one wash
with Tris-Saline-Tween-20 (TSTw; 25 mM Tris-HCl in 0.15 M NaCl and
0.05% Tween 20, pH 7.2) and a further 2 washes of distilled water.

To determine the optimal dilution for samples, a preliminary ELISA was
done with pooled sera or RTW from the different time points. Sera were
assayed after being serially two-fold diluted from 1/100 to 1/800 in TSTw,
while pooled RTW were assayed neat or after being serially two-fold diluted
from 1/2 to 1/8. From these data, a 1/200 dilution was used to determine the
anti-OMP and anti-polysaccharide responses in individual sera and a 1/4
dilution was used for individual RTW. VW and FE were assayed without
further dilution. Samples (50 (utl) were added in triplicate to the wells and

Chapter 5

page 115

incubated for 1.5 h at 37 °C. Plates were washed as before and 50 pi of the
following dilutions

of horseradish

peroxidase

(HRP)-conjugated

anti

murine antibodies (diluted in TSTw) were added to the respective plates: IgG
(1/1000 dilution; Silenus, Hawthorn, Vic, Australia), IgA (1/400 dilution;
Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA), IgM (1/1000
dilution; Silenus), IgE (1/1000 dilution; Southern Biotechnology Assoc. Inc.,
Birmingham AL, USA), IgGl (1/600 dilution; Zymed, San Francisco, CA,
USA), IgG2a (1/200 dilution; Zymed), IgG2b (1/600 dilution; Zymed) or IgG3
(1/1000 dilution; Zymed). Plates were incubated for 1.5 h at 37 °C, washed as
before, and visualized by adding 50 pi of freshly prepared 0.4% (w/v) ophenylenediamine

dihydrochloride

(0.4%

w/v

o-phenylenediamine

dihydrochloride {Sigma} dissolved in citrate phosphate buffer {0.025 M Citric
acid, 0.05 M Na2H P 04, pH 5) and 0.03% {v/v} H20 2) to each well. Colour
development was stopped after 10 min by adding 25 pi of 2.5 M H2S 0 4to each
well. Optical densities were measured at 492 nm with an iEMS microplate
reader (Labsystems, Norway).

5.2.4

Optimization of OMP dose for assessment of immunological recall
in immunized mice

8 to 12 wk old naive female BALB/c mice (4 per group) were injected
intraperitoneally with 300 pi of an anaesthetic mixture containing 0.4
mg/ml xylazine HC1 (Troy Laboratories, Smithfield, NSW, Australia) and 4
mg/ml ketamine HC1 (Parnell Laboratories, Silverwater, NSW, Australia).
Anaesthetized mice were inoculated intranasally with either 5, 50, 500 or
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5000 ng OMP (in 25 \xl PBS, pH 7.2). Anti-OMP IgG and IgA responses were
assessed in serum and RTW after 7 days.

5.2.5

Recall of immunity in immunized mice

Recall of immunity against OMP was assessed 21 weeks after primary
immunization by intranasally inoculating mice with 50 ng of OMP. This
dose of OMP was established in a preliminary experiment (described in
Section 5.2.4). Serological responses to OMP in serum

and RTW

of

intradermally immunized mice were assessed over a 3 week period
following intranasal inoculation.

5.2.6

Enumeration of OMP-specific antibody-secreting cells by ELISPOT

The number of OMP-specific IgG or IgA antibody-secreting cells (ASC) in the
spleens and lung tissue of mice were determined over a 3-week period
following intranasal inoculation

of mice with .50 ng OMP. Single-cell

suspensions from pools of 3 to 4 collagenase-digested lung tissue were
prepared for each group as described in Chapter 2. Cells were washed twice
with RPMI-1640/10% (v/v) NBS and resuspended in cell culture m edium
(RPM1-1640 containing 54 mg/ml sodium benzyl penicillin {CSL}, 90 mg/ml
streptomycin sulfate {CSL}, 2mM L-glutamine {Cytosystems}, 2 mM sodium
pyruvate {Cytosystems}, 58 mM b-MSH {Koch} and 10% {v/v} FCS {GibcoBRL,

Life

Technologies,

Mulgrave,

Vic,

Australia}).

Erythrocyte-free

splenocytes were prepared from individual spleens as described in Chapter 2
and resuspended in culture medium.
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ASC were enumerated by the ELISPOT technique [381], Briefly, 96-well nitro
cellulose bottom plates (Multiscreen HA 96 well filtration plate, Millipore,
Lane Cove, NSW, Australia) were pre-coated with 100 pi of 50 pg/ml OMP
in PBS, pH 7.2 at 4 °C overnight. Unbound antigen was removed by washing
plates 3 times with PBS. Plates were blocked for 1 h at 37 °C with 200 pi/well
of RPMI-1640/5% (v/v) foetal calf serum (CSL). Routinely, 2 xlO5 cells (in 100
pi of supplemented RPMI-1640) were added in triplicate to ELISPOT plates
and incubated for either 3 h (for splenocytes) or overnight (for lung cells) at
37 °C in a 5% C 0 2 humidified incubator. Plates were washed three times in
PBS to remove cells. To each well was added 100 pi of a 1/1000 dilution (in
TSTw) of HRP-conjugated anti-murine IgG (Silenus) or a 1/400 dilution of
HRP-conjugated anti-murine IgA (Kirkegaard and Perry Laboratories). Plates
were incubated for 1.5 h at 37 °C and then washed as before. Wells were
incubated with 200 pi 10 mM Tris-HCl, pH 7.6 at room temperature for 5
min. Plates were flicked dry and 100 pi of freshly prepared 0.04% (w/v) AEC
substrate (3-amino-9-ethycarbazole {Sigma}; 20 mg dissolved in 2.5 m l
dimethylformamide and made up to 50 ml in 50 mM acetate buffer; filtered
through a 0.22 m filter {Millipore}, and containing 0.02% {v/v} H20 2.) was
added for spot colour development.
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5.2.7

Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
(PAGE) and immunoblotting

OMP or OMP-derived polysaccharide preparations were electrophoresed by
discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) in a Mini-PROTEAN II assembly (Biorad) under reducing
conditions described elsewhere [380]. Samples were reduced and denatured
by boiling at 95 °C for 5 min

in the presence of 20%

(v/v) 2-|3-

mercaptoethanol (Biorad), 4% (v/v) glycerol and 8% (w/v) sodium dodecyl
sulphate in 0.25 mM Tris-HCl, pH 6.8. Denatured OMP and polysaccharide
samples were loaded onto a 12% (w/v) acrylamide (Biorad) gel overlaid with
a 4% stacking gel. Samples were electrophoresed at a constant voltage (130V)
in Tris-Glycine buffer (25 mM Tris-HCl, 0.19 M glycine, 0.1% {w/v} SDS, pH
8.6). Electrophoresis was stopped when the 0.05% (w/v) bromophenol blue
tracking dye had migrated to the bottom of the gel. Electrophoretically
resolved polypeptides were stained with 0.025% (w/v) coomassie brilliant
blue R-250 dissolved in 40% (v/v) methanol, 7% (v/v) glacial acetic acid) at
37 °C and destained with a solution containing 13.5% (v/v) ethanol and 3%
(v/v) acetic acid. Polysaccharides were silver-stained as described elsewhere
[382].

Electrophoretically resolved OMP or polysaccharide preparations were
transferred onto nitrocellulose membranes (Optitrans BA-S 85, Schleicher &
Schuell) overnight in a Hoefer TE series transphor blotting apparatus under
conditions described elsewhere [383]. Immunoblots were washed in TSTw
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for 5 min and then blocked for 1 h at 25 °C with 5% (w/v) skim m ilk
(Allowrie, Eastwood, NSW, Australia) dissolved in TSTw. The blots were
washed 3 times with TSTw and then reacted for 1.5 h at 25 °C with either
pooled sera (1/500 dilution) or pooled RTW

(1/10 dilution) from the

Control, OMP Antigen or OMP Vaccine groups. Blots were washed as before
and

incubated

with

HRP-conjugated

anti-murine

im m unoglobulin

(Silenus; 1/2000 dilution) for 1.5 h at 25 °C. After further washes, blots were
incubated in 10 mM Tris-HCl, pH 7.6 for 10 min at 25 °C and then reacted
with freshly prepared 0.05% (w/v) DAB substrate (freshly prepared solution
of 0.5 mg/ml 3,3-diaminobenzidine substrate {Sigma} dissolved in 10 m M
Tris-HCl, pH 7.6 and 0.03% {v/v} H20 2). Colour development was stopped by
rinsing blots in water.

5.2.8

Determination of antibody responses against SAMA4 iscoms by
enzyme-linked immunosorbent assay (ELISA)

Serum antibody reactivity (IgG) against SAMA4 was assayed by ELISA as
described above. SAMA4 was prepared as described in Chapter 2 and coupled
to ELISA plates at dilutions ranging from 1/10 to 1/80 prepared in coating
buffer. A 1/40 dilution of SAMA4 was used to assay serum reactivity from
the Adjuvant

and OMP Vaccine

groups.

Antibody

responses

were

determined on 1/100 dilutions of the individual sera prepared in TSTw.

5.2.9

Determination of antibody responses against OVA by enzyme-linked
immunosorbent assay (ELISA)

Intradermally immunized
Chapter 5
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cellular response
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profiles irrespective of whether the immunizing antigen was OMP or OVA
(Chapter 2 and 3). To determine if a similar immunoglobulin

response

profiles were also elicited against OMP and OVA, female BALB/c mice aged
8 to 12 weeks (17 per group) were immunized intradermally with 100 jil of
either PBS, pH 7.2 (Control group), OVA (OVA Antigen group) or SAMA4OVA (OVA Vaccine

group) as described in Chapter 3. OVA-specific

immunoglobulins in serum and RTW were detected by ELISA as described
above, except that 10 pg/ml OVA solution was used to couple the ELISA
plates. Antibody responses were determined from 1/100 dilutions of the
individual sera and 1/4 dilutions of the individual RTW prepared in TSTw.

5.2.10

Statistical analyses

The results reported represent the mean (± sem). The means of different
groups at individual time points were compared by two-tailed Student's ttest. Changes were considered significant at P<0.05.

5.3

5.3.1

Serum

anti-OMP

RESULTS

antibody

responses

following

intradermal

immunization
The serum antibody responses elicited against OMP over a 21 week period
following immunization are depicted in Fig. 5.1a-d. Compared to controls,
the OMP Antigen and OMP Vaccine groups elicited a rapid increase in IgG (P
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Weeks
FIGURE 5.1. Serum anti-OMP (a) IgG, (b) IgM and (c) IgA responses over a 21
week period following primary immunization in mice from the Control
(unfilled squares), OMP Antigen (unfilled diamonds) or OMP Vaccine (filled
diamonds) groups, (d) IgG subclass responses at Week 13 in mice from the
Control, OMP Antigen or OMP Vaccine groups. Total IgG (filled columns),
IgGl (hatched columns), IgG2a (wavy columns), IgG2b (stippled columns) and
IgG3 (unfilled columns). Each data point represents the mean (± sem) from 4
mice per group. Arrows designate time of intradermal immunization.
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< 0.005; Fig. 5.1a), IgM (P < 0.02; Fig. 5.1b) and IgA (P < 0.02; Fig. 5.1c). Peak
serum antibody responses in mice from the Antigen and Vaccine groups
were essentially similar, but declined faster over time in the OMP Antigen
group. Serum immunoglobulins in the OMP Vaccine group remained
elevated beyond Week 21 and were significantly higher than in the OMP
Antigen group at this time (P < 0.05).

Both groups also showed significant elevations (P < 0.01 for all subclasses) in
IgGl, IgG2a, IgG2b and IgG3 at Week 13 post-immunization (Fig. 5.1d). IgGl
and IgG3 were the predominant subclasses with IgG2a and IgG2b showing
smaller increases. Significant changes in serum IgE levels was not detected at
any time during the first 4 weeks of immunization (data not shown).

5.3.2

Mucosal anti-OMP antibody response

Intradermal immunization with OMP primarily induced an IgG response
against OMP in the RTW of OMP Antigen and OMP Vaccine groups (Fig.
5.2a). OMP-specific IgM or IgA were not detected (data not shown). RTW IgG
rose significantly to a peak at Week 13 post-immunization in both groups (P
< 0.05). The peak response in the OMP Antigen group was significantly
greater (2.5-fold) than in the OMP Vaccine group (P < 0.05), but fell m ore
rapidly than in the OMP Vaccine group. As for serum, the increase in total
RTW IgG in both groups was due predominantly to a rise in IgGl and IgG3,
with

a

Chapter 5

smaller

rise

in

IgG2a

and

IgG2b

(Fig.

5.2b).
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FIGURE 5.2. (a)RTW IgG responses in mice from the Control (unfilled squares), OMP Antigen (unfilled
diamonds) or OMP Vaccine (filled diamonds) groups over a 21 week period post-immunization, (b) IgG
subclass responses at Week 13 in mice from the Control, OMP Antigen or OMP Vaccine groups. Total IgG
(filled columns), IgGl (hatched columns), IgG2a (wavy columns), IgG2b (stippled columns) and IgG3 (unfilled
columns), (c) FE IgG response over a 21 week period post-immunization. Each data point represents the m ean
(± sem) from 4 mice per group. Arrows designate time of intradermal immunization.

A small, but significant, IgG response (P < 0.05) against OMP was detected at
Week 13 post-immunization in faecal pellet extracts (FE) prepared from the
OMP Vaccine group, but not the OMP Antigen group (Fig. 5.2c). Significant
increases in OMP-specific FE IgA, or VW IgG or IgA, were not detected over
the entire 21-week post-immunization period (data not shown).

5.3.3

Antibody response against OMP polysaccharide antigens in serum
and respiratory tract washings from mice immunized with OMP

The presence of polysaccharides in the OMP preparations was determined by
a standard silver-staining technique for carbohydrate [379, 382]. Although the
types of polysaccharides present in OMP preparations were not identified,
work done by others

[232] indicates

that

they

consist

of

capsular

polysaccharides and/or lipopolysaccharide co-purified with OMP.

Intradermal immunization with OMP elicited a rapid increase in serum IgG
against the polysaccharide components of OMP in both the OMP Antigen
and OMP Vaccine groups (P < 0.05; Fig. 5.3a). An anti-polysaccharide IgA
response was not detected over a 21 week period post-immunization in the
serum of the different treatment groups (data not shown). In the OMP
Antigen group, a significant (12-fold) increase in IgG3 (P < 0.05) accounted
for much of the rise in total IgG between 2 to 6 weeks post-im m unization
(Fig. 5.3b). IgG3 levels declined with a concomitant increase in IgGl. IgGl
levels rose significantly (P < 0.05) to a peak at W eek 13 before also declining.
Elevations in both IgGl and IgG3 were sustained for at least 21 weeks in the
OMP Vaccine group.
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W eeks
FIGURE 5.3. (a)Serum anti-polysaccharide IgG responses in mice from the Control (unfilled squares), OMP
Antigen (unfilled diamonds) or OMP Vaccine (filled diamonds) groups over a 21 week period post
immunization. (b) Serum IgG subclass responses at Weeks 6 and 13 in mice from the Control, OMP Antigen or
OMP Vaccine groups. Total IgG (filled columns), IgGl (hatched columns), IgG2a (wavy columns), IgG2b
(stippled columns) and IgG3 (unfilled columns). Each data point represents the mean (± sem) from 4 mice per
group. Arrows designate time of intradermal immunization.

Intradermal immunization with OMP primarily induced an IgG response
against the polysaccharide components of OMP in RTW of the OMP Antigen
and OMP Vaccine groups (Fig. 5.4a). RTW IgG rose significantly to a peak at
Week 13 (P < 0.05) in both groups. The peak response was significantly
greater (4.5-fold) in the OMP Antigen group than in the OMP Vaccine group
(P < 0.05). The rise in total IgG in OMP Antigen and OMP Vaccine groups
were attributed to increases in IgGl and IgG3 (Fig. 5.4b). Peak R TW
immunoglobulin responses in the OMP Antigen group declined faster than
in the OMP Vaccine group.

5.3.4
A

Immunob lotting
typical

Coomassie

blue

stained

SDS-PAGE

profile

of

A.

p l e u rop n eu m on ia e serovar 1 strain HS54 is shown in Fig. 5.5, Lane 2. At
least 36 polypeptide bands ranging in size from 14 to 94 kDa can be seen.
Purified OMP (Fig. 5.5, Lane 3) contained five major bands with apparent
molecular masses of 14, 22, 33, 37 and 39 kDa. Outer membrane-derived
polysaccharides were visualized by silver-staining (Fig. 5.5, Lane 4). These
antigens appeared as dispersed smears in two zones with a range in
molecular mass between 45-80 kDa and between 14-22 kDa, respectively.
These two antigen zones correspond to the capsular polysaccharide (CP) and
lipopolysaccharide (LPS) antigens, respectively, which normally co-purify
with OMPs prepared by the sucrose density gradient procedure. The protein
and polysaccharide profiles were consistent to those reported by others [232,
384].
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Weeks
FIGURE 5.4. (a) RTW anti-polysaccharide IgG responses in mice from the
Control (unfilled squares), OMP Antigen (unfilled diamonds) or OMP Vaccine
(filled diamonds) groups over a 21 week period post-immunization, (b) R T W
IgG subclass responses at Week 13 in mice from the Control, OMP Antigen or
OMP Vaccine groups. Total IgG (filled columns), IgGl (hatched columns),
IgG2a (wavy columns), IgG2b (stippled columns) and IgG3 (unfilled columns).
Each data point represents the mean (± sem) from 4 mice per group. Arrows
designate time of intradermal immunization.
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FIGURE 5.5. SDS-PAGE profile of A. pleuropneumoniae antigens. Pharmacia
low molecular weight protein standards (lane
1), denatured A.
p l e u r o p n e u m o n i a e serovar 1, HS54 (lane 2) and outer membrane proteins
(lane 3) stained with Coomassie blue; silver-stained SDS-PAGE profile of
proteinase K-extracted polysaccharide (lane 4).
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5.3.5

Serum

and

RTW

immunoreactivity

against

OMP

and

polysaccharide
The serum anti-OMP responses elicited by the OMP Antigen and OMP
Vaccine groups were very similar, therefore, it was of interest to examine if
any differences existed in the antigens recognized by the two groups. The
target reactivity of sera (Fig. 5.6) and RTW (Fig. 5.7) collected at Week 13
(peak antibody responses) from mice in different treatment groups was
assessed by immunoblotting against either OMP or a deproteinized OMPderived polysaccharide preparation. Serum or RTW antibodies from Control
mice did not react against either OMP protein or polysaccharide components
(data not shown). When reacted against OMP, pooled serum and RTW from
the OMP Antigen group showed weaker reactivity against the 22, 26, 28, 33,
36 and 37 kDa proteins (Fig. 5.6, Lane 1; Fig. 5.7, Lane 1) than the Vaccine
group (Fig. 5.6, Lane 3; Fig. 5.7, Lane 3). Both groups showed strong reactivity
against a 14 kDa band.

When

reacted against the

deproteinized

OMP-derived polysaccharide

preparation, both groups showed strong serum reactivity, but only against
the high molecular mass polysaccharide antigens (Fig. 5.6, Lanes 2 and 4).
Only the Antigen

group had strong reactivity against polysaccharide

antigens in RTW (Fig. 5.7, Lane 2). By comparison, the Vaccine group had
weak reactivity against both high and low molecular mass polysaccharide
antigens (Fig. 5.7, Lane 4).
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F IG U R E 5.6. Immunoblot profile of pooled serum samples obtained from

mice in the OMP Antigen or OMP Vaccine groups at Week 13 post
immunization. Serum immunoblot profile of the OMP Antigen group
against OMP (lane 1) or OMP-derived polysaccharides (lane 2). Serum
immunoblot profile of the OMP Vaccine group against OMP (lane 3) or
OMP-derived polysaccharide (lane 4). Molecular weights of polypeptide
bands were calculated using low molecular weight protein standards
(indicated on the left).
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FIGURE 5.7. Immunoblot profiles of pooled RTW samples obtained from
mice in the OMP Antigen or OMP Vaccine groups at Week 13 post
immunization. RTW immunoblot profile of the OMP Antigen group
against OMP (lane 1) or OMP-derived polysaccharides (lane 2). R TW
immunoblot profile of the OMP Vaccine group against OMP (lane 3) or
OMP-derived polysaccharide (lane 4). Molecular weights of polypeptide
bands were calculated using low molecular weight protein standards
(indicated on the left).
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5.3.6

Recall of immunological memory against OMP in serum and RTW

To test whether intradermally immunized mice developed systemic and
mucosal immunological memory against OMP, 50 ng OMP was intranasally
inoculated into mice 21 weeks after primary immunization. This dose was
established by intranasally inoculating groups of naive BALB/c mice with
either 5, 50, 500 or 5000 ng OMP. Anti-OMP IgG and IgA responses were
detected after 7 days in serum and RTW of mice given 500 or 5000 ng OMP,
but were not detected in mice given 5 or 50 ng (Fig. 5.8a-d).

Intranasal inoculation boosted the declining serum IgG in the OMP Antigen
group. In this group, serum IgG rose significantly over a 3-week period (P <
0.05), and was equivalent to that present in the OMP Vaccine group at this
time (Fig. 5.9a). By comparison, the peak serum IgG level reached at about
Week 6 in the OMP Vaccine group did not decline significantly by Week 21.
As a result, intranasal inoculation with OMP did not boost serum IgG levels
in the OMP Vaccine group further.

Intranasal inoculation with OMP also boosted the declining serum IgA
levels in the OMP Antigen group. In this group, serum IgA rose significantly
(3.5-fold) over a 3-week period (P < 0.05) (Fig. 5.9b). By comparison, the
small, but significantly elevated serum IgA levels reached at about Week 6
in the OMP Vaccine group did not decline significantly by Week 21. As a
result, intranasal inoculation with OMP did not boost serum IgA levels
further. Nevertheless, serum IgA was significantly higher than in the
Control group over the entire 3-week period (P < 0.05).
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OMP Dose (ng/ 25 ml)

OMP Dose (ng/ 25 ml)

FIGURE 5.8. Titration of OMP dose for assessment of immunological recall
in immunized mice. Serum (a) IgG and (b) IgA and RTW (c) IgG and (d) IgA
responses in naive mice at Day 0 (unfilled columns) and Day 7 (filled
columns) after intranasal inoculation with different doses of OMP. The
results represent the mean (± sem) from 4 mice per group.

Intranasal inoculation with OMP boosted RTW IgG in the OMP Antigen
group by 6-fold (P < 0.05) over a 3-week period following (Fig. 5.9c). RTW IgG
in the OMP Vaccine group was significantly elevated (P < 0.05) as a result of
C h a p te r 5

p a g e 133

primary immunization 21 weeks earlier. RTW IgG in the OMP Vaccine
group did not rise further due to intranasal inoculation but was significantly
higher than in the Control group over the entire 3-week period post
inoculation. RTW IgA in the OMP Antigen group rose significantly (4-fold)
over a 3-week period following intranasal inoculation (P < 0.05) (Fig. 5.9d).
The OMP Vaccine group also elicited a small rise in RTW IgA over the same
period.

Transudation of serum antibodies may have caused the rise in RTW IgG
following intranasal inoculation with OMP. To clarify this, the numbers of
OMP-specific antibody secreting cells (ASC) was determined in both lung
and spleen tissue. Before intranasal inoculation very few OMP-specific IgAASC (Fig. 5.10a and c) or IgG-ASC (Fig. 5.10b and d) were present in lung or
spleen

tissue,

respectively.

However,

by one

week

after

intranasal

inoculation the numbers of IgA or IgG-ASC in lung and spleen tissue of
both OMP antigen and OMP vaccine groups rose significantly (P < 0.01). The
increase in OMP-specific ASC in lung tissue confirmed that antibody was
produced locally. The small rise in spleen IgA-ASC in the Control group
may have represented a small primary response to intranasal inoculation
with OMP, but was not associated with detectable increases in serum
antibodies.
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FIGURE 5.9. Serum and RTW anti-OMP responses over a 3-week period after
intranasal inoculation with 50 ng OMP in mice from Control (unfilled
squares), Antigen (unfilled diamonds) or Vaccine groups (filled diamonds), (a)
Serum IgG, (b) serum IgA, (c) RTW IgG and (d) RTW IgA. Each data point
represents the mean (± sem) from 4 mice per group.
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FIGURE 5.10. Enumeration of IgA (a and c) and IgG (b and d) OMP-specific
antibody secreting cells in collagenase-digested lung tissue (a and b) and spleen
(c and d) from mice in either Control (unfilled squares), Antigen (unfilled
circles) or Vaccine groups (filled circles) after intranasal inoculation with 50 ng
OMP. Results represent responses in pools of 3 to 4 lungs or individual
spleens (n= 3 to 9) and the group mean (+).

5.3.7

Antibody response against SAMA4 iscoms following intraderm al
im m unization

Fig. 5.11 demonstrates the lack of detectable antibody reactivity (IgG) against
SAMA4 in the Adjuvant

or OMP Vaccine groups at Day 11 post

immunization. The same level of reactivity was present until at least Day 28
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(data not shown) By comparison, a strong response against OMP was present
in the OMP Vaccine group over the same period.
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FIGURE 5.11. Comparison of serum anti-SAMA4 IgG response in Control
(unfilled column), Adjuvant (hatched column) and OMP Vaccine (filled
column) groups at Day 11 post-immunization with the response obtained by
the OMP Vaccine group against OMP (wavy column). Each data point
represents the combined mean (± sem) from 3 mice.

5.3.7

Antibody

response

against

OVA

following

intradermal

im m unization
Compared to controls, mice in the OVA Vaccine group elicited a significant
increase in IgG, reaching a peak by Day 14 (P<0.0005) before declining at Day
21 (Fig. 5.12a). An increase in serum IgG was not detected in the OVA
Antigen group over the same period. An increase in serum IgA was not
detected in either the OVA Vaccine or the OVA Antigen group (Fig. 5.12b)
although a small increase in IgM was present at Day 21 in the OVA Vaccine
group (Fig. 5.12c). The increase in total IgG in the OVA Vaccine group was
predominantly due to a rise in IgGl (Fig. 5.12d). No increases in OVAspecific immunoglobulins were detected in the RTW of any group (data not
shown).
Chapter 5

page 137

FIGURE 5.12. Serum anti-OVA (a) IgG, (b) IgA and (c) IgM responses in mice
from the Control (unfilled squares), OVA Antigen (unfilled diamonds) and
OVA Vaccine (filled diamonds) groups over a 21 Day period following
intradermal immunization. (D) IgG subclass responses over a 21 Day period
in mice from the Control, OVA Antigen and OVA Vaccine (filled
diamonds) groups. Total IgG (filled squares), IgGl (filled circles), IgG2a
(unfilled squares), IgG2b (unfilled circles) and IgG3 (crossed-squares). Each
data point represents the combined mean (± sem) from 4 mice.
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5.4

DISCUSSION

Mucosal vaccination is believed to be the best means of achieving im m unity
against mucosal pathogens such as A. p l e u r o p n e u m o n i a e [196]. However,
mucosal vaccination is not generally practiced because of the lack of
commercially available mucosal vaccines against A. p l e u r o p n e u m o n ia e and
the difficulties involved in immunizing large pig herds by a mucosal route
[9]. There are now numerous reports demonstrating IgA production, and/or
protection against mucosal pathogens, following peripheral im m unization.
For example, in separate studies, intra-pelvic [82, 209], subcutaneous [202],
intramuscular [224] and intradermal immunizations [102, 161, 222] have all
resulted in production of high levels

of mucosal IgA. Against this

background, a number of studies [100, 102, 103] have demonstrated that
intradermal vaccination is a practicable alternative to other im m unization
routes for eliciting mucosal and systemic antibody responses in different
livestock species, without many of the limitations

imposed by other

vaccination routes. Therefore, this study assessed the kinetics of systemic
and

mucosal

antibody

production,

and

isotype

distribution

of

immunoglobulins elicited against OMP in intradermally immunized mice.

Different immunoglobulin classes have distinct functional properties in an
immune response, for example, with respect to their ability to activate
complement [386, 387], mediate antibody-dependent cellular cytotoxicity
[144], mediate opsonophagocytosis [388], and react against protein

or

carbohydrate antigens [389]. Therefore, the ability to induce a range of
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different im m unoglobu lin isotypes is an important attribute of prospective
vaccines [77, 390]. In this study, intraderm al im m unization of mice w ith
either OMP antigen or OMP vaccine elicited comparable increases in OMPspecific serum and RTW

IgG l, IgG2a, IgG2b and IgG3 antibodies, w ith

reactivity against protein and polysaccharide components. OMP-specific IgM
and IgA were also readily detected in serum, although the reactivity in R T W
were negligible. Antibodies directed against SAMA4 were not detected.

The com plem ent-fixing and opsonizing properties of antibodies present in
the convalescent sera of naturally or experimentally infected swine are
considered im portant for clearance of A. pleuropneumoniae [232-236]. These
antibodies are typically directed against the outer membrane
capsular

polysaccharides

pleu ropn eu m on iae

and

lipopolysaccharide

proteins,

components

of

A.

[232-236]. Therefore, it was likely that the antibody

isotypes elicited in mice following intraderm al im m unization would also
The

rapid

clearance of bacteria from the lungs of intradermally immunized

m ice

play a protective

role in A.

pleu ropn eu m on iae

infection.

follow ing intranasal challenge w ith A. pleu rop n eu m on ia e

(Chapter 7)

supported such a role for these antibodies.

Recovery from natural infection w ith A. p l e u r o p n e u m o n i a e confers life
long im m unity [373], therefore, an efficacious pleuropneum onia

vaccine

should also possess such an attribute. To test whether im m unized m ice
developed im m unological memory, a subim m unogenic dose of OMP (50
ng) was inoculated intranasally 21 weeks after primary im m unization. T h e
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increase in serum OMP-specific IgG and IgA in the OMP Antigen group
following re-exposure to OMP suggested that intradermally im m unized
mice

developed

antigen-specific

immunological

memory.

Although

present, the recall response in the OMP Vaccine group was less evident. In
the Vaccine group, peak serum and RTW IgG and IgA responses were
reached at Week 6 and did not wane substantially over the 24 week period
following intradermal immunization. The antibody increases in serum or
RTW from mice in this group following low dose intranasal inoculation of
OMP at Week 21 may have been attenuated by high prevailing background
levels of OMP-specific antibodies in these mice. However, the significantly
increased numbers of OMP-specific IgG and IgA-antibody secreting cells in
collagenase-digested lung tissues from the OMP Antigen or OMP Vaccine
groups confirmed that the detectable IgG and IgA responses in the lung
following intranasal inoculation of OMPs were due to local antibody
production. These findings indicated that, although systemic lymphoid
tissues contain relatively few IgA-committed

B cell precursors

[128],

sufficient numbers were stimulated by intradermal immunization to elicit a
detectable recall response following re-exposure to antigen.

The prolonged immunological responses against antigen are due to the
generation of memory T and B cells during the primary response [391].
Without repeated antigenic stimulation, immunological memory decays
over a period of weeks [391]. It is not clear whether memory is due to the
persistence of long-lived B cells in the germinal centres of secondary
lymphoid tissues, the continuous proliferation of antigen-specific B cells, or
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the continuous

generation of new short-lived B cells [392, 393]. The

retention of antigen on the dendritic processes of follicular dendritic cells (in
the form of immune complexes or iccosomes) is believed to be required for
continued stimulation of antigen-specific memory B cells in the germinal
centres

of the

immunological

spleen
memory

and lymph

nodes,

and

the

maintenance

of

[392, 394]. Increased release of iccosomes by

follicular dendritic cells shortly after re-exposure to antigen and endocytosis
of iccosomes by antigen-specific B cells, together with T cell help, leads to
enhanced recall of antigen-specific responses [394, 395]. UytdeHaag et al
(1991) [396] also proposed that a distinct self-renewing B cell lineage, B-l or
CD5+ B cells [397], may undergo antigen-driven somatic mutation after
exposure to antigen and play a role in the maintenance of immunological
memory in the absence of antigen. An additional component in the
maintenance of immunological memory is the continued exposure to cross
reactive environmental

antigens, which may by itself be sufficient to

maintain memory T and B cell numbers [398].

The presence of elevated immunoglobulins

over the 24-week period

following primary immunization was consistent with ongoing antigenic
stimulation. One explanation was that antigen retained at the intradermal
injection site was available for repeated secondary stimulation of B cells
over a long period. Such a mechanism has been proposed for repository
adjuvants, such as Freund's adjuvant [41, 43]. However, Lascelles et al (1989)
[44] showed that the rate of release of antigen from the "depots" formed by
repository adjuvants were insufficient to sustain maximal antibody levels in
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serum. Beh and Lascelles (1985) [35] demonstrated in sheep that soluble
antigen disappeared from the injection site over a few hours at identical
rates for subcutaneous or intradermal administration. W atson et al (1989)
[37] and Lovgren Bengtsson and Sjolander (1996) [68] also showed that
subcutaneously injected iscom-antigen complexes rapidly disappear from
the site of injection and accumulate in the draining lymph nodes and
spleen. Since OMP antigen or OMP vaccine were soluble preparations, it is
unlikely that retention at the intradermal injection

site explained the

maintenance of the strong immunoglobulin responses detected.

The skin route, however, was obviously an efficient means for delivering
antigen and prolonging stimulation of B memory cells in immunized mice.
Skin, like the mucosal surfaces of the lungs and gut, is continuously exposed
to environmental antigens and pathogens, and like these mucosal surfaces,
also has a well developed immune surveillance network capable of rapidly
initiating immune responses [228, 230]. Kératinocytes in the skin produce
cytokines, such as IL-1, IL-6 TNF-a, and heat shock proteins that can activate
and recruit APC and lymphocytes to the injection site [229]. Langerhans cells,
which belong to the dendritic cell lineage, are abundant throughout the
skin. Langerhans cells are very efficient antigen presenters [107] and inducers
of naive T helper cells [111]. The skin also contains migratory and transient
T and B cells, that circulate continuously through skin-draining lymph
nodes. The migration of activated APC following antigen exposure to
inductive sites in the skin-draining lymph nodes results in antigen-specific
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proliferation of T and B lymphocytes [230, 399].

Fearon (1996) [116] and others [107-115, 117] proposed that the responses
generated by the innate immune

system against antigen instruct and

modulate induction of adaptive immune responses. It was evident from the
similar kinetics of antibody production and antibody isotype patterns in the
OMP Vaccine and OMP Antigen groups that the innate immune responses
promoted by SAMA4-OMP were not essential for stimulating

strong

mucosal and systemic immunity against OMP. However, differences in the
rate and/or efficiency of phagocytosis and antigen presentation in the OMP
Vaccine and OMP Antigen groups were manifested as differences in the
humoral

responses.

Complexing

of OMP with

SAMA4

significantly

prolonged the duration of serum and RTW antibody responses in the OMP
Vaccine group, compared to the OMP Antigen group. Immunoblot analyses
also demonstrated differences in specificity of serum and RTW antibodies
from the OMP Antigen and OMP Vaccine groups. Serum or RTW from
OMP Vaccine group reacted strongly against most (7 out of 10) of the OMP
polypeptides whereas antibodies from OMP Antigen group mice reacted
only weakly and to fewer (3) OMP polypeptides. An increase in OMP-specific
IgG was also detected in faecal pellet extracts from the OMP Vaccine group,
but not the OMP Antigen group. The impact of complexing antigen w ith
SAMA4 on the immune

response was further demonstrated with the

weaker antigen, OVA. Whereas the OVA Antigen group did not elicit
detectable antibody responses, the OVA Vaccine group elicited strong anti
OVA responses in serum. Cytotoxic T cell responses against OVA-expressing
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lines were also detected only in the OVA Vaccine group and not in the OVA
Antigen group (Chapter 6).

Serum and RTW antibodies in the OMP Antigen and OMP Vaccine groups
had strong reactivity against high molecular mass polysaccharide antigens.
Previous

studies

[232, 237, 370, 400] have

demonstrated

that

these

polysaccharides are composed of surface-exposed capsular polysaccharides
(CP) and/or lipopolysaccharides (LPS) that co-purify with OMP. CP are
believed to be involved in adherence of A p leu ro p n eu m o n ia e to the lung
mucosal surfaces, and inhibit

phagocytic clearance

and complement-

mediated killing of bacteria [401, 402]. LPS may also be involved in bacterial
colonization and, along with the haemolysin, APX1, is responsible for the
lung lesions that develop during infection [374].

CP and LPS can directly induce production of antibodies without T cell help
[403]. The more rapid induction of antibodies by the T cell independent
pathway than by the T cell dependent route [404] may facilitate a swifter
immune response early in infection than would otherwise be possible.
Fenwick et al (1986) [405] also showed that pigs immunized with cultures of
A. p leu ro p n eu m o n ia e

<18 hrs old, which have

a high LPS content

compared to older cultures, stimulated strong production of cross-reactive
antibodies against LPS from different A. p leu ro p n eu m o n ia e
Therefore,

immunity

against cross-reactive

antigens

serovars.

of LPS may be

important for protection against A. pleuropneumoniae.
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Conversely, using capsule-deficient mutants, Ward and Inzana (1994) [402]
showed that high levels of anti-LPS antibodies actually inhibit bacterial
clearance from the lungs. Anti-LPS antibodies block the deposition of C9, a
component

of the

complement

membrane

attack complex.

Anti-CP

antibodies are also ineffective at initiating complement-mediated lysis in
encapsulated strains. If so, the value of eliciting high levels of anti-CP or
anti-LPS antibodies may be limited. Further studies are required to compare
the contributions of opsonizing antibodies against CP or LPS to protection. If
future studies demonstrate that induction of anti-CP or anti-LPS responses
are beneficial for protection then, given the toxicity of LPS preparations [405],
intradermal vaccination may be a safe and feasible approach.

In summary, the results demonstrated that intradermal immunization is a
feasible and practicable alternative
Intradermal immunization

to

direct mucosal

elicits both strong mucosal

immunization.
and systemic

immune responses, and stimulates long-lived antigen-specific mucosal and
systemic immunological memory. Complexing of antigens with SAMA4
significantly increased the duration of the antibody responses and increased
the immune

responsiveness against T dependent antigens, which are

important for the development of long-lived immunity against pathogens.
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CHAPTER 6
Generation of T Cell Cytotoxicity
in Intradermally Immunized
Mice

6.1

INTRODUCTION

Although humoral responses alone are often sufficient for eliminating
extracellular pathogens, induction of cytotoxic responses are necessary to
overcome disease caused by viruses, intracellular parasites and bacteria [283,
406], or to destroy tumour cells [242]. In mice, two cell populations, natural
killer (NK) cells and CD8+ cytotoxic T lymphocytes (CTL), elicit the
predominant cytotoxic activity against affected cells. NK cells belong to the
innate immune system and can spontaneously and non-specifically lyse
virally infected target cells [267, 407] and tumour cells [284]. In disease, NK
cells limit the spread of infection during the period required for induction of
the adaptive immune response by lysing damaged or infected cells [119, 283].
\
CTL are part of the adaptive immune

system and elicit antigen-specific

cytotoxicity against target cells expressing foreign endogenous antigens
associated with class I MHC molecules [267]. Endogenous antigens are so
called because they are synthesised in, or introduced into, the cytoplasm of
cells by intracellular pathogens or tumour cells [267, 283]. Endogenous
antigens are proteolytically degraded into peptides that bind to class I MHC
glycoproteins and (32-microglobulin [123]. Expression of antigen-class I MHC
complexes at the cell surface and recognition by antigen-specific CTL lead to
induction of cytotoxic activity against the affected cells [8]. Therefore,
antigen-specific cytotoxic activity elicited by CTL reflects entry of antigen into
the endogenous pathway for antigen processing.
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Exogenous

antigens,

such

as those

present in vaccines,

are readily

endocytosed and degraded via the class II MHC pathway. Recognition of
antigen peptide-class II MHC complexes on the cell surface of APC by
antigen-specific

CD4+ T helper

cells leads to induction

of antibody

production by B cells. Soluble exogenous antigens present in vaccines do not
readily enter the class I MHC antigen-processing pathway and therefore fail
to induce CTL responses [3, 99]. The inability of antigens in most vaccines to
enter the class I pathway for antigen processing limits the range of effective
immune

responses that are elicited by vaccines

against intracellular

pathogens. One exception to this includes vaccines prepared from antigens
complexed in iscoms. Previous studies [95, 98, 99] have shown that these
vaccines

can

induce

strong

CTL responses

when

delivered

orally,

intraperitoneally or subcutaneously. Since induction of CTL responses is
important for protection against disease by intracellular pathogens, the
ability of intradermal immunization to allow entry of antigen into the class I
MHC pathway was investigated in intradermally immunized mice.

6.2

6.2.1

MATERIALS AND METHODS

Immunization of mice

Female C57/B6 (H-2b) mice aged 8 to 12 weeks were obtained from the John
Curtin School of Medical Research (JCSMR) Animal Facility, Australian
National University, Canberra, ACT. Mice were kept at 23 ± 1 °C under a 12 h
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day/night cycle. Antibiotic-free commercial mouse pellets and water were
supplied ad libitum. Mice (8 per group) were intradermally immunized with
100 ^1 of either PBS, pH 7.2 (Control group), SAMA4 (Adjuvant group),
OVA (OVA Antigen group) or SAMA4-OVA (OVA Vaccine group) on days
0 and 7.

6.2.2

Target cell lines used

EL4, YAC-1, and G7 thymoma target cell lines were kindly provided by Dr
Arno Mullbacher (Division of Immunology and Cell Biology, JCSMR). The
G7 cell line originated from EL4 cells transfected with OVA cDNA [408]. G7
cells constitutively synthesize and secrete ovalbumin.

6.2.3

51Chromium-labelling of target cells

EL4, YAC-1 and G7 target cells were suspended at a concentration of 6 x 106
cells/ml in 500 ¡ul of F15 medium (Gibco) supplemented with 5% (v/v) FCS
and incubated with 100 ¡lxI of 6 mCi/ml 51Cr (Amersham) for 1 h at 37 °C.
Cells were washed twice and resuspended in F15 medium to give a final cell
concentration of 2 x 105 cells/ml. A portion of the 51Cr-labelled EL4 cells were
resuspended in 2 ml of F15 medium containing 10"4 M OVA peptide and
incubated for 2 hrs at 37 °C. The OVA peptide (kindly provided by Dr Arno
Mullbacher, JCSMR) was an octamer with the amino

acid sequence

SIINKFEL-OH (amino acids 257-264 of the ovalbumin molecule). The OVA
peptide used is known to represent the immunodominant peptide for the
H-2Kb MHC molecule in C57/B6 (H-2b) mice [409]. This OVA peptide binds
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with high affinity to the peptide-binding groove of the class I MHC
molecules on OVA-specific cytotoxic T cells [408]. Cells were washed twice as
before and resuspended in F15 medium to give a final cell concentration of 2
x 105 cells/ml. These cells were designated EL4+OVA peptide.

6.2.4

Preparation of effector cells

Splenocytes were obtained from intradermally immunized mice on Day 14
by gently teasing apart the spleen in F15 medium supplemented with 5%
FCS. Cells were pelleted by centrifugation (200 g for 10 min at 4 °C) and
erythrocytes removed by hypotonic lysis in 4.5 ml of distilled water.
Isotonicity was immediately restored by the addition of 0.5 ml of lOx Hanks
Balanced Salt Solution (Trace Scientific) followed by 5 ml of F15 medium.
The cells were centrifuged (200 g for 10 min at 4 °C) and resuspended in cold
F15 medium.

6.2.5

Measurement of OVA-specific cytotoxic activity

Splenocyte suspensions were assayed in triplicate for cytotoxic activity
against 51Cr-labelled G7, EL4+OVA peptide, EL4 or YAC-1 target cells at
effector-to-target cell ratios ranging from 90:1 to 3:1. After incubating cells for
6 h at 37 °C in a humidified C 0 2 incubator, 100 pi of cell-free supernatants
were removed

and the radioactivity measured in a gamma-counter.

Spontaneous 51Cr release was determined by incubating 51Cr-labelled target
cells in culture medium. Maximal 51Cr release was determined by incubating
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3lCr-labelled target cells in 2% Triton-X 100. Percentage cytotoxicity was
calculated as follows:

% cytotoxicity =

Experimental release - spontaneous release

x

100%

Total release - spontaneous release

6.3

RESULTS

Intradermal immunization with OVA vaccine primed mice for a strong
cytotoxic T cell response against OVA-expressing target cells within 6 h of in
vitro culture. Splenocytes from the OVA Vaccine group lysed G7 cells (EL4
cells transfected with OVA cDNA) and EL4+OVA peptide cells (EL4 cells
sensitized with OVA peptide) by an equivalent amount (Fig. 6.1a and b).
These findings, together with the lack of cytotoxicity against the nontransfected EL4 cells (Fig. 6.1c) indicated that cytotoxic activity in the OVA
Vaccine group was OVA-specific. Since EL4 cells express only class I MHC
molecules [410], cytotoxic T cell activity against G7 and EL4+OVA peptide
cells was class I MHC-restricted.

Non-specific cytotoxicity, as measured by lysis of YAC-1 cells, was always less
than 22% (Fig. 6.1d). Mice inoculated with SAMA4 failed to lyse target cells
at higher than background levels. Contrary to one previous report [411], but
consistent with another [408, 412], immunization with soluble OVA antigen
also did not prime mice for OVA-specific cytotoxic activity.
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FIGURE 6.1. Percentage OVA-specific T cell cytotoxicity in spleens taken
from mice in Control (unfilled columns), Adjuvant (hatched columns),
OVA antigen (stippled columns) and OVA vaccine (filled columns) groups
following intradermal immunization. Activity against (a) G7 cells (b)
EL4+OVA peptide cells, (c) EL4 cells and (d) YAC-1 cells is shown. Values
represent the mean of triplicate cultures.
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6.4

DISCUSSION

Soluble antigens produced from the breakdown of bacterial products during
infection,

or

phagocytosed

purified
and

antigens

administered

degraded by APC.

Peptide

by

vaccination,

fragments

are

formed

by

intracellular degradation of "exogenous" antigens bind to class II MHC
molecules and are expressed on the surface of APC. Recognition of peptideclass II MHC complexes by T helper cells results in induction of antigenspecific antibody responses. Antigen processing via the class II pathway was
clearly reflected by the antigen-specific antibody responses elicited in OVA
vaccine-primed mice and OMP-primed mice (Chapter 5). This present study
further demonstrated that immunizing with SAMA4-OVA complexes also
primed mice for class I MHC-restricted antigen-specific CTL responses.
Therefore, the adjuvant effect of SAMA4 included promoting entry of
intradermally administered antigen into both class I and class II MHC
antigen processing pathways.

A number

of

iscom-containing

vaccines,

delivered

subcutaneously,

intraperitoneally or orally, have also been shown to prime mice for in v itro
antigen-specific T cell cytotoxicity [81, 90, 95, 98, 99, 206]. By comparison,
conventional

adjuvants,

such

as

complete

or

incomplete

Freund's

Adjuvant, do not generate antigen-specific cytotoxic T cell responses against
the same antigens [81]. These data indicate that iscoms may have

a

preferential effect on CTL activity. Although the mechanism by which this
occurs is unclear, direct fusion of antigen-bearing liposomes (SAMA4) [11,
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54] or iscoms [37, 74, 87], to the cell membrane of APC may enhance antigen
uptake and breakdown by both antigen processing pathways. More efficient
antigen uptake, and preferential

selection of immunodominant

OVA

peptides that best bind to class I MHC molecules may be consequential to the
strong innate immune responses in the OVA Vaccine group. If so, it may
explain the strong CTL responses in this group and the unresponsiveness of
OVA Antigen mice (which did not elicit a strong innate response).

The finding in this study that soluble OVA alone did not prime for CTL
activity is in agreement with at least two other reports [408, 412]. However,
two studies [411, 413] have shown results to the contrary. One explanation
for the apparent difference, proposed by Ishioka et al (1989) [412], is that i n
vitro "pre-processing" of antigen by APC, either prior to immunization or
during in vitro restimulation of cells, results in the generation of antigenic
peptides that can be processed by the class I MHC pathway, and can
circumvent the normal entry into antigen processing pathways. Staerz et al
(1987) [411] suggested that the class I and class II pathways are not
functionally separate, thereby providing a mechanism by which exogenous
antigens can be presented in conjunction with class I MHC molecules to be
presented or during restimulation of cells.

The

data

demonstrated

that,

unlike

many

vaccines,

intradermal

immunization with SAMA4-antigen complexes allowed entry of antigen
into the class I and class II MHC antigen processing pathways, resulting in
the generation of antibody and CTL responses. These attributes make
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intradermal immunization
effective

for

protecting

with SAMA4-antigen complexes potentially
against

both

extracellular

and

intracellular

pathogens.
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CHAPTER 7
Protective
Immunity
in
Intradermally Immunized Mice
After Exposure to Actinobacillus
pleuropneum oniae

7.1

INTRODUCTION

Inhaled A. p leu ro p n eu m o n ia e very rapidly adhere to the epithelial cells of
the lower respiratory tract, beginning the disease process [414]. Disease
pathogenesis in swine is histologically well documented, and includes:
alveolar and interlobular oedema; dilatation of lymph vessels; congestion
and haemorrhage of blood vessels and alveolar capillaries; intravascular
fibrinous thrombosis; and exudation of fluid and fibrin into the pulmonary
parenchyma [369, 415, 416]. Previous studies have shown that the destructive
effects of A. p leu ro p n eu m o n ia e infection are due in large part to the
haemolytic and cytotoxic action of RTX toxins, designated APX1 APXII and
APXIH [278, 417-420] and LPS [197, 374] released into the lung tissue during
infection. Production of APX1 by phagocytosed bacteria is believed to
inactivate phagocytes, enabling ingested bacteria to become liberated [234].
Pro-inflammatory factors released by damaged lung cells and phagocytes can
exacerbate tissue damage by initiating microvascular platelet aggregation and
thrombosis, activating the coagulation, kinin and complement pathways,
and attracting greater numbers of phagocytes to the infection site [374, 416].

The similarities in disease pathogenesis between swine and mice infected
with A. p leu ro p n eu m o n ia e

has meant that mice provide a suitable

laboratory model for investigating different aspects of the disease process
[421-427]. Most studies with infected swine and mice have concluded that
protection against A. p leu ro p n eu m o n ia e

is principally

the

result

of

immunity against surface exposed antigens, such as OMP, LPS and capsular
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polysaccharides [235, 278, 374-376]. Although mucosal IgA is believed to be
important for protection against A. p leu ro p n eu m o n ia e [428], Hensel et al
[196] and others [160, 184] have shown, that oral immunization does not
prevent colonization or disease, and that serum antibodies contribute
significantly to protection. Since bacterial challenge results in significant
increases in both systemic and pulmonary antibody levels, the relative
contributions to bacterial clearance of locally produced IgA and IgG, and IgG
resulting from serum transudation, remain unresolved.

Bhatia et al [423] and Fenwick et al [405] discovered that, compared to the
strong antibody responses, cell mediated immunity (CMI) was not strongly
implicated in protection from disease. Pabst et al [429] also found that the
small changes in the numbers of T and B cells in bronchoalveolar lavage
following A. p leu ro p n eu m o n ia e infection of swine did not account for the
uniform protection achieved in immunized animals. Different studies [196,
429] have coincidently observed increases in phagocytic cells, such as
macrophages and granulocytes, in the lung following bacterial challenge. By
incubating fluorescein-labelled bacteria with convalescent pig serum or with
immune

sera from

demonstrated

in

immunized

vitro

that

pigs, Thwaits

antibodies

to

et

OMP

al

[388, 430]

also

are

important

for

opsonophagocytosis of bacteria in pigs. Rapid recruitment of phagocytic cells
and the presence of opsonizing antibodies may, therefore,

make

an

important contribution to clinical protection.

Chapter 7

page 159

The aim of this study was to quantify and compare, using flow cytometry,
changes in leukocyte populations in unimmunized and immunized mice
following intranasal exposure to A. pleuropneumoniae. Since effective host
defense against lung bacterial infection is primarily dependent on rapid
clearance of the organisms from respiratory tract [279], the rates of clearance
of bacteria from the lungs of mice were interpreted in the context of
background antibody levels detected in unimmunized and immunized mice
in Chapter 5, and the cellular recruitment patterns in mice.

7.2

7.2.1

MATERIALS AND METHODS

Bacteria and growth conditions

A. p leu ro p n eu m o n ia e serovar 1, strain HS54 was recovered from frozen
glycerol stocks by streaking onto chocolate blood agar plates (4.5% {w/v} GC
agar {Oxoid}, 1% {w/v} soluble haemoglobin {Oxoid} and 40 pg/ml NAD
{Calbiochem}). Bacteria were grown for 24 h at 37 °C in a 5% (v/v) C 0 2
incubator. Colonies grown on chocolate blood agar plates were inoculated
into 20 ml brain-heart infusion broth (Oxoid) supplemented with 40 pg/ml
NAD and grown overnight with shaking at 170 rpm (Gallenkamp & Kuhner
CH orbital mini-shaker) at 37 °C. A 5 ml aliquot of the overnight culture was
transferred into 95 ml of brain-heart infusion broth and incubated as before
until an O.D. 650 nm of 0-8 was reached (log-growth phase). This O.D.
corresponded to about 8 x 108 colony-forming units (CFU)/ml. A 10 m l
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aliquot of the bacterial culture was centrifuged at 30,000 g for 10 minutes at 4
°C in a Beckman J2-21M/E centrifuge. The bacterial pellet was washed twice
with 10 ml sterile PBS, pH 7.2 and resuspended in sterile PBS at the desired
concentration. The bacterial suspension was kept on ice and used to
inoculate mice intranasally within 1 h of preparation.

7.2.2

Mice

Female BALB/c mice aged 8 to 12 weeks were immunized intradermally
with 100 \xl of either PBS, pH 7.2 (Control group), OMP (OMP Antigen group)
or SAMA4-OMP (OMP Vaccine group) on Days 0 and 7, as described in
Chapter 2. Mice were maintained at 23 ± 1 °C under a 12 h day/night cycle
and given antibiotic-free commercial mouse pellets and water ad libitu m
before and after intranasal challenge with bacteria.

7.2.3

Titration of bacterial inoculum

A preliminary experiment was conducted to confirm the susceptibility of
BALB/c mice to A. p leu ro p n eu m o n ia e infection and to determine the
appropriate inoculum

to be used for subsequent intranasal

challenge

experiments. Mice (10 per group) were anaesthetised as described in Chapter
5 and intranasally inoculated with 0 (PBS only), 1 x 107, 4 x 107, 1 x 108, 5 x 108
or 2 x 109 CFU/dose of A. p le u r o p n e u m o n ia e , serotype 1, strain HS54. The
number of live bacteria in the inoculum was determined by incubating 10 (xl
aliquots of serial dilutions of the bacterial suspension on chocolate blood
agar plates overnight at 37 °C in a 5% (v/v) C 0 2 incubator. Bacteria were
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quantified according to the formula:
CFU /ml = Mean number of colonies x dilution factor x 100

7.2.4

Clinical Assessment of mice following intranasal inoculation with
bacteria

The clinical condition of mice was assessed after intranasal inoculation
using criteria described elsewhere [431]. At 0, 4, 12, 24 and 36 h following
intranasal

inoculation

with

bacteria,

mice

from

each

group

were

individually scored on the level of activity, difficulty in breathing, preening
of fur, squinting of eyes, and hunching. Mice were given a score of 0
(normal), 1 (mild-moderately affected) or 2 (severely affected) for each
parameter. If necessary, because of the severity of their symptoms, mice were
euthanased by intraperitoneal injection with 50 pi of 300 mg/ml sodium
pentobarbitone (Jurox). Mice that were euthanased due to the severity of
symptoms or that died between observation periods were given the
maximum combined score (10).

7.2.5

Enumeration of live bacteria in the lungs following intranasal
challenge

On Week 5 after intradermal immunization, mice (12 per group) were
anaesthetised and intranasally inoculated with 1 x 108 CFU/dose (20 pi) of A.
p le u r o'pneum oniae, serotype 1, strain HS54. Mice (4 per group) were
euthanased at 4, 12 or 24 h and blood and tissues removed. Blood was
collected immediately after euthanasia into sterile 1 ml tubes containing 50
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[d sodium heparin. The lung and spleen from each infected mouse were
removed

aseptically,

cut

into

pieces

and

each

organ

individually

homogenized for 7 x 1 minute cycles in a Colworth Stomacher 80. Bacteria in
the lungs were quantified as described in Section 7.2.3. Bacterial numbers in
the spleen and blood were not quantified.

7.2.6

Assessment

of cell

population

changes

following

intranasal

challenge
On Week 5 after intradermal immunization, mice from the Control (16 per
group), OMP Antigen (12 per group) and OMP Vaccine groups (12 per group)
were intranasally inoculated with 1 x 108 CFU live A. p leu ro p n eu m o n ia e.
Lungs, spleen and femoral bone marrow were removed at 0, 12 and 36 h
post-inoculation as described in Chapters 2 and 4. Cell suspensions prepared
from these tissues were stained with a panel of monoclonal anti-murine
antibodies and analysed by flow cytometry as described in Chapters 2 and 4.

7.2.7

Partial purification of APX1 haemolysin and raising of polyclonal
antibodies against APX1 in mice

The OMP preparations used to prepare vaccines may have inadvertently
contained APX1, a protective component of A. pleu ropn eu m on iae

[278]. To

exclude this component as a possible contributor to the outcomes reported
following bacterial challenge of mice, APX1 was partially purified and tested
for its haemolytic and cytotoxic activity. The presence of APX1 in OMP
preparations was assessed using antibodies raised in mice against APX1.
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7.2.7.2. Bacterial growth

conditions.

A.

pleuropneum oniae

was grown

overnight (as described above) in 50 ml of brain-heart infusion broth (Oxoid)
supplemented with 40 ng/ml NAD. A 10 ml aliquot was transferred into a
flask containing 590 ml of NAD-supplemented Columbia broth (Bacto
Laboratories) and incubated at 37 °C with shaking (170 rpm) until an O.D. 650
nm of about 1.0 (at approximately 5 h) was reached.

7.2.7.2. Partial purification of APX1. The bacterial culture was centrifuged at
30,000 g for 10 min at 4 °C in a Beckman J2-21/ME centrifuge. The culture
supernatant was passed through a pre-filter (Millipore) and then filtered
using a 0.22 \i filter (Millipore) to remove residual bacteria. The cell-free
culture supernatant was ultrafiltered through a 100 kDa molecular weight
cut-off membrane (YM100; Amicon Division, WR Grace and Co, USA) fitted
to a stirred cell assembly (Amicon)

and reduced from

a volume

of

approximately 600 ml to about 15 ml. To decrease the retention of low
molecular mass proteins, 300 ml PBS, pH 7.2, was added to the retentate at
this time and then ultrafiltration resumed until the volume was once again
reduced to about 15 ml. The retentate was passed through a 10 kDa
molecular weight cut-off membrane (YM10; Amicon) to reduce the volum e
of the retentate to about 2.5 ml.

The relative purity of APX1 preparations was determined from coomassie
brilliant blue-stained electrophoretic gels using an LKB laser densitometer
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(Pharmacia LKB, Uppsala, Sweden).

7.2.7.3. Assessm ent

of in vitro haemolytic

activity. In vitro

haemolytic

activity of neat culture supernatant, YM100 retentate and ultrafiltrate was
determined using a modification of the procedures described elsewhere [420,
432]. Briefly, 100 \x\ of a 5% sheep erythrocyte suspension prepared in assay
buffer (10 mM CaCl2 in 10 mM Tris-HCl, 0.85% saline, pH 7.4) and 100 ¡il of
either cell-free culture supernatants, ultrafiltrate or retentate were incubated
in a covered round-bottom 96-well microtitre plate, with shaking at 200 rpm
(Ika-Vibramax-VXR electronic shaker, John Morris Scientific), for 2 h at 37
°C. After incubation, the plate was centrifuged (300 g for 5 min at 4 °C) to
sediment the erythrocytes. Following centrifugation, 100 jil of cell-free
supernatant was transferred to a flat-bottom 96-well microtitre plate. Optical
densities were measured at 541 nm with an iEMS microplate reader.
Spontaneous haemolysis was determined by incubating 100 ¡j ! sheep
erythrocytes with 100 ^1 buffer as described above. One haemolytic unit was
defined as the absorbance at 541 nm when 50% of sheep erythrocytes were
haemolysed. This was determined by incubating 50 \x\ sheep erythrocytes
with 150 \x\ distilled water. Percentage haemolysis was calculated as follows:

% h a e m o l y s i s = ( S a m p l e O .D .5 4 1 n m - S p o n t a n e o u s h a e m o l y s i s O . P . 5 4 1 n m )

x 50%

(5 0 % S t a n d a r d O .D . 5 4 1 n m - S p o n t a n e o u s h a e m o l y s i s O .D . 5 4 1 n m )
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7.2.7A. Assessment of in vitro cytotoxic activity. To assess the cytotoxicity of
APX1

preparations,

splenocytes,

thymocytes,

and

lung

cells

from

collagenase-digested lung, were incubated at 37 °C overnight in a humidified
5% C 0 2 incubator with serial two-fold dilutions of YM100 retentate in RPMI1640/10% (v/v) FCS, pH 7.4. Cell viability was determined by propidium
iodide exclusion using flow cytometry.

72.7.5. Raising

polyclonal

antisera

against APX1. Polyclonal antibodies

against APX1 were raised in BALB/c mice
subcutaneously with 50 pg of heat-denatured

(n=10)

by im m unizing

APX1 emulsified

with

complete Freund's adjuvant (CSL). A booster injection of denatured APX1
emulsified

with

incomplete

Freund's

adjuvant

(CSL)

was

given

subcutaneously 3 weeks later. Immune sera were obtained after a further 3
weeks.

72.7.6. SDS-PAGE, im m unoblotting

and

neutralizing

activity

of APX1

antibodies. Culture supernatant preparations were electrophoresed by SDSPAGE and immunoblotting were done as described in Chapter 5 except that
samples were loaded onto an 8% (w/v) polyacrylamide gel overlaid with a
4% stacking gel. To assess the APXl-neutralizing properties of antiserum,
serial two-fold dilutions were prepared in assay buffer (10 mM CaCl2 in 10
mM Tris-HCl, 0.85% saline, pH 7.4). 200 pi of each dilution or PBS was
incubated with or without 200 pi of neat cell-free culture supernatant for 2 h
at 37 °C.
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7.2.8

Histology

Lungs were removed from freshly killed infected or uninfected mice and
fixed in 10% (v/v) phosphate-buffered formalin. The lungs were embedded
in paraffin using standard techniques. Sections (4 fxm thick) were prepared
and stained with H&E for microscopic examination.

7.2.9

Statistical analyses

The results reported represent the mean (± sem). The means of different
groups at individual time points were compared by two-tailed f-test.
Changes were considered significant at P < 0.05.

7.3

7.3.1

RESULTS

Susceptibility of BALB/c mice to intranasal inoculation with A.
p le u r o p n e u m o n ia e

Differences

in

the

susceptibility

of

different

mouse

strains

to

A.

p leu ro p n eu m o n ia e infection have been documented J421-427, 433]. Since
few studies [433, 434] have used BALB/c mice as the experimental host, it
was necessary to establish the susceptibility of BALB/c mice to intranasal
challenge.

To

determine

pleu ropn eu m on iae

the

susceptibility

of BALB/c

mice

to

A.

infection, groups of mice were inoculated intranasally

with 1 x 107, 4 x 107, 1 x 108, 5 x 108 or 2 x 109 CFU/dose. Mice were observed
hourly for the first 12 h and then every 12 h for up to 7 days. A dose-
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dependent deterioration in the condition of mice was seen. Mice receiving 5
x 108 or 2 x 109 CFU/dose were euthanased within 8 to 12 h of inoculation
due to the severity of their symptoms. Mice receiving 1 x 108 CFU/dose were
severely affected by intranasal inoculation and were euthanased within 24 h.
Mice given 1 x 107 and 4 x 107 CFU/dose displayed only mild overt
symptoms of infection.

Compared to control mice, which had histologically normal lung structure
(Fig. 7.1a), the lungs from mice inoculated with 2 x 109 CFU/dose showed
areas of mild to moderate neutrophil infiltration into alveoli (Fig. 7.1b) and
gross thickening of alveolar walls (Fig. 7.1c). Oedema was present around the
large peribronchiolar blood vessels as well as areas of haemorrhage (Fig.
7.1d). Coccobacilli were present in nearly every acinus of the lung in these
mice. The lungs of mice inoculated with 1 x 107 CFU/dose had similar areas
of neutrophil infiltration and alveolar thickening, but bacteria were harder
to find.

7.3.2

Clinical Assessment of mice following intranasal inoculation with
bacteria

On the basis of the results described in Section 7.3.1, mice from the Control
(28 per group), OMP Antigen (24 per group) and OMP Vaccine groups (24 per
group)

were

intranasally

p le u r o p n e u m o n ia e

inoculated

with

1

x

108 CFU

5 weeks after primary immunization.

live

Mice

A.
were

euthanased at 4, 12 and 24 h for assessment of bacterial numbers (Section
7.3.4) or 0, 12 and 36 h for flow cytometric assessment of cellular
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FIGURE 7.1. Lung sections taken from mice inoculated with 2 x 109 CFU/ml
dose of A. pleuropneumoniae. (A) Controls lung, (B) infected lung showing
areas of neutrophil infiltration (1), (C) infected lung showing thickening of
the alveolar walls (2), (D) infected lung showing oedema around large blood
vessels (3). x 400 magnification.
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changes in different organ compartments (Section 7.3.6). At 0, 4, 12, 24 and
36 h after intranasal inoculation, the clinical condition of these mice was
assessed using the specific criteria listed in Section 7.2.5. The clinical scores
are shown in Table 7.1. The condition of Control mice steadily deteriorated
following intranasal inoculation. All Control mice were euthanased before
36 h post-inoculation due to the severity of symptoms. The condition of
mice in the OMP Antigen or OMP Vaccine groups worsened over the first 12
h but then did not deteriorate further in either group over the next 24 h.
Clinical scores for mice in the OMP Vaccine group were consistently lower
than for mice in the OMP Antigen group although this trend was not
statistically significant. The

clinical

scores for immunized

mice were

generally lower than for Control mice at all time points except 0 and 4 h.

TABLE 7.1. Mean clinical scores per group following intranasal inoculation
with A. p leu ro p n eu m o n ia e. Results represent the median clinical score
(range) of 24 mice per group.

Time post-inoculation (hrs)
Group

0

4

12

24

36

Controls

0(0)

1(0)

7(0)

8 (7-10)

10 (0)

OMP Antigen

0(0)

1(0)

7 (0-7)

0 (0-10)

10 (3-10)

OMP Vaccine

0(0)

1(0)

7 (0-7)

0 (0-10)

10 (0-10)
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7.3.3

Assessment of bacterial clearance following intranasal challenge

The number of bacteria in the lungs of mice was determined at 4, 12 and 24 h
after intranasal inoculation and is shown in Fig. 7.2. At 4 h the average
number of viable bacteria in mice from each group ranged from 2.4 x 106 to 6
x 106 CFU/lung. Thereafter, bacterial numbers in the lungs of Control mice
increased significantly (8-fold) in the first 12 h (P < 0.005) before declining
slightly in the second 12 h period. By comparison, bacteria were recovered
from 3 out of 4 mice in the OMP Antigen and OMP Vaccine groups at 12 h
post-inoculation, with the average bacterial count dropping to 7 x 104, and
2.7 x 105 CFU/lung, respectively. At 24 h post-inoculation, only 1 out of 4
mice in the OMP Antigen group had recoverable live bacteria in the lungs.
This mouse had 7.2 x 106 CFU/lung and was extremely ill. Bacteria were
recovered from 2 out of 4 mice in the OMP Vaccine group at 24 h, with the
average number of bacteria being 9.5 x 103 CFU/lung.

Viable A. pleur opneum oniae

were also recovered, but were not quantified,

from spleen and blood samples taken from all mice at 4 h. No bacteria were
recovered in spleen or blood samples taken at 12 or 24 h post-inoculation in
any group.

7.3.4

Cellular changes in the lungs following intranasal inoculation with
A . p le u ro p n eu m o n ia e.

Total numbers of viable cells (as determined by trypan blue exclusion) in the
lungs of mice in the Control, OMP Antigen and OMP Vaccine groups
increased significantly (2- to 3-fold) in the first 12 h post-inoculation (P <
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0.0005, P < 0.05, P < 0.01, respectively) but then declined toward norm al
levels by 36 h (Fig. 7.3a). Data is not available for Control mice beyond 12 h
because these mice did not survive intranasal infection past 24 h.

Control
Group

OMP Antigen
Group

OMP Vaccine
Group

Post-inoculation (hrs)
FIGURE 7.2. Pulmonary clearance of A. p leu ro p n eu m o n ia e 5 weeks after
intradermal immunization in the PBS (unfilled squares), OMP Antigen
(unfilled diamonds) and OMP Vaccine groups (filled diamonds). Results
represent the CFU estimates from triplicate measurements of individual
lungs at 4, 12 and 24 h post-inoculation.

Flow cytometric analysis demonstrated that the rise in cell numbers in the
lung

was predominantly

granulocytes, (Fig. 7.3b) and
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due

to

increases

in

Mac-1+Gr-1+ cells,

or

Mac-1+Gr-1' cells, or macrophages (Fig. 7.3c).
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FIGURE 7.3. Changes in (a) total live cells (b) granulocyte and (c) macrophage numbers in the lungs of mice from the Control
(unfilled columns), OMP Antigen (stippled columns) and OMP Vaccine groups (filled columns) following intranasal
inoculation with A. pleur opneumoniae. Results represent the mean (± sem) of 4 mice per group. Control mice did not survive
past 24 h post-inoculaton.

Compared to pre-inoculation levels, lung granulocytes in Control mice rose
significantly (11-fold) at 12 h post-inoculation (P < 0.005). The OMP Antigen
group showed a slightly greater increase in lung granulocytes of 14-fold (P <
0.01), while the OMP Vaccine group showed the greatest increase (27-fold) by
12 h post-inoculation(P < 0.02).

Increases in macrophage numbers following intranasal inoculation were
almost identical in all groups. Macrophage numbers rose significantly (3.5to 4-fold) at 12 h in all groups (P < 0.02, P < 0.0001, P < 0.01, respectively).
Macrophage numbers declined thereafter, but at 36 h, continued to be 2- to 3
fold higher than pre-inoculation levels in the OMP Antigen and the OMP
Vaccine groups .

CD4+, CD8+T cells and yô+ T cell numbers in Control mice increased (1.7, 1.6
and 3.2-fold, respectively)

by 12 h

post-inoculation

(Table

7.2).

By

comparison, T cell numbers in the OMP Antigen and OMP Vaccine groups
changed very little over this period, and then declined slightly in the
subsequent 24 h. The shifts in CD4+ and CD8+ T cell numbers in the different
groups were confirmed by similar changes in total a(3-TCR+ cells over the
same period. B220+ (B) cell numbers also rose (1.3 to 1.7 fold) in all groups in
the first 12 h, and were up to 2.5-fold higher than baseline levels (P < 0.05) by
36 h post-inoculation in the OMP Antigen and OMP Vaccine groups.
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TABLE 7.2. Changes in T and B lymphocyte numbers in the lungs of mice
from the Control, OMP antigen and OMP vaccine groupsfollowing
intranasal inoculation with A. p le u r o p n e u m o n ia e . Results represent the
mean (± sem) of 4 mice per group.

Time Post-inoculation (h)
Phenotype
CD4+

CD8+

yô+

ap +

B220+

Group
Control

0

12

5.7 (0.2)*

9.6 (1.0)

36
-

Antigen

-

6.4 (0.3)

5.1 (0.1)

Vaccine

-

5.0 (1.2)

7.3 (2.1)

Control

2.4 (0.3)

3.8 (1.0)

Antigen

-

2.5 (0.3)

1.7 (0.1)

Vaccine

-

1.9 (0.3)

2.9 (1.0)

Control

1.3 (0.3)

3.1 (1.0)

Antigen

-

1.9 (0.1)

1.6 (0.6)

Vaccine

-

1.1 (0.2)

1.7 (0.2)

Control

7.6 (0.6)

12 (2.3)

Antigen

-

6.7 (0.6)

4.8 (0.7)

Vaccine

-

5.9 (1.4)

7.3 (2.2)

Control

5.4 (0.8)

8.9 (3.3)

Antigen

-

9.2 (2.8)

11.1 (3.0)

Vaccine

-

7.1 (1.9)

13.4 (3.6)

* Numbers in parentheses indicate standard errors
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7.3.5

Cellular

changes

in

the

bone

marrow

following

intranasal

inoculation with A. p leu ropn eu m on iae.
Viable cell numbers in the bone marrow declined in all groups following
intranasal inoculation (Fig. 7.4a). Cell numbers in the Control and OMP
Antigen groups dropped rapidly (40%) by 12 h post-inoculation (P < 0.03),
whereas cell numbers in the OMP Vaccine group declined more slowly.
Declines in all the phenotypes examined contributed to the overall loss of
cells detected in the bone marrow. Dead cell numbers in the bone marrow
also declined by 50 to 60% over the 36 h period (Fig. 7.4b).

Compared

to

pre-inoculation

levels,

haematopoietic

progenitor

cell

numbers, which includes lineage uncommitted haematopoietic stem cells
and early progenitor cells, dropped by 40 to 60% in Control (P < 0.01) and
OMP Antigen groups (P < 0.03) in the first 12 h post-inoculation (Fig. 7.4c).
This decline continued until at least 36 h post-inoculation in the OMP
Antigen group. By comparison, the decline in haematopoietic progenitor
cells in the OMP Vaccine group was significantly less than in the other
groups in the first 12 h (P < 0.02), but by 36 h post-inoculation cell numbers
had also declined significantly (60%) (P < 0.01).

B lineage cell numbers, as identified using the CD45R/B220 cell marker [435],
dropped significantly (40 to 60%) within 12 h post-inoculation (P < 0.02) in
the Control and OMP Antigen groups, with little decline in the OMP
Vaccine group (Fig. 7.4d). By 36 h, cell numbers in the OMP Antigen and
OMP Vaccine groups dropped significantly (50%) (P < 0.03).
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Time (h) post-inoculation

FIGURE 7.4. Changes in the numbers of (a) total viable cells (b) dead cells (c)
haematopoietic progenitor cells and (d) CD3'B220+ cells in the bone marrow
of mice from the Control (unfilled columns), OMP Antigen (stippled
columns) and OMP Vaccine groups (filled columns) following intranasal
inoculation with A. pleuropneumoniae. Results represent the mean (± sem)
of 4 mice per group. Control mice did not survive past 24 h post-inoculation.
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CD4+ and CD8+ T cells, which normally comprised less than 3% of bone
marrow cells, declined significantly over 12 and 36 h post-inoculation in all
groups. CD4+ T cell numbers fell by 50% in the Control (P < 0.05) and OMP
Antigen group (P < 0.02) in the first 12 h, and continued declining in the
latter group over the 36 h period (Fig 7.5a). A smaller, insignificant decline
was detected in the OMP Vaccine group over the entire period. CD8+ T cell
numbers declined only slightly in all groups in the first 12 h, but then
dropped by about 50% in the OMP Antigen and OMP Vaccine groups by 36 h
(Fig 7.5b).

Granulocyte (Gr-1+) and monocyte (Mac-1+) lineage cell numbers declined
following intranasal inoculation. Gr-1+ cell numbers dropped by 50 to 70% in
the Control (P < 0.005), OMP Antigen (P < 0.05) and OMP Vaccine groups (P
< 0.02) over the 36 h period (Fig 7.5c). Over the same period Mac-1+ cell
numbers dropped by 30 to 50% in the Control (P < 0.005), OMP Antigen (P <
0.001) and OMP Vaccine groups (P < 0.05) (Fig 7.5d).

7.3.6

Cellular changes in the spleen following intranasal inoculation with
A . p le u r o p n eu m o n ia e.

Total viable cell numbers in the spleens of the Control and OMP Antigen
groups did not change significantly in the first 12 h, but then increased by
30% in the OMP Antigen group by 36 h post-inoculation (NS) (Fig. 7.6a). By
comparison, viable cell numbers in the OMP Vaccine group were 40%
higher than pre-inoculation levels at 12 h (P < 0.03), before declining to pre
inoculation levels by 36 h. Dead cell numbers rose steadily (2 to 3-fold) in the
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FIGURE 7.5. Changes in the numbers of (a) Thy+CD4+ cells, (b) Thy+CD8+
cells, (c) G r-l‘M ac-l+ cells (macrophages) or (d) Gr-1+Mac-1+ cells
(granulocytes) in the bone marrow of mice from the Control (unfilled
columns), OMP Antigen (stippled columns) and OMP Vaccine groups (filled
columns) following intranasal inoculation with A. p l e u r o p n e u m o n i a e .
Results represent the mean (± sem) of 4 mice per group.
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FIGURE 7.6. Changes in the numbers of (a) total viable cells, (b) dead cells, (c)
Gr-1+Mac-1+ cells (granulocytes) or (d) Gr-l'M ac-l+ cells (macrophages) in the
spleen from mice from the Control (unfilled columns), OMP Antigen
(stippled columns) and OMP Vaccine groups (filled columns) following
intranasal inoculation with A. p l e u r o p n e u m o n ia e . Results represent the
mean (± sem) of 4 mice per group. Control mice did not survive past 24 h
post-inoculation.
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spleens of all groups over the 36h period post-inoculation (P < 0.01) (Fig.
7.6b).

Cellular

changes

in

the

spleen

mainly

affected

granulocytes

and

macrophages. A 3-fold increase in granulocyte numbers at 12 h post
inoculation contributed to the overall increase in viable cell numbers in the
OMP Vaccine group (P < 0.05) (Fig. 7.6c). Granulocyte numbers in the OMP
Vaccine group were normal at 36 h post-inoculation. Granulocyte numbers
in the Control or OMP Antigen group changed only slightly over the same
period. Macrophage numbers changed very little, rising only slightly (20%)
in the OMP Vaccine group at 12 h, but showing slight overall declines in all
groups at 36 h (Fig. 7.6d).

Intranasal inoculation had little effect on splenic T or B lymphocytes (Table
7.3). All groups elicited little or no change in the numbers of splenic CD4+,
CD8+ or yô+ T cells over 36 h post-inoculation. The lack of movement in
CD4+ and CD8+ T cell numbers in the different groups was confirmed by
assessment of ap+T cells over the same period. By comparison, B (B220+) cell
numbers increased by about 30% in the OMP Antigen and OMP Vaccine
group over 36 h.

7.3.7

Partial purification of APX1 and detection in OMP preparations

The in vitro haemolytic activity of culture supernatant increased during the
log-growth phase before plateauing in the late-log phase (Fig. 7.7).
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TABLE 7.3. Changes in T and B lymphocyte numbers in the spleen following
intranasal inoculation with A. p l e u r o p n e u m o n i a e of mice from the
Control, OMP Antigen and OMP Vaccine groups. Results represent the
mean (± sem) of 4 mice per group. Control mice did not survive past 24 h
post-inoculation.

Time Post-inoculation (h)
Phenotype
CD4+

CD8+

yô+

ap+

B220+

Group
Control

0

12

16.0 (0.7)

12.7 (2.0)

36
-

OMP Antigen

-

13.0 (1.0)

17.9 (1.3)

OMP Vaccine

-

16.9 (1.9)

14.0 (3.0)

Control

8.1 (0.2)

6.8 (1.3)

OMP Antigen

-

8.1 (0.9)

10.0 (0.6)

OMP Vaccine

-

10.3 (0.6)

7.6 (1.6)

Control

0.2 (0.1)

0.3 (0.1)

OMP Antigen

-

0.4 (0.1)

0.1 (0.1)

OMP Vaccine

-

0.5 (0.1)

0.3 (0.1)

24.1 (1.3)

19.3 (4.3)

Control
OMP Antigen

-

21.8 (3.1)

28.1 (2.0)

OMP Vaccine

-

25.4 (4.6)

22.1 (6.0)

Control

31.0 (1.4)

23.4 (5.6)

OMP Antigen

-

35.5 (3.7)

40.8 (5.8)

OMP Vaccine

-

42.7 (3.3)

32.9 (6.0)

* Numbers in parentheses indicate standard errors
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2

4-1

Tim e
FIGURE 7.7. Timecourse of increase in haemolytic activity (unfilled circles)
of culture supernatant compared with bacterial growth (filled circles) over
the same period.

In one typical preparation, the specific haemolytic activity of culture
supernatant was increased from 1.5 HU/mg protein (in the neat culture
supernatant) to 437 HU/mg protein (in the retentate), or a 291-fold increase
in specific activity. The relative purity of APX1 preparations ranged from 75
to 88%. Fig. 7.8 shows a typical densitometer scan. YM100 retentate was also
cytotoxic to a range of different murine cell types (Fig. 7.9). Ultrafiltrate was
not cytotoxic to these cells.

Protein bands were not detected in coomassie blue-stained polyacrylamide
gels of neat culture supernatant or YM100 ultrafiltrate (Figure 7.10, lanes 2
and 3). However, a 110 kDa protein corresponding to APX1 was detected in
the YM100 retentate (lane 4). The additional lower molecular

weight

proteins detected in culture retentate (lane 4) were most likely OMP retained

Chapter 7

page 183

FIGURE 7.8 LKB laser densitometer scan of a partially purified APX1
preparations. The arrow marks the APX1 peak.

Reciprocal of Retentate Dilution
FIGURE 7.9. Cytotoxicity of YM100 retentate to splenocytes (filled circles),
thymocytes (filled diamonds) and lung cells (filled squares) by propidium
iodide exclusion. No cytotoxicity was present when cells were incubated with
equivalent dilutions of YM100 filtrate (unfilled squares).
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during ultrafiltration. During growth, Gram-negative bacteria shed the outer
membrane as blebs [239]. Native proteins embedded in outer membrane blebs
are be trapped in the retentate during ultrafiltration. This is confirmed by
comparing the molecular weights of these proteins with those of Lanes 5 and
6, which show purified OMP proteins and proteins from denatured whole
cells, respectively.

kDa
116
97
66

45

31
22

FIGURE 7.10. Coomassie blue-stained SDS-PAGE and immunoblot of APX1
preparations from A. pleuropneumoniae. Lane 1: Biorad broad range molecular
weight proteins standards; Lane 2: neat culture supernatant; Lane 3: YM100
filtrate; Lane 4: YM100 retentate; Lane 5: purified OMP; Lane 6: denatured
whole cells. Immunoblot showing reactivity of anti-APXl serum against YM100
retentate (lane 7), neat culture supernatant (Lane 8) and purified OMP (Lane 9).

Immunoblotting demonstrated that pooled murine APX1 antiserum reacted
strongly against a 110 kDa band corresponding to APX1 present in the
YM100 retentate (Fig. 7.10, lane 7) and bacteria-free mid-log phase culture
supernatant (lane 8). Pooled APX1 antiserum reacted against multiple lower
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molecular weight bands present in the YM100 retentate and two bands, 33
and 37 kDa, in the OMP preparation (lane 9). These bands were consistent
with outer membrane proteins previously identified in coomassie bluestained gels (Chapter 5). The most likely cause of the reactivity of APX1
antiserum against OMP proteins was contamination of APX1 preparations
used for mouse immunizations with OMP. Most significantly, a protein
band corresponding to APX1 was not detected in OMP preparations.

Murine APX1 antiserum neutralized haemolytic activity of log-phase A.
ipleuroipneumoniae culture supernatant. Percentage residual haemolytic
activity

and percentage inhibition

of haemolytic

activity

of culture

supernatant is shown in Fig. 7.11.

100

100

0

------ 1-------r—

1000

2000

3000
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Reciprocal of Serum Dilution

FIGURE 7.11. The percentage residual haemolytic activity of culture
supernatant (unfilled squares) and percentage inhibition of haemolytic
activity of culture supernatant (filled circles) after incubation with
antiserum raised in BALB/c mice.
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7.4

DISCUSSION

The outcome of intranasal inoculation with A. p le u r o p n e u m o n ia e in
susceptible mice stains depends on the inoculum size. This finding is
consistent with previous results in other mouse species [425]. If the dose is
large enough, bacteria multiply rapidly and the mouse dies [425]. Clinical
signs, if present, can include weakness, ruffled hair, anorexia and épistaxis,
at or near death [425]. Sublethal doses, on the other hand, can produce either
subacute infection leading to chronic lesions or no lesions at all [425].
Although

not

as widely used

for laboratory

investigations

of A.

p l e u r o p n e u m o n i a e infection [433, 434], BALB/c mice were also found to be
susceptible to infection in a dose-dependent manner. Inoculating mice
intranasally with 1 x 107 CFU or greater resulted in cellular changes in the
lungs that were histologically consistent with those found in porcine
pleuropneumonia [415, 416, 436]. Inoculating BALB/c mice intranasally with
at least 1 x 108 CFU caused peracute (very rapid onset) infection, with
unimmunized mice eliciting severe clinical symptoms, and death within 12
to 24 h post-inoculation. This finding was consistent with previous reports
in pigs demonstrating very rapid onset of clinical symptoms when infected
intranasally with high doses of A. p l e u r o p n e u m o n ia e [414, 437]. A dose of 1
x

108

CFU

was

used

for

all

subsequent

investigation

of

A.

pl eu ro pneu m onia e infection in mice.

The transient recovery of viable bacteria from the blood and spleen at 4 h
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post-inoculation indicated that A. p l e u r o p n e u m o n i a e rapidly enters the
blood stream, possibly via the pharyngeal lymphoid tissue [421] and the
pulmonary lymphatic circulation [369]. The disappearance of bacteria at
subsequent time points, suggested rapid clearance of bacteria from the
circulation. One possibility may be phagocytosis of bacteria by resident
macrophages (Kupffer cells) and neutrophils in liver sinusoids [438]. This is
a major mechanism for clearance of bacteria from the bloodstream [438].
Flow

cytometric

measurements

demonstrated

clearly

that

leukocyte

populations in tissues as widespread as the lung, bone marrow and spleen
were adversely affected by infection. It was also possible that the cellular
changes detected in these tissues resulted from direct bacterial toxicity or
circulating toxins in these organs.

Macrophages are the predominant resident phagocytes present in the
normal lung, with PMN being much fewer in number [439]. However, very
rapidly following A. pleuropneumoniae infection in mice, PMN became the
most prominent cell type, with relatively fewer macrophages. The rapid
influx of high numbers of PMN into the lungs from the large reservoir in
the pulmonary vascular bed appears to be crucial for the prompt clearance of
bacteria [279, 440] and reflects the different roles of macrophages and PMN in
response to bacterial infection [279, 441]. Infection by pathogens as diverse as
Pseudomonas
monocytogenes

aeruginosa
[444],

[442], Chlamydia

Mycobacterium

trachomatis

a v iu m

[445]

[443], Listeria
and

Klebsiella

pneumoniae [446] elicit a similar response. The greater PMN numbers may
reflect superior bactericidal activity against a broad range of micro-organisms
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[438, 442]. Cruijsen et al (1992) [234], for example, showed that PMN have
much greater in vitro killing capacity against A. p l e u r o p n e u m o n i a e than
resident

or inflammatory

susceptible

to the

macrophages.

cytotoxic action

Macrophages

of RTX

toxins

are

than

also

more

PMN

[234].

Nevertheless, the rapid rise and fall in PMN and macrophage numbers in
the first 12 to 24 h following infection clearly demonstrated a major role for
the innate immune system as a primary defense mechanism, regardless of
the immune status of mice.

In mice, bone marrow, blood, secondary lymphoid tissues and non
lymphoid tissues all serve as potential sources of phagocytic cells for
recruitment during infection, but upregulation of splenic haematopoiesis is
a principal mechanism for meeting acute increases in demand for phagocytic
cells [280]. Upregulation of splenic haematopoiesis in mice occurs during
viral, bacterial and protozoan infections [325, 334, 447, 448]. It is likely,
therefore, that strong upregulation of splenic haematopoiesis in the OMP
Vaccine

group,

along with

tissue

recruitment

of granulocytes

and

macrophages, contributed to the greatly increased numbers of these cells in
the spleen and lung of mice during infection. The absence of such dramatic
increases in the spleens of the Control and OMP Antigen groups did not
exclude these mechanisms from also operating, but possibly reflected a lower
level of upregulation in splenic haematopoiesis following infection.

Irrespective of the immune status of mice, cell numbers in the bone marrow
declined during infection. The uniform decline in dead cell numbers in all
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groups made it unlikely that the smaller declines in viable cell numbers in
the OMP Vaccine group was due to lower necrotic or apoptotic death in this
group than in other groups. Efflux of cells from the bone marrow to the
lungs and other peripheral tissues may account for the decline in viable cell
numbers from the bone marrow [279]. The greater cell numbers, especially in
haematopoietic progenitor cells, B lineage and monocytic lineage cells, in
the bone marrow of the OMP Vaccine group suggested that these mice had
been more effectively primed by intradermal immunization than the OMP
Antigen group and were predisposed for greater proliferative responses on
subsequent challenge.

Pro-inflammatory factors released by bacteria and damaged cells attract
greater numbers of phagocytic cells to the infection site [374, 416]. Binding of
LPS from Gram-negative bacteria to CD14 on macrophages and monocytes,
for example, stimulates an increase in production of a range of cytokines,
such as IL-1, IL-2, IL-4, IL-6, IL-7, IL-11, IL-12, IL-13, IFN-y, TN F-a, M IP-la,
and MIP-2, that stimulate recruitment of lymphocytes and phagocytic cells to
the site of infection [105, 443, 446, 449]. Baarsch et al (1995) [450] showed that
A. p l e u r o p n e u m o n i a e infection in pigs rapidly causes cellular activation
and increased production of TN F-a, IL-1 and IL-8 by alveolar macrophages.
Other cell types, such as eosinophils [440], mast cells [451], alveolar epithelial
cells, interstitial macrophages, endothelial

cells and lymphocytes, also

recruit inflammatory cells to the site of infection by secreting TN F-a,
RANTES and MCP-1 [446]. Cytokines, such as TNF-a, IL-1 and IL-6, stimulate
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increased production

of superoxide anions

and H20 2, and release of

lysozymes by PMN that can directly destroy bacteria [442, 446, 452], while
binding of C3b or antibodies to the surface of bacteria (opsonization)
facilitates their phagocytosis by PMN recruited to the site of infection [449].

Despite

the

large

post-inoculation

increases

in

PMN

(11-fold)

and

macrophage (4-fold) numbers, unimmunized mice did not clear bacteria
from their lungs, and died within 24 h. Mice in the OMP Antigen group, on
the other hand, elicited almost equivalent increases in granulocytes and
macrophages, but rapidly cleared bacteria from their lungs and survived. At
the other extreme, the rate of bacterial clearance and degree of morbidity in
the OMP Vaccine group, which showed the greatest recruitment of PMN to
the lungs (almost twice that for the other groups) was not significantly better
than in the OMP Antigen group. These different outcomes clearly suggested
that rapid recruitment and activity of phagocytic cells to the infection site, by
itself, was insufficient to overcome lethal infection.

The high background levels of circulating and mucosal antibodies against
OMP and LPS (Chapter 5) most likely provided the additional protective
component in immunized mice. Numerous studies in swine [233-236, 388,
430] have shown that antibodies in convalescent serum directed against A.
p l e u r o p n e u m o n i a e , are important opsonins for phagocytic clearance of
bacteria from the lungs, and protection. Therefore, it was likely that
elevations in OMP- and LPS-specific antibodies in serum and respiratory
tract washings of both groups of intradermally immunized mice enabled
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more efficient phagocytic clearance of bacteria from the lungs than was
possible in unimmunized mice.

It is not clear from the current study whether the rapid bacterial clearance
and reduced morbidity in immunized mice was due predominantly to the
action of antibodies specific against OMP-derived proteins

or LPS, or

whether their effects were complementary. Both virulence factors have
important biological functions in disease pathogenesis. OMP allow nutrient
transport and uptake, chemosensing, motility, cell-cell communication and
adhesion [220, 453-455]. LPS facilitates bacterial adhesion to the mucosal
surfaces of the lung [401] and, along with secreted haemolysins, causes the
lung lesions

present

during infection

[374]. Antibodies

against both

virulence factors would therefore be expected to have an impact on the
pathogen's ability to colonize and invade the host. Future studies that utilize
vaccines containing either purified OMP-derived proteins or LPS, or passive
immunization

of animals with antisera against either component may

determine the relative contributions to protection of both virulence factors.
One may argue, however, that the more rapid induction of antibodies
against T-cell independent antigens, such as LPS [404], may give an
additional protective advantage in some cases, for example, very early
following bacterial colonization in unimmunized animals.

A 110 kDa protein, APX1, is also considered to be an important virulence
factor in disease pathogenesis [278, 417, 456-458]. APX1 is one of at least three
pore-forming
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serovars
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pleuropneumoniae [418, 420, 432]. APX1 is strongly haemolytic and cytotoxic
against a range of different cell types in vitro [459, 460] and mediates much of
the tissue necrosis and cytotoxicity against granulocytes and macrophages
associated with porcine pleuropneumonia [278, 416]. APXl-deficient mutants
elicit dramatically reduced disease in infected animals [418]. The inability of
commercial

bacterin-based vaccines to fully protect swine

against A.

p l e u r o p n e u m o n ia e is believed to be due to the lack of important virulence
factors, such as APX1 [197, 233].

Mice were immunized against OMP, but it was essential to exclude the
possibility that mice were inadvertently immunized against contaminating
APX1 co-purified with OMP. If present, anti-APXl antibodies may have
contributed

to the

protection

observed following

challenge.

Murine

antibodies raised against anti-APXl were used as a serological reagent to
detect the presence of APX1 in OMP preparations. The authenticity of APX1
used to raise anti-APXl antibodies was confirmed by measuring its in vitro
haemolytic

and

immunoblotting

cytotoxic
and

activity,

inhibition

in

detection

by

neutralization

SDS-PAGE
assays.

The

and
data

confirmed that APX1 was not detectable in OMP preparations. Surprisingly,
despite the lack of APX1 in the OMP vaccines

used,

intradermally

immunized mice were significantly protected when challenged with an
APXl-producing strain of A. p l e u r o p n e u m o n ia e . These results suggested
that antibodies against surface-exposed OMP and polysaccharides may
mediate swift clearance of bacteria from the lungs and thereby m inim ize
tissue damage to lungs caused by bacterial toxins.
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It

is

generally

believed

that

IgA is

the

most

important

secreted

immunoglobulin isotype for protection against mucosal pathogens, and that
serum antibodies and non-IgA isotypes do not contribute significantly to
protection [9, 148, 196]. However, a protective role for serum antibodies, and
for immunoglobulin isotypes other than IgA, against mucosal pathogens
has been suggested by this and other studies [158-160, 184]. In this study,
intradermally immunized mice did not have significant levels of OMPspecific RTW IgA at the time of infection but had strong IgG responses in
serum and respiratory tract washings (Chapter 5). These mice showed
significantly better clearance of bacteria from the lungs and reduced
morbidity than control mice. Although the relative contributions of serum
and RTW IgG was not investigated, the results argued strongly in favour of
a prominent role for the IgG class in protecting against disease caused by A .
;p l e u r o p n e u m o n i a e .

Previous studies [233, 405, 423, 429] have demonstrated a lack of prom inent
changes in pulmonary lymphocyte distribution and CMI involvement in
swine

following

exposure to A.

p l e u r o p n e u m o n i a e . Under

norm al

circumstances, down-regulation of CMI responses in the lungs by resident
macrophages prevents lymphocytes from reacting to irrelevant antigens
[279, 441, 461, 462] and this may explain the absence of significant CMI in
infected swine. This present study confirmed the lack of significant changes
in T and B cells. The strong influx of granulocytes and macrophages
demonstrates that a very strong, T cell independent, innate response is the
first

line
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unimmunized mice, and if they survive long enough, may limit the spread
of infection in the period required for induction of T cell dependent
immune responses. However, in this study the effectiveness of such a
response for clearing A. pleuropneumoniae from the lungs was curtailed by
the very high inoculation dose. By contrast, the efficient clearance of bacteria
in immunized mice, which co-incidently had elevated levels of OMP- and
LPS-specific antibodies, demonstrated that induction of adaptive im m une
responses are ultimately necessary for the clearance of infection.

The monoclonal antibody used to detect B cells in this study, RA3-6B2, reacts
against the 220 kDa isoform of the CD45 antigen, and is a well established B
cell marker [248]. However, the rapidity and almost identical increase in
B220+ cell numbers

in both unimmunized

or immunized

mice was

inconsistent with an antigen-specific B cell response. Since upregulated
expression of the B220 epitope on non-T, non-B cells is associated with an
increase in MHC-unrestricted cytolytic activity [293, 294, 463], the results
suggested that intranasal challenge elicited an increase in the numbers of
lytically active cells in mice. This epitope is also expressed on activated afTTCR+, yb-TCR+ T cells and NK cells [463, 464]. Specific staining ruled out
increased B220 expression on ap- or y^-TCR T cells in infected mice.
Increased NK cell activity was not detected shortly after intradermal
immunization (Chapter 2), but this did not exclude an increase in NK
activity following exposure of mice to A. p l e u r o p n e u m o n i a e . In vitro
assessment of NK cell activity was not measured and flow cytometry of NK
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cells was not undertaken for the reasons mentioned in Chapter 2.

In summary, an in v iv o mouse model was used to quantitatively assess
differences in the leukocyte response to intranasal A. p l e u r o p n e u m o n i a e
infection in unimmunized

and immunized mice. Although all groups

elicited a strong innate cellular response, protection appeared to require the
presence of specific antibodies with opsonic properties. Binding to surface
exposed protein and polysaccharide components of A. p l e u r o p n e u m o n i a e
facilitated

clearance

of bacteria from

the

lungs

by phagocytic cells.

Significantly, the data indicated that, in the absence of mucosal IgA, IgG was
important for mucosal protection. This is contrary to the accepted dogma,
that protection against mucosal pathogens is the best achieved by mucosal
immunization

and

secretion

of

mucosal

IgA.

Finally,

the

results

demonstrated that intradermally immunized mice were protected against A.
pleuropneumoniae in fectio n .
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CHAPTER 8
Summary of Results and General
Discussion

In practical terms, control over the type of immune

responses elicited

following immunization is confined to: selecting the im m unodom inant
antigens that correlate with protection from

disease [2], choosing an

adjuvant [18, 24, 30, 465] and deciding the immunization route to be used [8,
107, 466]. The historical basis for using an adjuvant has been to increase the
immunogenicity of injected antigens and thus guarantee that an im m une
response is elicited [13-15, 35, 467]. Adjuvants increase the immunogenicity
of antigens by provoking the innate immune system [11, 16], but beyond the
general appreciation that adjuvants

activate macrophages there is an

incomplete understanding of adjuvant action.

This is partly because of the heterogeneity in the chemical composition of
adjuvants [21], and because most studies have focused predominantly on the
endproduct of immunization,

namely the humoral

or cell mediated

immunity elicited [24, 33, 34, 51, 54, 102, 126, 217, 224, 231, 468, 469].
Nevertheless, the dependence on vaccines for disease control and the
widespread use of adjuvants to ensure immunological responses [8] raise
issues of vaccine safety and efficacy that require a greater understanding of
adjuvant action in order to be resolved.

The cellular events induced in the innate immune system by vaccination
direct the development of the adaptive immune response [116]. Therefore, it
is meaningful to define the cellular changes that are induced with and
without adjuvant. One outcome of this is that, if the important events are
identified, it may be possible to manipulate them more precisely to achieve
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the desired outcomes. This type of investigation may also reveal that some
antigens do not require adjuvant enhancement

to induce the desired

immune response. Because many adjuvants are toxic, limiting their use
may lower the incidence of adverse reactions. Investigation of cellular
changes induced by alterations to vaccine formulations may also show that
dissimilar antigens incorporated into a vaccine cause adjuvants to generate
different cellular responses. This approach would provide a rational basis for
selecting alternative adjuvants.

A murine model was established to evaluate the leukocyte changes that
occurred when the immune system was provoked by immunization, and to
assess the

importance

of these

changes

for

determining

the

final

immunological responses. The intradermal route was used together with
the liposome-iscom hybrid adjuvant, SAMA4 (Skin and Mucosal Adjuvant
version 4, Patent No. PCT/AU95/00206) for vaccine delivery because
previous studies [100-102] have shown that this combination induces both
systemic and mucosal immune responses. Leukocyte changes induced by
intradermal immunization were quantified by flow cytometry, a technique
that enabled simultaneous

phenotypic

identification

of different cell

populations in cell suspensions prepared from murine tissues. Mice were
immunized with either SAMA4 (Adjuvant group), OMP purified from the
respiratory pathogen, A. pleuropneumoniae (OMP Antigen group), SAMA4OMP (OMP Vaccine group) or PBS (Control group). This approach was a
significant departure from that used by previous reports for investigating
adjuvant action, both in the use of flow cytometry for measurement of post
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immunization

cellular changes, and in directly comparing changes in

leukocyte populations across different vaccine formulations.

Adjuvant alone elicit moderate cellular changes following intradermal
immunization.

The

combination

of antigen and

adjuvant,

however,

synergistically increased the magnitude of cellular changes in the OMP
Vaccine group. Qualitatively similar changes were elicited when OVA, an
innocuous antigen, was complexed with SAMA4, but were absent from the
Antigen-only groups. One prominent effect of intradermal im m unization
with SAMA4-OMP complexes was an increase in tissue and circulating
levels of PMN and macrophages. The bone marrow in the adult mouse has
limited reserve haematopoietic capacity for responding to increased cellular
demands [280]. It was demonstrated that haematopoietic progenitor and
lineage-committed precursor cell populations rapidly declined in the bone
marrow following intradermal immunization. The splenic morphological
and histological changes in the OMP Vaccine group suggested that the
spleen assumes a haematopoietic role during this period, with upregulation
of haematopoietic activity in the spleen induced by an im m unizationinduced increase in demand for phagocytic cells.

Surprisingly, a rapid effect evoked by SAMA4-OMP complexes was depletion
of DP cells in the thymus and leukocyte precursors (predominantly B220+
cells and haematopoietic progenitor cells) in the bone marrow. Cell losses
occurred within 12 to 24 h following the first intradermal injection and
preceded the cellular increases in the spleen by several days. Although only
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a small increase in the percentage of apoptotic cells was detected in the
thymus, and no increase was detected in the bone marrow, the susceptibility
of DP cells and B220+ cells to apoptosis [301, 331] made this the most likely
explanation. Apoptotic and dead cells are rapidly recognized and removed by
macrophages [303, 470], therefore, the lack of detectable increases in apoptosis
may have been due to the limited the ability of the method to detect in v i v o
apoptosis. Other indicators of apoptosis, such as TUNEL, which detects in
situ

DNA

fragmentation,

apoptosis-related

cell

markers

[263],

and

measurem ent of changes in mitochondrial transmembrane potential that
occur during apoptosis [261], may yield a more accurate picture of the level of
apoptosis

in

the

thymus

and

bone

marrow

following

intradermal

im m unization.

The outcomes in the bone marrow and thymus in the OMP Vaccine group
were significant in that they are a previously unreported outcome of
im m unization by any route. Massive cell depletion may be a bystander
responses with no direct relevance to the immune response, but it had the
potential to suppress or delay development of the immune response. From
an evolutionary perspective it seems unlikely that immune suppression
precipitated by massive lymphoid cell depletion

confers any survival

advantage to an animal faced with an immunological challenge, unless the
depletion has a specific immunological purpose, and/or other mechanisms
were in place for protecting the host during this period. One explanation for
the significant loss of immature cells in the bone marrow and thymus is that
depletion of lymphocyte precursors prevents tolerance being inappropriately
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induced against the immunizing antigen. During the period of cell loss,
protection was achieved by a significant increase in innate defenses, nam ely
polymorphonuclear granulocytes and macrophages. In disease, recruitm ent
and increased phagocytosis by these cells, along with other innate defences,
limits the spread of infection, reduces the circulating antigen load and
stimulates induction of strong adaptive immune
following immunization,

adjuvant-mediated

responses. Sim ilarly

stimulation

of phagocyte

recruitment potentially enhanced phagocytosis and antigen processing by
these cells and induced strong humoral and cellular responses against the
immunizing antigen. Nieuwenhuis et al (1988) [307] and Westermann et al
(1996) [309] showed that intrathymic circulation of activated leukocytes or
antigen from the periphery increases during an immune

response. By

analogy, antigen presentation by circulating APC may provide the stim ulus
for an antigen-driven

increase in

turnover

of T and B cells.

The

supranormal levels of B220+ cells in the bone marrow and thymocytes later
in the post-immunization period may have reflected a period of increased
lymphopoiesis

and

lymphocyte

maturation,

potentially

shifting

the

antigenic repertoire of developing cells toward those with greater specificity
for the immunizing antigen.

Synergism between the antigen and the adjuvant was confirmed by the
inability of OMP alone to provoke similar leukocyte changes. It was likely
that the synergistic effect of SAMA4-OMP on leukocyte populations was a
consequence of the slow lymphatic clearance of antigen-iscom complexes
and greater accumulation of vaccine in the spleen and lymph nodes,
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compared to free antigen or adjuvant alone [37, 59, 69, 74, 87, 92]. Binding of
iscoms to DEC 205, a carbohydrate binding protein present on the surface of
phagocytic cells, is one mechanism proposed for enabling efficient uptake of
antigen-iscom complexes [39].

Multimeric antigen presentation on the

surface of iscoms [69, 92], together with high circulating phagocytes numbers,
also provided the right environment for an increased rate of antigen uptake
and processing, compared to free antigen.

It remained to be determined how the immune response in mice reflected
the disparate cellular

responses

in

the various

groups. Intradermal

immunization

with free or SAMA4-complexed OMP stimulated strong

systemic

and

IgG

IgA,

and

mucosal

IgG

responses.

Intradermal

immunization also primed mice for recall of mucosal IgG and IgA responses
as evidenced by increased levels of OMP-specific IgG and IgA in RTW, and
increased numbers of IgG and IgA antibody secreting cells in the lungs after
intranasal inoculation of a sub-immunogenic dose of OMP. Both the OMP
Antigen and OMP Vaccine groups were equally protected against intranasal
exposure to a lethal dose of A. p l e u r o p n e u m o n i a e . Bacterial challenge
elicited a rapid influx of PMN and macrophages into the lungs, regardless of
the immune status of mice. However, protection, as measured by rapid
clearance of bacteria from the lungs and reduced morbidity, was ultimately
dependent on the presence of anti- OMP and anti-LPS antibodies in the
serum and respiratory tract.
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An obvious outcome of this investigation was that the OMP Antigen group
elicited almost identical responses, in terms of antibody profiles and
protective immunity, as the OMP Vaccine group. This result was consistent
with bacterial OMP being sufficiently immunogenic, due to its chem ical
heterogeneity and antigenic complexity of its protein and polysaccharide
components, that it did not require adjuvant enhancement to induce an
immune response. In the case of OMP then, the adjuvant effect of SAM A4
was to significantly prolong the duration of serum and mucosal antibody
responses in mice, and increase reactivity against T dependent antigens in
OMP. Considering the similar outcomes, these results would suggest that,
for OMP at least, the strong cellular changes induced by SAMA4 were
unnecessary. However, when mice were immunized

with a simpler,

innocuous and poorly immunogenic antigen, such as OVA, the adjuvant
effect of SAMA4 was much more obvious. CTL and antibody responses were
only elicited when OVA was complexed with SAMA4. These results for
OVA clearly demonstrated that the strong cellular responses promoted by
SAMA4 in the presence of antigen contributed to beneficial im m unological
outcomes

detected.

These

differences

between

antigens

places

great

emphasis on adequately evaluating the composition and efficacy of vaccine
formulations.

The findings that intradermally immunized mice elicited mucosal im m u n e
responses; that IgG was the predominant immunoglobulin isotype present
in RTW at the time of intranasal challenge with A. pleuropneumoniae.; and
that a protective role for IgG was strongly implicated, were contrary to the
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current dogma, that mucosal im m unization is necessary to elicit m ucosal
(IgA) immunity [471]. There are many similar reports that describe the
induction of mucosal immunity
including intra-muscular

by systemic im m unization

[82, 209, 224], subcutaneous

strategies,

[202, 225], and

intradermal im m unizations [102, 161]. These findings suggest that the idea
of a mucosal immune

system that only surveys the mucosal surfaces,

predominantly secretes IgA, and is functionally independent to the systemic
immune

system

[136,

148]

is

incorrect.

Compartmentalization

of

immunological responses and im m unoglobulin isotypes in this way would
potentially limit the range of protective responses elicited during infection.
Daynes and Araneo [469] demonstrated that T cells may be " re-program m ed"
by the action of different im m unom odulators in v iv o, thus providing a
basis for generating both mucosal and systemic immune responses. In this
study, the use of an adjuvant,

and mobilization

and recruitment

of

sufficient numbers of immune effector cells by intradermal im m un ization ,
provided the necessary stimulus to induce both mucosal and systemic
immune responses in mice.

Intradermal im m unization may, in fact, be preferable to direct m ucosal
immunization in a number of circumstances. Most of the phenom ena
associated with mucosal im m unity have been investigated in rodents,
therefore, the general applicability of mucosal vaccination strategies to other
species is still unknown
intradermal

im m unization

[472]. Numerous
may be effective

studies
in

have

shown

circumstances

that

where

mucosal immunization fails to elicit strong or protective mucosal responses,
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or when the requirement for multiple and frequent im m unization doses is
impractical [206], such as in place of oral and intravaginal im m u n ization s
[82, 390] or due to economic or geographic and storage conditions. Agerelated, dietary and biological variations in the uptake of antigen through
the mucosal epithelium
influence

and in the composition of mucosal flora may

the efficacy of mucosal vaccination

[472]. The

presence

of

concurrent pathology, such as vomiting or diarrhoea, intestinal allergies,
parasitic infections, and drug therapy may also affect the rate absorption
across the gut epithelium [472]. Intradermal immunization offers several
practical advantages over other immunization routes in the veterinary field
in terms of reduced animal handling; vaccination during livestock feeding;
and automated vaccination with compressed-air guns. This latter technology
will eliminate the requirement for needles that can often lead to extraneous
bacterial infection under farm conditions [473, 474].
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